<html xmlns="http://www.w3.org/1999/xhtml" class=" js flexbox flexboxlegacy canvas canvastext webgl no-touch geolocation postmessage no-websqldatabase indexeddb hashchange history draganddrop websockets rgba hsla multiplebgs backgroundsize borderimage borderradius boxshadow textshadow opacity cssanimations csscolumns cssgradients no-cssreflections csstransforms csstransforms3d csstransitions fontface generatedcontent video audio localstorage sessionstorage webworkers applicationcache svg inlinesvg smil svgclippaths"><!--MODERNIZED PAGE--><head id="coid_website_head" profile="http://www.w3.org/2005/10/profile"><style type="text/css">@charset "UTF-8";[ng\:cloak],[ng-cloak],[data-ng-cloak],[x-ng-cloak],.ng-cloak,.x-ng-cloak,.ng-hide{display:none !important;}ng\:form{display:block;}.ng-animate-block-transitions{transition:0s all!important;-webkit-transition:0s all!important;}</style>
	<meta http-equiv="content-type" content="text/html; charset=UTF-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<meta name="description" content="View on Westlaw or start a FREE TRIAL today, SmithKline Beecham Corp. v. Apotex Corp., Cases">







<script>
	

	(function () {
		window['$$errors'] = [];

		//handle js errors (it will be overwritten in GlobalPageHandlers.js. And any error will be processed when this script is loaded on the page.)
		window.onerror = function() {
			window['$$errors'].push(arguments);
		}
	})();
</script>




	<title>SmithKline Beecham Corp. v. Apotex Corp. | Cases | Westlaw</title>

	
	



	
	
	



	




    
    <link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/utilities.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/core.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/components.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/features.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/document.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/print.css" type="text/css" rel="stylesheet" media="print">
<!--[if gte IE 6]>
<link href='https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/ie.css' type='text/css' rel='stylesheet' />
<![endif]-->


	<link rel="shortcut icon" type="image/vnd.microsoft.icon" href="https://ia.next.westlaw.com/favicon.ico">
	<link rel="apple-touch-icon" href="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v2/iphone-webclip-icon.png">
<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.923c80f054c89ca796f84c4fbed803b0.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.e94d5ee75e94c1087b529e979a552bed.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.83634f9482d1ddf27e96c8f1d9498ac3.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.82967e6fecb235c1f97c6591de01f9f7.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/Website/Views/Document/DocumentTabView.bootstrap.js"></script><link id="Markman_MarkmanDisplayState"><link id="Markman"></head>



<body class="co_t2Left co_docDisplay">
	<div id="co_pageContainer" class="co_bodyToolbar">
		<div id="co_mainContainer">
			











<div id="co_headerWrapper" class="wlnv2 ">
	<div id="co_newHeader"><div id="co_privacyPolicyContainer"> 
	<p id="co_privacyPolicy">
		<b>We've updated our Privacy Statement.</b> Before you continue, please read our new <a id="coid_website_privacyPolicyLinkOut" href="javascript:void(0)">Privacy Statement</a> and familiarize yourself with the terms.
		<button type="button" id="coid_website_privacyPolicyAcknowledged" title="Close message to acknowledge privacy statement" class="co_absolute">
			<span class="icon25 icon_close_x"></span>
		</button>
	</p>
</div>
		<div id="co_headerContainer">
			<div id="co_newHeader_top" class="headerContent" role="banner">
					<div class="skipButtonContainer"><a href="javascript:void(0);" data-jumpto="co_docHeaderTitle" class="co_tbButton skipButton">Skip to Document</a><a href="javascript:void(0);" data-jumpto="co_footerLinks" class="co_tbButton skipButton">Skip to Footer</a></div>
						<ul id="co_mainNav" class="co_inlineList" role="navigation">
							
														<li id="co_kmFirmNameContainer"></li>


	<li id="co_clientIdContainer" class="navigation_link co_menuListFirst"><div id="co_clientID_title_0" class="co_dropdownTabCollapsed"><span class="co_clientID_label" id="co_clientID_label_0">Client ID:</span><span></span></div><div id="co_clientID_list_0" class="co_clientID_list co_hideState" aria-hidden="true">

<div class="co_dropdownBoxExpanded">
	<div class="co_dropdownBoxHeader">
		<span></span>
	</div>
	<div class="co_dropdownBoxContent">
		<button id="co_clientID_close_0" class="co_overlayBox_closeButton" type="button">Close</button>
		<div class="co_dropdownBoxContentRight" id="co_clientID_content_0"></div>
	</div>
	<div class="co_dropdownBoxFooter">
		<span></span>
	</div>
</div></div></li>
									<li id="co_recentHistoryContainer"><div id="tabIndicator" class="co_dropdownTabCollapsed"><div class="co_dropdownTab"><a href="javascript:void(0);" class="co_dropdownBoxanchorLabel"><span class="icon"></span>History</a><button class="co_hasTooltip co_dropdownArrowCollapsed" title="Recent History Menu"><span class="th_simple_icon icon_down_arrow reversed"></span><span class="co_accessibilityLabel" aria-hidden="true" id="coid_dropdownAriaLabel_1">History Menu</span> </button></div></div><div class="co_dropdownBoxCollapsed" aria-hidden="true" aria-labelledby="coid_dropdownAriaLabel_1"><span class="co_accessibilityLabel">Beginning of history window.</span><div class="co_dropdownBoxContent"><div class="co_recentResearch iac-a11y-header-redesign" id="co_recentResearch">
	<div class="co_recentDocuments co_floatLeft">
		<div class="co_globalNavDropdownBox_header">
			<h3 class="co_recentDocumentsHeader">Recent Documents</h3>
			<a class="co_floatRight co_recentDocumentsAll" href="javascript:void(0);" id="co_recentDocumentsLink">View all</a>
		</div>
		<div class="co_scrollWrapper">
			<ul class="co_recentDocumentsList" id="co_recentDocumentsList"></ul>
		</div>
	</div>
	<div class="co_recentSearches co_floatRight">
		<div class="co_globalNavDropdownBox_header">
			<h3 class="co_recentSearchesHeader">Recent Searches</h3>
			<a class="co_floatRight co_recentSearchesAll" href="javascript:void(0);" id="co_recentSearchesLink">View all</a>
		</div>
		<div class="co_scrollWrapper">
			<ul class="co_recentSearchesList" id="co_recentSearchesList"></ul>
		</div>
	</div>
	<div class="co_clear"></div>
</div></div><button class="co_overlayBox_closeButton" type="button" title="Close history menu">Close Recent History window</button><span class="co_accessibilityLabel">End of history window.</span></div></li>
								<li id="co_signOffContainer" class="">

									<div class="co_dropdownTabCollapsed">
										<div class="co_dropdownTab">
											<button id="coid_website_signOffRegion" class="co_dropdownBoxanchorLabel co_hasTooltip iac-a11y-header-redesign" title="Settings &amp; Sign Off">
												<span class="th_simple_icon icon_user reversed"></span>
												<span class="th_simple_icon icon_down_arrow reversed"></span>
												<span class="co_accessibilityLabel" aria-hidden="true">Settings &amp; Sign Off</span>
											</button>
										</div>
									</div>
									<div class="co_dropdownBoxCollapsed co_globalNavDropdownBox" aria-hidden="true" aria-labelledby="coid_dropdownAriaLabel_0"><span class="co_accessibilityLabel">Beginning of profile settings window.</span>
										<div class="co_globalNavDropdownBox_header">
											<h3 id="coid_dropdownAriaLabel_0">Profile Settings</h3>
										</div>
										<div class="co_globalNavDropdownBox_content">
											<div class="co_signOff_profile">
												<h4></h4>
												<ul>
													<li></li>
												</ul>
											</div>

											<div class="co_signOff_links">
												<ul>


	<li>
		<a id="coid_website_mycontent" href="/MyPlan/Show\?transitionType=Default&amp;contextData=(sc.Default)">My Content</a>
	</li>


													<li>
														<a id="coid_website_userSetting" href="javascript:void(0);">My Preferences</a>
													</li>
													<li>
														<a class="co_signOff_updateProfile" href="https://onepass.westlaw.com/v2/profile/general?productid=CBT&amp;viewproductid=&amp;returnto=1.next.westlaw.com">Update OnePass Profile</a>
													</li>
												</ul>

											</div>

											<div class="co_signOff_buttons">
												<div>
													<button type="button" class="co_primaryBtn js_website_signoff">Sign Off</button>
												</div>
											</div>
										</div>
									<button class="co_overlayBox_closeButton" type="button" title="Close profile menu">Close Profile Settings window</button><span class="co_accessibilityLabel">End of profile settings window.</span></div>

								</li>
						</ul>

			</div>
			<div id="co_newHeader_bottom" class="headerContent">







<div id="headerLogo" class="" data-compartment-start-page-id="">

	<a id="coid_website_logo" href="/?transitionType=Default&amp;contextData=(sc.Default)" tabindex="1" class="co_hasTooltip">
		<img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v2/logo.png" title="Westlaw Home">
		<span class="co_accessibilityLabel" aria-hidden="true">Westlaw Home</span>
	</a>
</div>







<div id="coid_website_searchWidget" style="display:none;"></div>
<div id="co_headerSearch" class="">
	<div id="co_searchWidgetInnerId" class="co_noAdvancedSearch">
		<form action="" onsubmit="return false;">
			<div id="co_searchFormLeft">
				<a href="javascript:void(0);" id="co_categorySearchButton">
					<span id="co_currentSelectedCategoryText">291 PATENTS</span>
					<span id="co_currentSelectedCategoryToggle" class="th_simple_icon icon_down_arrow co_hasTooltip">
						<span class="co_accessibilityLabel">Content Menu</span>
					</span>
				</a>
				<div class="co_dropdownBoxCollapsed" id="co_searchCategoryDropdown"><ul>  <li class="co_tabLeft" id="co_searchWidgetAllWestlawTab" title="Search All Content">    <div class="co_tabRight"><a href="#" onclick="return false;">All Content</a></div>  </li>  <li class="co_tabLeft co_hideState" id="co_searchWidgetCompartmentCustomTab" title="compartmentCustomTab">    <div id="compartmentCustomTabDivId" class="co_tabRight"><a title="Search " href="#" onclick="return false;">{compartmentCustomTabLinkText}</a></div>  </li>  <li class="co_tabActive co_tabLeft" id="co_searchWidgetCustomTab">    <div id="customTabDivId" class="co_tabRight"><a title="Search 291 PATENTS" href="#" onclick="return false;">291 PATENTS</a></div>  </li></ul>

				</div>
			</div>
			<div class="co_searchFormOuter">
				<div class="co_searchInputContainer" id="co_searchInputContainer">
					<div class="co_inputTop">
						<div class="co_inputTopRight"></div>
					</div>
					<div class="co_inputMidLeft">
						<div class="co_inputMidRight">
							<!-- Search text box -->
							<div class="co_textarea">
								<label id="searchInputIdLabel" for="searchInputId">Search:</label>
									<textarea style="" title="Search" name="searchInputId" aria-label="Westlaw Search. Search suggestions available after typing 3 characters. Use arrow keys to navigate suggestions." id="searchInputId" rows="1" spellcheck="false" autocorrect="off" autocapitalize="off" class="co_defaultInput"></textarea>
							</div>

							<!-- Medical litigator check box container -->
							<div id="co_medLitExpandedTerms" class="co_floatRight co_formInline"></div>



<!-- Recent search query toggle -->
<a id="co_searchLast10Link" class="th_simple_icon icon_down_arrow co_hasTooltip" href="#" onclick="return false;" title="Recent Searches Menu">
		<span class="co_accessibilityLabel">Recent Searches Menu</span>
</a>
						</div>
					</div>
					<div class="co_inputBottom">
						<div class="co_inputBottomRight"></div>
					</div>


<!-- Hold recent query drop down -->
<div id="co_recentQueryListBox" class="co_hideState">
	<ul class="co_searchSuggestionContainer" id="co_searchLast10List"></ul>
</div>
				<span role="application" id="searchBoxIndexSpan" style="display: none;"><p class="co_accessibilityLabel" id="co_resultsAvailable">Results are available, use up and down arrow keys to navigate</p><p class="co_accessibilityLabel" id="co_endOfList">End Of List</p><div id="co_typeAheadStatusAlert" aria-live="assertive" role="alert" aria-labelledby="co_resultsAvailable"></div><ul class="co_searchSuggestionContainer" aria-live="polite" aria-relevant="additions removals" id="co_searchSuggestion" style="display: none;" tabindex="-1"><li class="co_autoCompleteSection" id="coid_westlawanswers_elastic_westlawanswers_allcases" style="display:none"></li><li class="co_autoCompleteSection" id="coid_westlawanswers_elastic_westlawanswers" style="display:none"></li><li class="co_autoCompleteSection" id="coid_westlawanswers_elastic_westlawanswers" style="display:none"></li><li class="co_autoCompleteSection" id="coid_snapshotExactMatch_elastic_snapshots" style="display:none"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_categorypage"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_case"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_docket"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_statute"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_regulation"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_admindecision"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_analytical"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_pendingstatute"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_othercourtdocument"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_snapshots"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers_static_questions"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers_static_questions_allcases"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers_it_depends_question"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_antitrust"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_arbitration"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_bankruptcy"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_capmarket_corpgovern"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_commtrans"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_corp_mna"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_empbenefits_excomp"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_fedcivilpract"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_finance"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_inhousecounsel"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_intelprop_tech"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_labor_emp"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_realestate"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_startup_smallbus"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_trust_estate"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointpicks_practicallaw"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointpicks_forms"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointpicks_secondarysrc"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepoint_rulebooks"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepoint_categorypage"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicallaw"></li></ul></span></div>
			</div>
			<div id="co_searchFormRight">
				<div id="co_searchFormRightWrapper">
					<!-- Jurisdiction selected -->
					<div id="co_jurisdictionWidgetContainer" class="">

<a class="co_jurisdictionSelectorDropDownArrowCollapsed" href="javascript:void(0);" id="jurisdictionId">
    <span id="jurisdictionIdInner">Federal Circuit</span>
</a>
</div>
					<!-- Search button -->
					<button title="Search" id="searchButton" class="co_hasTooltip" aria-label="Search 291 PATENTS">


						Search Westlaw
						<span class="co_accessibilityLabel">Search 291 PATENTS</span>
					</button>
					<!-- Advanced search -->
					<a href="#" onclick="return false;" class="co_hideState" id="co_search_advancedSearchLink" title="Advanced Search">Advanced</a>
					<!-- Holder jurisdiction pop up -->
					<div id="co_searchJurisdictionHoverContainer"></div>
				</div>
			</div>
			<!-- Search error container -->
			<div id="co_searchInputErrorMessageContainer" class="co_hideState"></div>
		</form>
	</div>
</div>
						<div id="coid_website_searchWidget" class="co_hideState"></div>
						<div id="co_researchAcceleratorWrapper">
							
						</div>
						<div class="co_skipToLink">
							<a id="coid_website_startContent" name="coid_website_startContent"></a>
						</div>

			</div><!--newHeader_bottom-->
		</div><!--headerContainer-->
	</div><!--newHeader-->
</div><!--co_headerWrapper-->




	
	
<!-- moved delivery toolbar to separate ascx control -->	








	<div id="co_body">
		<!-- BODY HEADER -->
		<div id="co_bodyHeader"></div>
		

	
	<!-- Reporting Name is "CTA" for document with guid "I0a98a911a82a11d9bdd1cfdd544ca3a4". -->
	
	<!-- CENTER COLUMN -->  
	<div id="co_contentWrapper">
		<div id="co_contentColumn">
			<div class="co_innertube">










<div id="co_docHeaderContainer">
	<a class="co_skipToLink" href="#coid_website_errorsSummaryPlaceHolder">
		Skip Page Header
	</a>
	<div id="co_docHeader">
		<div id="co_docFixedHeader"><div id="co_docHeaderCitatorFlag"><span class="co_citatorFlag"><a href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;transitionType=Document&amp;originationContext=docHeaderFlag&amp;contextData=(sc.CustomDigest)"><img class="crsw_DocumentIndicator" alt="KeyCite Yellow Flag - Negative Treatment" src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v1/flag_yellow.png" title="KeyCite Yellow Flag - Negative Treatment"></a><span class="co_citatorFlagText">KeyCite Yellow Flag - Negative Treatment</span></span></div><div id="co_docHeaderTitle"><h2 id="co_docHeaderTitleLine" title="SmithKline Beecham Corp. v. Apotex Corp."><span id="title"><a class="co_drag" href="https://1.next.westlaw.com/Document/I0a98a911a82a11d9bdd1cfdd544ca3a4/View/FullText.html?listSource=Search&amp;navigationPath=Search%2fv1%2fresults%2fnavigation%2fi0ad62aef0000016306ea58342bf062c8%3fNav%3dCUSTOMDIGEST%26fragmentIdentifier%3dI0a98a911a82a11d9bdd1cfdd544ca3a4%26startIndex%3d1%26contextData%3d%2528sc.CustomDigest%2529%26transitionType%3dCustomDigestItem&amp;list=CUSTOMDIGEST&amp;rank=122&amp;listPageSource=b1be020b4aba9e28af6c04f62c735c28&amp;originationContext=docHeader&amp;contextData=(sc.CustomDigest)&amp;transitionType=Document&amp;needToInjectTerms=False&amp;enableBestPortion=True&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470">SmithKline Beecham Corp. v. Apotex Corp.</a></span></h2><ul id="co_documentStatusIcons" class="co_document_indicators"></ul><h3 id="co_docHeaderCitation" title="United States Court of Appeals, Federal Circuit. | April 8, 2005 | 403 F.3d 1331 | 74 U.S.P.Q.2d 1398&nbsp;(Approx. 39 pages)"><span id="courtline">United States Court of Appeals, Federal Circuit.</span><span id="filedate">April 8, 2005</span><span id="cite0">403 F.3d 1331</span><span id="cite1">74 U.S.P.Q.2d 1398</span><em>&nbsp;(Approx. 39 pages)</em></h3><h4 id="co_docHeaderNegativeTreatment"><span id="co_document_compositeHeader_citatorFlag" class="co_citatorFlag"></span></h4></div></div>
		<div class="co_clear"></div>
		<div id="co_docPrimaryTabNavigationContainer" class="co_docTabs">
				<a id="co_iPadKeyCiteMenuToggle">
					Toggle Menu
				</a>
			<ul id="co_docPrimaryTabNavigation" class="co_tabs">










<li id="DocumentTab" class="co_tabLeft co_tabActive co_dropdownTab">
	<h2 class="co_tabRight">
		<a id="coid_DocumentTab_link" class="co_tabLink" href="javascript:void(0);">
			<span>Document</span>
		</a>
				<div class="co_clear"></div> 
	</h2>
	</li>







<li id="riFilingsTab" class="co_tabLeft" countstatus="" categoryenum="riFilings">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_riFilings_link" class="co_tabLink" href="/RelatedInformation/I0a98a911a82a11d9bdd1cfdd544ca3a4/riFilings.html?originationContext=documentTab&amp;transitionType=Filings&amp;contextData=(sc.CustomDigest)&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;rulebookMode=false" hiddenhref="/RelatedInformation/I0a98a911a82a11d9bdd1cfdd544ca3a4/riFilings.html?originationContext=documentTab&amp;transitionType=Filings&amp;contextData=(sc.CustomDigest)&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;rulebookMode=false">
			
			<span>
				Filings 
			 (96)</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>







<li id="kcNegativeTreatmentTab" class="co_tabLeft" countstatus="" categoryenum="kcNegativeTreatment">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcNegativeTreatment_link" class="co_tabLink" href="/RelatedInformation/I0a98a911a82a11d9bdd1cfdd544ca3a4/kcNegativeTreatment.html?originationContext=documentTab&amp;transitionType=NegativeTreatment&amp;contextData=(sc.CustomDigest)&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;rulebookMode=false" hiddenhref="/RelatedInformation/I0a98a911a82a11d9bdd1cfdd544ca3a4/kcNegativeTreatment.html?originationContext=documentTab&amp;transitionType=NegativeTreatment&amp;contextData=(sc.CustomDigest)&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;rulebookMode=false">
			
			<span>
				Negative Treatment 
			 (9)</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>







<li id="kcJudicialHistoryTab" class="co_tabLeft" countstatus="" categoryenum="kcJudicialHistory">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcJudicialHistory_link" class="co_tabLink" href="/RelatedInformation/I0a98a911a82a11d9bdd1cfdd544ca3a4/kcJudicialHistory.html?originationContext=documentTab&amp;transitionType=History&amp;contextData=(sc.CustomDigest)&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;rulebookMode=false" hiddenhref="/RelatedInformation/I0a98a911a82a11d9bdd1cfdd544ca3a4/kcJudicialHistory.html?originationContext=documentTab&amp;transitionType=History&amp;contextData=(sc.CustomDigest)&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;rulebookMode=false">
			
			<span>
				History 
			 (34)</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>







<li id="kcCitingReferencesTab" class="co_tabLeft co_dropdownTab" countstatus="" categoryenum="kcCitingReferences">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcCitingReferences_link" class="co_tabLink" href="/RelatedInformation/I0a98a911a82a11d9bdd1cfdd544ca3a4/kcCitingReferences.html?originationContext=documentTab&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;rulebookMode=false" hiddenhref="/RelatedInformation/I0a98a911a82a11d9bdd1cfdd544ca3a4/kcCitingReferences.html?originationContext=documentTab&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;rulebookMode=false">
			
			<span>
				Citing References 
			 (2,156)</span>
		</a>





<span id="co_kcCitingReferencesNavAnchor" class="co_dropdownArrowCollapsed">Navigate Citing References</span>
		<div class="co_clear"></div> 
	</h2>
		<div id="co_kcCitingReferencesNavContent" class="co_dropdownBoxCollapsed" style="display:none;"></div>
</li>







<li id="kcTableOfAuthoritiesTab" class="co_tabLeft" countstatus="" categoryenum="kcTableOfAuthorities">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcTableOfAuthorities_link" class="co_tabLink" href="/RelatedInformation/I0a98a911a82a11d9bdd1cfdd544ca3a4/kcTableOfAuthorities.html?originationContext=documentTab&amp;transitionType=TableOfAuthorities&amp;contextData=(sc.CustomDigest)&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;rulebookMode=false" hiddenhref="/RelatedInformation/I0a98a911a82a11d9bdd1cfdd544ca3a4/kcTableOfAuthorities.html?originationContext=documentTab&amp;transitionType=TableOfAuthorities&amp;contextData=(sc.CustomDigest)&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;rulebookMode=false">
			
			<span>
				Table of Authorities 
			</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>




<li id="co_powByKCContainer">
	<a id="co_powByKC" href="javascript:void(0)">
		Powered by KeyCite
	</a>
</li>

			</ul>
		</div>
		<div class="co_clear"></div>
		<div id="co_docToolbarContainer" class="">
			<div id="co_docToolbar"><div><ul id="co_docToolbarMenuLeft"><li id="co_docToolbarBackToResults"><div id="co_documentFooterBreadcrumb"><a class="co_tbButton" href="/Search/Results.html?jurisdiction=CTAF&amp;contentType=CUSTOMDIGEST&amp;querySubmissionGuid=i0ad62aef0000016306ea58342bf062c8&amp;tocGuid=I4aee2539c6f64c1812a4c2f3395c2607&amp;categoryPageUrl=Home%2FWestKeyNumberSystem&amp;searchId=i0ad62aef0000016306ea4650fbf37b75&amp;collectionSet=w_cs_cd_toc&amp;transitionType=ReturnToList&amp;contextData=%28sc.CustomDigest%29#I0a98a911a82a11d9bdd1cfdd544ca3a4"><span class="icon25 icon_back_arrow btnOffset"></span>Return to list</a></div></li><li id="co_docToolbarDocumentNavigation"><div id="co_documentFooterResultsNavigation" class="co_prevNextNavigation"><button title="Previous Document" id="co_documentFooterResultsNavigationPrevious" class="co_prev co_tbButton">
	                <span class="icon25 icon_prev_arrow">Previous Document</span>
                </button>
                <span class="co_navigationText"><strong>122</strong> of <strong>718 results</strong></span>
                <button title="Next Document" id="co_documentFooterResultsNavigationNext" class="co_next co_tbButton">
                    <span class="icon25 icon_next_arrow">Next Document</span>
                </button></div></li></ul><ul id="co_docToolbarMenuRight"><li id="co_docToolbarMenuRightChildWidget0" class="co_hideState"></li><li id="co_docHeaderSearchGrading"></li><li id="co_docToolbarGoTo"><div class="co_dropdownTabCollapsed"><div class="co_dropdownTab"><a href="javascript:void(0);" class="co_dropdownBoxanchorLabel" role="button">Go to</a><a href="javascript:void(0);" role="button" class="co_dropdownArrowCollapsed">Open Skip to Menu</a></div></div><div id="co_docGoToWidget" class="co_dropdownBoxCollapsed"><div class="co_dropdownBoxContent" id="co_skipTo"><div class="co_dropdownBoxContentRight"><div><div><a href="#co_synopsis">Synopsis</a></div><div><a href="#co_headnoteHeader">West Headnotes</a></div><div><a href="#co_attorneysAndLawFirms">Attorneys and Law Firms</a></div><div><a href="#co_opinion">Opinion</a></div><div><a href="#co_concurrance_opinion">Concurring Opinion</a></div><div><a href="#co_allCitations">All Citations</a></div></div></div></div><div id="co_starPage" class="co_dropdownBoxContent"><div class="co_dropdownBoxContentRight"><label for="co_document_starPage_starPageNavInput">Page #</label><input id="co_document_starPage_starPageNavInput" maxlength="6" size="6" type="text"><span id="co_document_starPage_starPageNavGo" class="co_primaryBtn">Go</span><div id="co_document_starPage_starPageNavError"></div><div class="co_clear"></div></div></div></div></li><li id="co_docToolbarTocNavigation"></li><li id="co_docToolbarTocFlyout"></li><li id="co_docToolbarMenuRightChildWidget5"></li><li id="co_docToolbarMenuRightChildWidget6"></li><li id="co_docToolbarMenuRightChildWidget7" class="co_toolbarSeparator"></li><li id="co_docToolbarSearchWithinDocument"><div id="co_docSearchWithinContainer"><a role="button" href="javascript:void(0);" class="co_dropdownTitle" title="Search text in this document">Search Within this Document</a>
<div id="co_docSearchWithinDropdownContainer">
	<div id="co_docSearchWithinDropdownContainerInner">
		<div id="co_docSearchWithinDropdownContainerInnerContent" class="co_dropdownBoxCollapsed">
			<!-- toggle between co_dropDownBoxCollapsed and co_dropdownBoxExpanded to show/hide -->
			<div class="co_dropdownBoxHeader">
				<span></span>
			</div>
			<div class="co_dropdownBoxContent">
				<div class="co_dropdownBoxContentRight">
					<div id="co_docSearchWithin_input">
						
<div id="co_docSearchWithin_searchInputContainer_withRecentSearch">
	<a id="co_searchLast10Link" class="co_recentSearchesLink" href="javascript:void(0);" title="Recent Searches">
		Last 10 Searches
	</a>
	<div class="co_textarea">
		<textarea id="co_docSearchWithin_searchInput_withRecentSearch" rows="1" autocorrect="off" autocapitalize="off" role="textbox" aria-label="Enter term to search for in current document"></textarea>
	</div>
	<div id="co_documentRecentQueryListBox" class="co_hideState"><ul class="co_searchSuggestionContainer" id="co_documentSearchLast10List"></ul></div>
</div>

						<input id="co_docSearchWithin_searchButton" class="co_secondaryBtn" value="Search" role="button" aria-label="Search Within this Document" type="button">
					</div>
					<div class="co_prevNextNavigation co_hideState">
						<button title="Previous Term" class="co_prev co_tbButton">
							<span class="icon25 icon_prev_arrow">Previous Term</span>
						</button>
						<button title="Next Term" class="co_next co_tbButton">
							<span class="icon25 icon_next_arrow">Next Term</span>
						</button>
						<span class="co_navigationText co_hideState"></span>
					</div>
					<button id="co_docSearchWithin_help" class="co_helpLink">Terms &amp;amp; Connectors</button>
					<button id="co_docSearchWithinCloseButton" class="co_widget_closeIcon">Close</button>
					<div id="co_docSearchWithinMessage"></div>
					<div class="co_clear"></div>
				</div>
				<div id="searchWithinTncContainer" class="co_hideState"><div id="co_search_advancedSearch_tncLegendBox">  <h2 id="co_search_advancedSearch_tncHelpTitle">Connectors and Expanders</h2>  <a id="co_search_advancedSearch_tncHelpLink" href="#" class="co_hideState">Help</a>  <dl id="co_search_advancedSearch_tncLegendList">    <dt>&amp;</dt><dd>AND</dd>    <dt>/s</dt><dd>In same sentence</dd>    <dt>or</dt><dd>OR</dd>    <dt>+s</dt><dd>Preceding within sentence</dd>    <dt>/p</dt><dd>In same paragraph</dd>    <dt>""</dt><dd>Phrase</dd>    <dt>+p</dt><dd>Preceding within paragraph</dd>    <dt>%</dt><dd>But not</dd>    <dt>/n</dt><dd>Within n terms of</dd>    <dt>!</dt><dd>Root expander</dd>    <dt>+n</dt><dd>Preceding within n terms of</dd>    <dt>*</dt><dd>Universal character</dd>    <dt>#</dt><dd>Prefix to turn off plurals and equivalents</dd>  </dl></div></div>
			</div>
			<div class="co_dropdownBoxFooter">
				<span></span>
			</div>
		</div>
	</div>
</div></div></li><li id="co_docToolbarDisplayOptions"><a role="button" id="co_displayOptionsLink" class="co_tbButton" href="javascript:void(0);" title="Display Options"><span class="icon25 icon_text_resize">Display Options</span></a></li><li id="co_docToolbarDeliveryWidget"><div id="deliveryWidget1" class="co_dropDownMenu collapsed"><div class="co_dropDownButton"><a role="button" id="deliveryLink1" title="Email" class="co_tbButton" href="javascript:void(0);"><span class="icon25 icon_email">Email</span></a><a href="javascript:void(0);" class="co_tbButton co_dropDownAnchor" role="button" id="deliveryDropButton1" aria-label="Delivery menu" title="Delivery menu" aria-describedby="navigation1"><span class="icon25 icon_down_blue_arrow"></span></a><span id="navigation1" class="co_accessibilityLabel">Enter to open, tab to navigate, enter to select</span></div><div id="deliveryWidgetMenu1" class="co_dropDownMenuContent" role="document"><ul class="co_dropDownMenuList checkmarks icons" role="listbox" aria-multiselectable="true" aria-hidden="false" aria-expanded="true"><li id="deliveryRow1Email" name="Email" role="presentation" class="checked"><a title="Email" id="deliveryLinkRow1Email" role="option" aria-posinset="1" aria-setsize="3" class="co_deliveryLinkOptions" tabindex="0" aria-selected="true"><span class="icon25 icon_email"></span>Email</a></li><li id="deliveryRow1Print" name="Print" role="presentation"><a title="Print" id="deliveryLinkRow1Print" role="option" aria-posinset="2" aria-setsize="3" class="co_deliveryLinkOptions" tabindex="0" aria-selected="false"><span class="icon25 icon_print"></span>Print</a></li><li id="deliveryRow1Download" name="Download" role="presentation"><a title="Download" id="deliveryLinkRow1Download" role="option" aria-posinset="3" aria-setsize="3" class="co_deliveryLinkOptions" tabindex="0" aria-selected="false"><span class="icon25 icon_download"></span>Download</a></li></ul><div class="co_deliveryWidgetMenuFooter"></div></div><div id="co_deliveryWidget_Message1"></div></div></li><li id="co_docToolbarReadingModeWidget"><a role="button" id="co_fullscreenModeLink" class="co_tbButton" href="javascript:void(0);" title="Fullscreen Mode"><span class="icon25 icon_fullscreen">Fullscreen Mode</span></a></li></ul></div></div> 
			<div class="co_clear"></div>
		</div>
	</div>
</div>

				<div id="coid_website_errorsSummaryPlaceHolder"><div class="co_infoBox failure" style="display: none;"><div class="co_infoBox_container"><div class="co_infoBox_outer"><div class="co_infoBox_inner"><a id="co_website_errorSumarryCloseLink" class="co_infoBox_closeButton">Close</a><div class="co_infoBox_message" tabindex="-1">Sorry, there was an error on this page.<a href="javascript:void(0);" id="co_website_errorSummaryToggleLink">More info</a><a href="javascript:void(0);" id="co_website_errorSummaryToggleLinkLessInfo" style="display: none; margin-left: 6px;">Less info</a><ul class="co_website_errorsSummaryList" style="display: none;"></ul></div></div></div></div></div></div>
				<div id="coid_website_messagePlaceholder"></div>







				<div id="test_hplink"></div>
				<div class="co_scrollWrapper">





							<div id="coid_website_documentWidgetDiv" class=" co_khSpeedReadExpandAll">
<div id="co_briefItDiv" class="co_excludeAnnotations"><button id="co_briefItButton" class="co_primaryBtn co_floatRight">Brief It</button><div class="undefined"></div></div><div id="co_document" class="co_addFocusCorrection"><div id="co_document_0" class="co_document co_caselawNRS"><div id="co_readingModeKC" class="co_keyCiteFlagWidgetContainer co_excludeAnnotations"><div id="co_readingModeCitatorFlag"><span class="co_citatorFlag"><a href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;transitionType=Document&amp;originationContext=docHeaderSntTitleFlag&amp;contextData=(sc.CustomDigest)"><img class="crsw_DocumentIndicator" alt="KeyCite Yellow Flag - Negative Treatment" src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v1/flag_yellow.png" title="KeyCite Yellow Flag - Negative Treatment"></a><span class="co_citatorFlagText">KeyCite Yellow Flag - Negative Treatment</span></span></div><div id="co_readingModeNegativeTreatment"><span id="NegativeTreatmentWidget_I0a98a911a82a11d9bdd1cfdd544ca3a4"><span class="co_snt_treatmentPhrase">Distinguished by </span><a href="https://1.next.westlaw.com/Document/I5337d32605c311da8ac8f235252e36df/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3Fguid%3DI5337d32605c311da8ac8f235252e36df%26ss%3D2006436300%26ds%3D2007091567&amp;listSource=RelatedInfo&amp;list=NegativeCitingReferences&amp;rank=0&amp;originationContext=docHeader&amp;transitionType=NegativeTreatment&amp;contextData=%28sc.CustomDigest%29">Datamize, LLC v. Plumtree Software, Inc.</a><span>, </span><span class="co_snt_courtLine">Fed.Cir.(Cal.), </span><span class="co_snt_dateFiled">August 5, 2005</span></span></div></div><input id="co_keyCiteFlagPlaceHolder" type="hidden"><input id="co_document_starPageMetadata" value="{ &quot;citations&quot;: { &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;:&quot;403 F.3d 1331&quot; }, &quot;pubs&quot;: { &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;:&quot;506&quot; } }" alt="metadata" type="hidden"><div><a href="https://1.next.westlaw.com/Link/Document/Blob/I2B58C4AA1DD211B29E4B380092065EF5/403_F.3d_1331.pdf?targetType=NRS&amp;originationContext=pagepdflink&amp;transitionType=DocumentImage&amp;uniqueId=68c59d35-4f40-4e6f-b101-2f13e3f619ca&amp;contextData=(sc.CustomDigest)" class="co_blobLink" type="application/pdf"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v1/co_pdf-icon.gif" class="co_pdfIcon" alt="PDF">​Original Image of 403 F.3d 1331 (PDF)</a></div><div class="co_cites">403 F.3d 1331</div><input id="co_document_paraNumbersSourceCiteMetadata" value="{ &quot;paraNumbersSourceCite&quot;: &quot;403 F.3d 1331&quot;, &quot;publicationNumber&quot;: &quot;506&quot; }" alt="metadata" type="hidden"><div class="co_contentBlock co_briefItState co_courtBlock"><div><div class="co_hAlign2">United States Court of Appeals,</div>Federal Circuit.</div></div><div class="co_title"><div class="co_suit"><div class="co_partyLine">SMITHKLINE BEECHAM CORPORATION and Beecham Group, P.L.C., Plaintiffs–Appellants,</div><div>v.</div><div class="co_partyLine">APOTEX CORP., Apotex, Inc., and TorPharm, Inc., Defendants–Cross Appellants.</div></div></div><div class="co_docketDate"><div class="co_contentBlock co_briefItState co_docketBlock"><span>Nos. 03–1285, 03–1313.</span></div><div class="co_date"><span>DECIDED: April 8, 2005.</span><span>Rehearing En Banc Denied June 15, 2005.</span></div></div><div class="co_contentBlock co_briefItState co_synopsis"><h2 id="co_synopsis" class="co_printHeading">Synopsis</h2><div><div class="co_paragraph"><div class="co_paragraphText"><strong>Background:</strong> Pharmaceutical drug manufacturer brought action against generic drug manufacturer alleging infringement of patent for active ingredient in antidepressant drug. The United States District Court for the Northern District of Illinois, <a id="co_link_I66577dbb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0258143701&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Richard A. Posner</a>, Circuit Judge, sitting by designation, granted judgment for generic manufacturer, <a id="co_link_I66577dbc232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">247 F.Supp.2d 1011.</a> Plaintiff appealed.</div></div></div><div class="co_contentBlock co_briefItState co_synopsisHolding"><div class="co_paragraph"><div class="co_paragraphText"><strong>Holdings:</strong> Vacating its prior opinion, <a id="co_link_I66577dbd232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2004356611&amp;pubNum=506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">365 F.3d 1306,</a> upon rehearing en banc, the Court of Appeals, <a id="co_link_I66577dbf232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0168544101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Rader</a>, Circuit Judge, held that:</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F112006436300" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">1</a> patent claim encompassed, without limitation, paroxetine hydrochloride (PHC) hemihydrate;</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F142006436300" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">2</a> patent was not invalid for indefiniteness; and</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F192006436300" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">3</a> patent was invalid as inherently anticipated.</div></div></div><div class="co_paragraph"><div class="co_paragraphText">Affirmed on other grounds.</div></div><div class="co_paragraph"><div class="co_paragraphText">Gajarsa, Circuit Judge, filed concurring opinion.</div></div></div><div id="co_headnotes" class="co_headnotes co_fancyHeadnotes"><h2 id="co_headnoteHeader" class="co_headnoteHeader co_printHeading"><span class="co_headnoteHeaderSpan">West Headnotes (26)</span><a id="co_headnoteExpandCollapseLink" class="co_accLink co_excludeAnnotations co_disableHighlightFeatures" href="javascript:void(0);" role="button">Collapse West Headnotes</a></h2><div class="co_headnotesContentContainer"><div id="co_expandedHeadnotes"><div id="co_headnoteTools"><a id="co_headnotesShowOrHideFancy" href="javascript:void(0);" class="co_fancyHeadnotesShowHide co_excludeAnnotations co_disableHighlightFeatures">Change View</a></div><div class="co_headnoteRow" id="co_anchor_2006436300001"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F12006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_1"><a href="#co_anchor_B12006436300" class="co_internalLink">1</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EYKAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Federal Courts</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EYMAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Findings</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0E2NAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Federal Courts</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EKAAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603(2)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">“Clearly erroneous” standard of review in general</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Court of Appeals reviews a district court's judgment following a bench trial for errors of law or clearly erroneous findings of fact.</div></div><div id="co_headnoteId_200643630000120180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E6AAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630000120180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 1"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">6 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dc1232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170B</a></span><span class="co_headnoteTopicKey">Federal Courts</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dc2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII</a></span><span class="co_headnoteTopicKey">Courts of Appeals</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dc3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)</a></span><span class="co_headnoteTopicKey">Scope and Extent of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dc4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)2/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)2</a></span><span class="co_headnoteTopicKey">Standard of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dc5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3576/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3576</a></span><span class="co_headnoteTopicKey">Procedural Matters</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dc6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3603</a></span><span class="co_headnoteTopicKey">Findings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dc7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603(1)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3603(1)</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 170Bk848)</span></span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dc8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170B</a></span><span class="co_headnoteTopicKey">Federal Courts</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dc9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII</a></span><span class="co_headnoteTopicKey">Courts of Appeals</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dca232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)</a></span><span class="co_headnoteTopicKey">Scope and Extent of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dcb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)2/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)2</a></span><span class="co_headnoteTopicKey">Standard of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dcc232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3576/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3576</a></span><span class="co_headnoteTopicKey">Procedural Matters</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dcd232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3603</a></span><span class="co_headnoteTopicKey">Findings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dce232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603(2)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3603(2)</a></span><span class="co_headnoteTopicKey">“Clearly erroneous” standard of review in general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 170Bk850.1)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300002"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F22006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_2"><a href="#co_anchor_B22006436300" class="co_internalLink">2</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ERBAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EHDAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1555/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">In general;  comparison with patent claims</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Patent infringement proceeds under a two-step analysis; first, a court interprets the claims to determine their proper scope and meaning, and then the court measures the accused product or process against the standard of the properly interpreted claims.</div></div><div id="co_headnoteId_200643630000220180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E3DAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630000220180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 2"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">5 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dcf232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dd0232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dd1232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(A)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dd2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1554/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1554</a></span><span class="co_headnoteTopicKey">Substantial Identity of Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dd3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1555/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1555</a></span><span class="co_headnoteTopicKey">In general;  comparison with patent claims</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k226.6)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300003"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F32006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_3"><a href="#co_anchor_B32006436300" class="co_internalLink">3</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EOEAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EAGAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1965/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Scope, Standard, and Extent of Review</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Court of Appeals reviews patent claim construction without deference.</div></div><div id="co_headnoteId_200643630000320180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EDHAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630000320180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 3"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">2 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dd4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dd5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dd6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dd7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)7/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)7</a></span><span class="co_headnoteTopicKey">Appellate Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dd8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1965/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1965</a></span><span class="co_headnoteTopicKey">Scope, Standard, and Extent of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dd9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1966/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1966</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k324.5)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300004"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F42006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_4"><a href="#co_anchor_B42006436300" class="co_internalLink">4</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EVHAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EDKAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1970(15)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Infringement or noninfringement</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Court of Appeals reviews the second step of the patent infringement analysis, measurement of the accused product or process against the claim, as a question of fact.</div></div><div id="co_headnoteId_200643630000420180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EYKAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630000420180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 4"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">2 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dda232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577ddb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577ddc232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577ddd232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)7/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)7</a></span><span class="co_headnoteTopicKey">Appellate Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dde232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1965/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1965</a></span><span class="co_headnoteTopicKey">Scope, Standard, and Extent of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577ddf232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1970/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1970</a></span><span class="co_headnoteTopicKey">Particular Matters</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577de0232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1970(15)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1970(15)</a></span><span class="co_headnoteTopicKey">Infringement or noninfringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k324.55(5))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300005"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F52006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_5"><a href="#co_anchor_B52006436300" class="co_internalLink">5</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EKLAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E3MAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1965/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Scope, Standard, and Extent of Review</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">The review of patent indefiniteness proceeds as a question of law without deference. <a id="co_link_I66577de7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 112</a>.</div></div><div id="co_headnoteId_200643630000520180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E6NAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630000520180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 5"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">6 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577de1232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577de2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577de3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577de4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)7/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)7</a></span><span class="co_headnoteTopicKey">Appellate Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577de5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1965/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1965</a></span><span class="co_headnoteTopicKey">Scope, Standard, and Extent of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577de6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1966/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1966</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k324.5)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300006"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F62006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_6"><a href="#co_anchor_B62006436300" class="co_internalLink">6</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E1OAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ECQAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1341/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">State of the art</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Patent claim interpretation requires the court to ascertain the meaning of the claim to one of ordinary skill in the art at the time of invention.<input id="co_docMarker_0" type="hidden"></div></div><div id="co_headnoteId_200643630000620180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EXQAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630000620180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 6"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">21 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577de8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577de9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dea232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(A)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577deb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1341/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1341</a></span><span class="co_headnoteTopicKey">State of the art</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k161)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300007"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F72006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_7"><a href="#co_anchor_B72006436300" class="co_internalLink">7</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EJRAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ERSAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1312/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Intrinsic evidence in general</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0EGTAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E3UAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1320/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Context</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0ERVAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EZWAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1344/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Extrinsic Evidence</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Patent claim interpretation requires a court to place the claim language in its proper technological and temporal context; best tools for this enterprise are the various forms of intrinsic evidence and, when appropriate, extrinsic evidence.</div></div><div id="co_headnoteId_200643630000720180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E3XAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630000720180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 7"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">3 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dec232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577ded232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dee232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(A)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577def232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1312/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1312</a></span><span class="co_headnoteTopicKey">Intrinsic evidence in general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k159)</span></span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577df0232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577df1232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577df2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(A)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577df3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1314/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1314</a></span><span class="co_headnoteTopicKey">Claims and Limitations;  Language of Patent</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577df4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1320/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1320</a></span><span class="co_headnoteTopicKey">Context</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k165(3))</span></span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577df5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577df6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577df7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(A)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577df8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1344/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1344</a></span><span class="co_headnoteTopicKey">Extrinsic Evidence</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577df9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1345/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1345</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k159)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300008"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F82006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_8"><a href="#co_anchor_B82006436300" class="co_internalLink">8</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EOYAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EWZAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1313/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Multiple sources for construction</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">In patent claim interpretation, the intrinsic evidence, i.e., the patent itself, including the claims, the specification and, if in evidence, the prosecution history, is the most significant source of the legally operative meaning of disputed claim language.</div></div><div id="co_headnoteId_200643630000820180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EP1AE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630000820180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 8"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">7 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dfa232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dfb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dfc232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(A)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dfd232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1313/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1313</a></span><span class="co_headnoteTopicKey">Multiple sources for construction</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k168(2.1), 291k167(1), 291k165(1))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300009"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F92006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_9"><a href="#co_anchor_B92006436300" class="co_internalLink">9</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EH2AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E43AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1319/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Claims as measure of patentee's rights</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">At all times, the language of the patent claims governs their scope and meaning.</div></div><div id="co_headnoteId_200643630000920180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ES4AE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630000920180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 9"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">2 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dfe232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577dff232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e00232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(A)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e01232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1314/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1314</a></span><span class="co_headnoteTopicKey">Claims and Limitations;  Language of Patent</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e02232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1319/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1319</a></span><span class="co_headnoteTopicKey">Claims as measure of patentee's rights</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k165(2))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300010"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F102006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_10"><a href="#co_anchor_B102006436300" class="co_internalLink">10</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EE5AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EM6AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1341/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">State of the art</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Unless the intrinsic evidence compels a contrary conclusion, the patent claim language carries the meaning accorded those words in the usage of skilled artisans at the time of invention.</div></div><div id="co_headnoteId_200643630001020180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ECAAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630001020180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 10"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">7 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e03232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e04232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e05232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(A)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e06232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1341/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1341</a></span><span class="co_headnoteTopicKey">State of the art</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k161)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300011"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F112006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_11"><a href="#co_anchor_B112006436300" class="co_internalLink">11</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EUAAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E3BAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1383/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Chemicals</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Patent claim encompassed, without limitation, paroxetine hydrochloride (PHC) hemihydrate, a crystal form of paroxetine hydrochloride that contained one molecule of bound water for every two molecules of paroxetine hydrochloride in the crystal structure; although specification discussed superior handling properties of hemihydrate form that improved manufacture of PHC, specification disclosed PHC hemihydrate as compound without reference to its commercial applications, and nothing in patent limited that structural compound to its commercial embodiments.</div></div><div id="co_headnoteId_200643630001120180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E6CAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630001120180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 11"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">5 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e07232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e08232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e09232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(C)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(C)</a></span><span class="co_headnoteTopicKey">Particular Fields of Invention</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e0a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1383/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1383</a></span><span class="co_headnoteTopicKey">Chemicals</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e0b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1384/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1384</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k179)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300012"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F122006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_12"><a href="#co_anchor_B122006436300" class="co_internalLink">12</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ERDAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EHFAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1408/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Drugs and medicines</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">In the context of claim interpretation on a drug patent, description of characteristics does not redefine a compound with an established and unambiguous structural definition.</div></div><div id="co_headnoteId_200643630001220180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E3FAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630001220180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 12"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">1 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e0c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e0d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e0e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(C)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(C)</a></span><span class="co_headnoteTopicKey">Particular Fields of Invention</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e0f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1406/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1406</a></span><span class="co_headnoteTopicKey">Health Care and Medical Products</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e10232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1408/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1408</a></span><span class="co_headnoteTopicKey">Drugs and medicines</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k179)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300013"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F132006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_13"><a href="#co_anchor_B132006436300" class="co_internalLink">13</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EOGAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EEIAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1322/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Reading limitations or elements into claims, or disregarding limitations or elements</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">The scope of patent claims can neither be broadened nor narrowed based on abstract policy considerations regarding the effect of a particular claim meaning.</div></div><div id="co_headnoteId_200643630001320180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EZIAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630001320180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 13"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">4 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e11232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents<input id="co_docMarker_1" type="hidden"></span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e12232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e13232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(A)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e14232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1314/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1314</a></span><span class="co_headnoteTopicKey">Claims and Limitations;  Language of Patent</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e15232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1322/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1322</a></span><span class="co_headnoteTopicKey">Reading limitations or elements into claims, or disregarding limitations or elements</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k165(4))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300014"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F142006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_14"><a href="#co_anchor_B142006436300" class="co_internalLink">14</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ELJAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EBLAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k822/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Particular products or processes</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Patent on drug was not invalid for indefiniteness where claim unambiguously identified scope as “[c]rystalline paroxetine hydrochloride hemihydrate,” which was discernible chemical structure. <a id="co_link_I66577e1b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 112</a>.</div></div><div id="co_headnoteId_200643630001420180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EWLAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630001420180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 14"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">5 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e16232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e17232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e18232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(F)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(F)</a></span><span class="co_headnoteTopicKey">Other Challenges to Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e19232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k815/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k815</a></span><span class="co_headnoteTopicKey">Ambiguity, Uncertainty, or Indefiniteness</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e1a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k822/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k822</a></span><span class="co_headnoteTopicKey">Particular products or processes</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k101(6))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300015"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F152006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_15"><a href="#co_anchor_B152006436300" class="co_internalLink">15</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ERMAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EHOAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k914/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Requisites and sufficiency</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">To satisfy the requirement that the specification of a patent must conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention, the claim, read in light of the specification, must apprise those skilled in the art of the scope of the claim. <a id="co_link_I66577e21232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 112</a>.</div></div><div id="co_headnoteId_200643630001520180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E3OAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630001520180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 15"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">13 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e1c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e1d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291IV/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291IV</a></span><span class="co_headnoteTopicKey">Patent Applications and Proceedings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e1e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291IV(A)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291IV(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e1f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k910/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k910</a></span><span class="co_headnoteTopicKey">Assertion of Claims</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e20232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k914/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k914</a></span><span class="co_headnoteTopicKey">Requisites and sufficiency</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k101(5))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300016"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F162006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_16"><a href="#co_anchor_B162006436300" class="co_internalLink">16</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EXPAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E6QAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k815/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Ambiguity, Uncertainty, or Indefiniteness</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Patent claims need not be plain on their face in order to avoid condemnation for indefiniteness; rather, the claims must be amenable to construction, however difficult that task may be. <a id="co_link_I66577e27232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 112</a>.</div></div><div id="co_headnoteId_200643630001620180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ECSAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630001620180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 16"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">3 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e22232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e23232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e24232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(F)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(F)</a></span><span class="co_headnoteTopicKey">Other Challenges to Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e25232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k815/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k815</a></span><span class="co_headnoteTopicKey">Ambiguity, Uncertainty, or Indefiniteness</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e26232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k816/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k816</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k101(6))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300017"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F172006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_17"><a href="#co_anchor_B172006436300" class="co_internalLink">17</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E4SAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EFUAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k815/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Ambiguity, Uncertainty, or Indefiniteness</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">A compound claim, to be definite, must apprise a skilled artisan of the bounds of the patent claim. <a id="co_link_I66577e2d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 112</a>.</div></div><div id="co_headnoteId_200643630001720180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EIVAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630001720180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 17"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">19 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e28232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e29232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e2a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(F)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(F)</a></span><span class="co_headnoteTopicKey">Other Challenges to Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e2b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k815/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k815</a></span><span class="co_headnoteTopicKey">Ambiguity, Uncertainty, or Indefiniteness</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e2c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k816/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k816</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k101(6))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300018"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F182006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_18"><a href="#co_anchor_B182006436300" class="co_internalLink">18</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EDWAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ELXAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k815/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Ambiguity, Uncertainty, or Indefiniteness</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">The test for indefiniteness does not depend on a potential infringer's ability to ascertain the nature of its own accused product to determine patent infringement, but instead it depends on whether the claim delineates to a skilled artisan the bounds of the invention. <a id="co_link_I66577e33232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 112</a>.</div></div><div id="co_headnoteId_200643630001820180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EOYAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630001820180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 18"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">39 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e2e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e2f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e30232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(F)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(F)</a></span><span class="co_headnoteTopicKey">Other Challenges to Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e31232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k815/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k815</a></span><span class="co_headnoteTopicKey">Ambiguity, Uncertainty, or Indefiniteness</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e32232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k816/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k816</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k101(6))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300019"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F192006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_19"><a href="#co_anchor_B192006436300" class="co_internalLink">19</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EJZAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EJ2AG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k548/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Drugs and medicines</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Patent on paroxetine hydrochloride (PHC) hemihydrate was invalid as inherently anticipated by prior art patent on PHC anhydrate, although prior art did not discuss PHC hemihydrate, since practicing of prior art necessarily and naturally resulted in derivative production of at least trace amounts PHC hemihydrate. <a id="co_link_I66577e3a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. § 102(b)</a>.</div></div><div id="co_headnoteId_200643630001920180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E52AG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630001920180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 19"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">26 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e34232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e35232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e36232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)</a></span><span class="co_headnoteTopicKey">Novelty;  Anticipation</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e37232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)2/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)2</a></span><span class="co_headnoteTopicKey">Particular Fields of Invention</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e38232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k546/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k546</a></span><span class="co_headnoteTopicKey">Health Care and Medical Products</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e39232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k548/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k548</a></span><span class="co_headnoteTopicKey">Drugs and medicines</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k66(1.12))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300020"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F202006436300" tabindex="0"><span class="co_headnoteNumber" id="co_anchor_headNote_20"><a href="#co_anchor_B202006436300" class="co_internalLink">20</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E63AG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E44AG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Eligible Subject Matter</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0E35AG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ESABG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1319/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Claims as measure of patentee's rights</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">The scope of patent claims is not relevant to subject matter eligibility; subject matter does not take on a different eligibility status with adjustments in the scope of the proposed claim. <a id="co_link_I66577e44232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 101</a>.</div></div><div id="co_headnoteId_200643630002020180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EHBBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630002020180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 20"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e3b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e3c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity<input id="co_docMarker_2" type="hidden"></span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e3d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e3e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k441/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k441</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k2)</span></span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e3f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e40232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e41232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(A)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e42232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1314/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1314</a></span><span class="co_headnoteTopicKey">Claims and Limitations;  Language of Patent</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e43232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1319/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1319</a></span><span class="co_headnoteTopicKey">Claims as measure of patentee's rights</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k165(2))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300021"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F212006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_21"><a href="#co_anchor_B212006436300" class="co_internalLink">21</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ECCBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EQEBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k487(2)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Enablement</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0EFFBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EFHBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k599/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Enablement</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">For prior art to anticipate a patent claim it must be sufficient to enable one with ordinary skill in the art to practice the invention. <a id="co_link_I66577e52232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. § 102(b)</a>.</div></div><div id="co_headnoteId_200643630002120180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E1HBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630002120180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 21"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">55 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e45232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e46232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e47232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)</a></span><span class="co_headnoteTopicKey">Novelty;  Anticipation</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e48232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)1/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)1</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e49232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k483/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k483</a></span><span class="co_headnoteTopicKey">Prior Art and Relation of Claimed Invention Thereto</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e4a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k487/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k487</a></span><span class="co_headnoteTopicKey">Contents and Sufficiency of Prior Art in General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e4b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k487(2)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k487(2)</a></span><span class="co_headnoteTopicKey">Enablement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k65)</span></span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e4c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e4d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e4e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)</a></span><span class="co_headnoteTopicKey">Novelty;  Anticipation</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e4f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)4/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)4</a></span><span class="co_headnoteTopicKey">Prior Description in Printed Publication</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e50232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k597/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k597</a></span><span class="co_headnoteTopicKey">Sufficiency of Description</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e51232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k599/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k599</a></span><span class="co_headnoteTopicKey">Enablement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k69)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300022"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F222006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_22"><a href="#co_anchor_B222006436300" class="co_internalLink">22</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EWIBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EIKBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k582/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Questions of law or fact</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Whether a prior art reference is enabling is a question of patent law based upon underlying factual findings. <a id="co_link_I66577e58232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. § 102(b)</a>.</div></div><div id="co_headnoteId_200643630002220180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E4KBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630002220180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 22"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">27 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e53232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e54232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e55232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)</a></span><span class="co_headnoteTopicKey">Novelty;  Anticipation</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e56232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)3/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)3</a></span><span class="co_headnoteTopicKey">Evidence and Determination</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e57232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k582/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k582</a></span><span class="co_headnoteTopicKey">Questions of law or fact</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k314(5))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300023"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F232006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_23"><a href="#co_anchor_B232006436300" class="co_internalLink">23</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EZLBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ELNBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k582/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Questions of law or fact</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Anticipation in a patent invalidity claim is a question of fact. <a id="co_link_I66577e5e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. § 102(b)</a>.</div></div><div id="co_headnoteId_200643630002320180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EAOBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630002320180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 23"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">19 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e59232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e5a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e5b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)</a></span><span class="co_headnoteTopicKey">Novelty;  Anticipation</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e5c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)3/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)3</a></span><span class="co_headnoteTopicKey">Evidence and Determination</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e5d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k582/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k582</a></span><span class="co_headnoteTopicKey">Questions of law or fact</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k314(5))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300024"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F242006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_24"><a href="#co_anchor_B242006436300" class="co_internalLink">24</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E3OBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E3QBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k548/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Drugs and medicines</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Mere disclosure that practicing of prior art patent on paroxetine hydrochloride (PHC) anhydrate necessarily and naturally resulted in derivative production of at least trace amounts of PHC hemihydrate was sufficient to show that patent on PHC hemihydrate was invalid as inherently anticipated, and, consequently, competitor was not required to show that it was impossible to make PHC anhydrate that contained no PHC hemihydrate to prove anticipation claim. <a id="co_link_I66577e65232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. § 102(b)</a>.</div></div><div id="co_headnoteId_200643630002420180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ERRBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630002420180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 24"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">8 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e5f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e60232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e61232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)</a></span><span class="co_headnoteTopicKey">Novelty;  Anticipation</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e62232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(C)2/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(C)2</a></span><span class="co_headnoteTopicKey">Particular Fields of Invention</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e63232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k546/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k546</a></span><span class="co_headnoteTopicKey">Health Care and Medical Products</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e64232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k548/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k548</a></span><span class="co_headnoteTopicKey">Drugs and medicines</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k66(1.12))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300501"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_2006436300"><span class="co_headnoteNumber" id="co_anchor_headNote_25">25</span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ELSBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EJTBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">In general;  utility</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText"><a id="co_link_I66577e69232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">US Patent 4,007,196</a>. Cited.</div></div><div id="co_headnoteId_200643630050120180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E5TBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630050120180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 25"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e66232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e67232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291X/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291X</a></span><span class="co_headnoteTopicKey">Patents Enumerated</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e68232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k2091</a></span><span class="co_headnoteTopicKey">In general;  utility</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k328(2))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2006436300502"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_2006436300_0"><span class="co_headnoteNumber" id="co_anchor_headNote_26">26</span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EXUBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EVVBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">In general;  utility</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText"><a id="co_link_I66577e6d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">US Patent 4,721,723</a>. Invalid.</div></div><div id="co_headnoteId_200643630050220180308141910" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EKWBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;headnoteId=200643630050220180308141910&amp;originationContext=document&amp;docSource=b1bccecc3f504e84942ac3ffd6cd2470&amp;rank=122&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 26"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e6a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e6b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291X/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291X</a></span><span class="co_headnoteTopicKey">Patents Enumerated</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I66577e6c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k2091</a></span><span class="co_headnoteTopicKey">In general;  utility</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k328(2))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div></div></div><div> </div></div><a id="co_headnotesEnd"></a><h2 class="co_attorneyBlockLabel co_printHeading co_briefItState" id="co_attorneysAndLawFirms">Attorneys and Law Firms</h2><div class="co_contentBlock co_briefItState co_attorneyBlock"><div> <span class="co_starPage" id="co_pp_sp_506_1333"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1333&quot; }" alt="metadata" type="hidden">*1333</span> <a id="co_link_I66577e6e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0109800001&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Ford F. Farabow, Jr.</a>, Finnegan, Henderson, Farabow, Garrett &amp; Dunner, L.L.P., of Washington, DC, argued for plaintiffs-appellants. With him on the brief were <a id="co_link_I66577e70232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0175037601&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Robert D. Bajefsky</a>, <a id="co_link_I66577e71232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0214435801&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Howard W. Levine</a>, <a id="co_link_I66577e72232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0325759901&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Scott J. Popma</a>, <a id="co_link_I66577e73232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0325762101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Jennifer S. Swan</a>, <a id="co_link_I66577e74232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0325760201&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Aaron M. Raphael</a>.</div><div><a id="co_link_I66577e75232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0320748301&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Deanne M. Mazzochi</a>, Lord, Bissell &amp; Brook, of Chicago, Illinois, argued for defendants-cross-appellants. With her on the brief were <a id="co_link_I66577e77232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0115251801&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Hugh L. Moore</a>, <a id="co_link_I66577e78232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0125123701&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Keith D. Parr</a>, <a id="co_link_I66577e79232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0203653401&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Hugh S. Balsam</a>, and <a id="co_link_I66577e7a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0330010101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Kevin M. Nelson</a>. Of counsel were <a id="co_link_I66577e7b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0261873301&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Paul J. Molino</a>, <a id="co_link_I66577e7c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0320745701&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Scott B. Feder</a>, and <a id="co_link_I66577e7d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0203637401&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">William A. Rakoczy</a>.</div></div><div class="co_contentBlock co_briefItState co_panelBlock"><div>Before <a id="co_link_I66577e7e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0168544101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">RADER</a>, <a id="co_link_I66577e7f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0112582701&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">BRYSON</a>, and GAJARSA, Circuit Judges.<sup id="co_footnoteReference_B0012006436300_ID0EL4BG"><a href="#co_footnote_B0012006436300" class="co_footnoteReference">*</a></sup></div></div><div class="co_contentBlock co_briefItState co_opinionBlock"><h2 id="co_opinion" class="co_printHeading">Opinion</h2><div class="co_docDelivery_dottedLine"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/co_docDelivery_dottedLine.png" alt=""></div><div class="co_contentBlock x_opinionBlockBody"><div class="co_contentBlock x_opinionUndesignated"><div class="co_contentBlock x_voteBlock"><div class="co_contentBlock x_voteLine">Opinion for the court filed by Circuit Judge <a id="co_link_I66577e82232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0168544101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">RADER</a>. Concurring opinion filed by Circuit Judge GAJARSA.</div></div><div class="co_contentBlock x_opinionBody"><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28b95232211e89bf099c0ee06c731"></div></div></div><div class="co_contentBlock x_opinionLead"><div class="co_contentBlock x_leadAuthorLineBlock"><div class="co_contentBlock x_leadAuthorLine"><a id="co_link_I66577e84232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0168544101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">RADER</a>, Circuit Judge.</div></div><div class="co_contentBlock x_opinionBody"><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28b98232211e89bf099c0ee06c731"><div class="co_paragraph"><div class="co_paragraphText">Following a bench trial, the United States District Court for the Northern District of Illinois determined that the generic <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a">paroxetine</a> hydrochloride anhydrate <input id="co_docMarker_3" type="hidden"> <span class="co_starPage" id="co_pp_sp_506_1334"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1334&quot; }" alt="metadata" type="hidden">*1334</span> product to be produced by Apotex Corp., Apotex, Inc., and TorPharm, Inc. (collectively Apotex) will not infringe claim 1 of <a id="co_link_I66577e86232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent No. 4,721,723 ('723 patent)</a> owned by SmithKline Beecham Corp. and Beecham Group, P.L.C. (collectively SmithKline). <a id="co_link_I66577e87232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1052&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1052"><em>SmithKline Beecham Corp. v. Apotex Corp.,</em> 247 F.Supp.2d 1011, 1052 (N.D.Ill.2003)</a>. Based on this court's revision of the trial court's erroneous claim construction, Apotex's product would infringe claim 1 of the <a id="co_link_I66577e88232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. Nonetheless, because claim 1 of the <a id="co_link_I66577e89232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> is invalid as anticipated under <a id="co_link_I66577e8a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C. § 102(b)</a>, this court affirms the district court's judgment in favor of Apotex.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28b99232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">I.</span></div><div class="co_paragraph"><div class="co_paragraphText">In the late 1970s, a British company, Ferrosan, invented a new class of compounds, including a compound that became known as <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_0">paroxetine</a>. <em>See</em> <a id="co_link_I66577e8c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent No. 4,007,196 ('196 patent)</a>. The <a id="co_link_I66577e8d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> claims <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_1">paroxetine</a> and its salts and discloses their antidepressant properties. Ferrosan eventually developed a process to produce the crystalline hydrochloride salt of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_2">paroxetine</a>, or <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_3">paroxetine</a> hydrochloride (PHC). In 1980, Ferrosan licensed the <a id="co_link_I66577e91232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> and its other PHC-related technology to SmithKline. SmithKline began manufacturing PHC in its Harlow plant in England.</div></div><div class="co_paragraph"><div class="co_paragraphText">In March 1985, Alan Curzons, a chemist in SmithKline's Worthing, England laboratory, discovered a new crystalline form of PHC while attempting to improve PHC production. Curzons's test results established that the new product was the hemihydrous form of PHC (PHC hemihydrate). Ferrosan's original form was anhydrous PHC (PHC anhydrate). PHC anhydrate comprises crystals of PHC without bound water molecules. PHC hemihydrate comprises PHC crystals with one bound water molecule for every two PHC molecules. PHC hemihydrate proved more stable, and thus more easily packaged and preserved, than PHC anhydrate.</div></div><div class="co_paragraph"><div class="co_paragraphText">SmithKline filed a patent application in the British Patent Office on October 25, 1985 relating to “crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_4">paroxetine</a> hydrochloride, its preparation and its uses as a therapeutic agent.” The British application identified the invention as both the hemihydrate and the anhydrate form of PHC, as well as mixtures that contain a major portion of either form. One year later, on October 23, 1986, SmithKline filed a U.S. application claiming priority to the British application that issued as the <a id="co_link_I66577e93232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> in 1988. The <a id="co_link_I66577e94232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> does not claim PHC anhydrate and does not claim mixtures of the two PHC forms. The only claim at issue in this case is claim 1, which reads in its entirety: “Crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_5">paroxetine</a> hydrochloride hemihydrate.”</div></div><div class="co_paragraph"><div class="co_paragraphText">In 1993, after completing the necessary FDA approval process, SmithKline placed its antidepressant drug with PHC hemihydrate as the active ingredient on the market under the name Paxil®. In 1998, TorPharm, Inc., an Apotex affiliate and manufacturer of Apotex's generic antidepressant, filed an Abbreviated New Drug Application (ANDA) with the FDA, under <a id="co_link_I66577e96232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_267600008f864">21 U.S.C. § 355(j)</a>, seeking approval to market its own PHC antidepressant drug. Apotex identified the active ingredient in its antidepressant as PHC anhydrate. Apotex's ANDA included a paragraph IV certification, <em>see</em> <a id="co_link_I66577e97232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_77fc000049190">21 U.S.C. § 355(j)(2)(A)(IV)</a>, that indicated Apotex's intent to market the drug before the expiration of the <a id="co_link_I66577e98232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> because its drug would not infringe that patent.</div></div><div class="co_paragraph"><div class="co_paragraphText">In 1998, SmithKline initiated this infringement action against Apotex under  <span class="co_starPage" id="co_pp_sp_506_1335"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1335&quot; }" alt="metadata" type="hidden">*1335</span> <a id="co_link_I66577e99232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">35 U.S.C. § 271(e)(2)</a> on the basis of Apotex's ANDA filing. SmithKline alleges that Apotex's proposed drug will infringe claim 1 of the <input id="co_docMarker_4" type="hidden"><a id="co_link_I66577e9a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. SmithKline does not allege that claim 1 of the <a id="co_link_I66577e9b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> covers PHC anhydrate. After all, PHC anhydrate—the Ferrosan discovery—is prior art for the <a id="co_link_I66577e9c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. SmithKline asserts that Apotex will infringe by manufacturing PHC anhydrate tablets that necessarily contain, by a conversion process discussed below, at least trace amounts of PHC hemihydrate.</div></div><div class="co_paragraph"><div class="co_paragraphText">The parties filed various summary judgment motions, including cross motions for summary judgment that claim 1 of the <a id="co_link_I66577e9d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> was invalid (or valid) under <a id="co_link_I66577e9e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C. § 102(b)</a> for an impermissible public use. The <a id="co_link_I66577e9f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">§ 102(b)</a> motions acknowledged that clinical trials occurred more than one year before SmithKline's filing date for the <a id="co_link_I66577ea0232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>, but disputed whether those tests qualified for the experimental use negation. The district court denied Apotex's motion and granted SmithKline's motion, holding that the <a id="co_link_I66577ea1232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> was not invalid for public use under <a id="co_link_I66577ea2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">§ 102(b)</a>. The district court reasoned that the clinical trials qualified as experimental uses. <em>See </em><a id="co_link_I66577ea3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003685866&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_932&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_932"><em>SmithKline Beecham Corp. v. Apotex Corp.,</em> 286 F.Supp.2d 925, 932–38 (N.D.Ill.2001)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court then held a bench trial to determine the proper interpretation of claim 1 and to resolve the remaining infringement and validity issues. On the question of claim construction, the district court limited claim 1 to PHC hemihydrate in commercially significant amounts. <a id="co_link_I66577ea4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1030&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1030"><em>SmithKline Beecham Corp.,</em> 247 F.Supp.2d at 1030.</a> The trial record contained uncontested testimony that a PHC anhydrate-hemihydrate mixture would need to possess a percentage of PHC hemihydrate in the “high double digits” if the hemihydrate component were to contribute any commercial value. <em>Id.</em> The district court imported that commercial significance into the claim and held that Apotex's proposed PHC drug will not infringe claim 1 of the <a id="co_link_I66577ea6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. The district court found, as a factual matter, that Apotex's PHC anhydrate tablets will not contain commercially significant amounts of PHC hemihydrate and rejected SmithKline's evidence to the contrary. <a id="co_link_I66577ea7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1031–39.</a> The trial court also determined that claim 1 is not invalid.</div></div><div class="co_paragraph"><div class="co_paragraphText">SmithKline contested the district court's claim interpretation noting that claim 1 is clear on its face and encompasses PHC hemihydrate in any amount, however small or insignificant. In rejecting that proposed claim interpretation, the district court also opined that SmithKline's proposed construction would render claim 1 indefinite. The district court reasoned that SmithKline's interpretation would place potential infringers in the untenable position of never knowing whether their product infringes because even a single undetectable crystal of PHC hemihydrate would infringe. <a id="co_link_I66577ea8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1029–30.</a></div></div><div class="co_paragraph"><div class="co_paragraphText">To show that manufacture of PHC anhydrate tablets necessarily creates PHC hemihydrate, SmithKline proffered expert testimony on the so-called “seeding” or “disappearing polymorph” theory. Under this theory, Ferrosan may have originally created a crystalline compound, namely PHC anhydrate, in a relatively unstable form. For presently unknown reasons, the PHC anhydrate “morphed” into a more stable form, namely the PHC hemihydrate discovered in SmithKline's facilities. With this new form or polymorph in existence, SmithKline's experts explained, the general environment became “seeded”  <span class="co_starPage" id="co_pp_sp_506_1336"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1336&quot; }" alt="metadata" type="hidden">*1336</span> with crystals of PHC hemihydrate. In this seeded environment, the PHC anhydrate converts to the PHC hemihydrate upon its inevitable contact with seeds of PHC hemihydrate. In other words, the creation of pure PHC anhydrate became extremely difficult, if not impossible; the old polymorph, PCH anhydrate, has effectively disappeared in its pure form because it changes naturally into the new polymorph, PCH hemihydrate.<input id="co_docMarker_5" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">SmithKline's experts applied the “disappearing polymorph” theory to show that Apotex's PHC anhydrate tablets inevitably convert to hemihydrate when combined with moisture, pressure, and practically ubiquitous PHC hemihydrate seeds. The district court found that SmithKline's evidence on the “seeding” and the “disappearing polymorph” theories supported the inference that Apotex's PHC anhydrate tablets will contain at least trace, even if undetectable, amounts of PHC hemihydrate. <a id="co_link_I66577ea9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1042–43.</a> Thus, under SmithKline's claim construction, the district court held that Apotex's PHC anhydrate drug would infringe claim 1 of the <a id="co_link_I66577eaa232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. <a id="co_link_I66577eab232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a></div></div><div class="co_paragraph"><div class="co_paragraphText">Alternatively, if claim 1 was construed to cover any amount of PHC hemihydrate and was, therefore, infringed, the district court purported to create a new equitable defense to infringement in favor of Apotex. <a id="co_link_I66577eac232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1043–45.</a> Under this new defense, SmithKline was responsible for producing the hemihydrate, which, by virtue of SmithKline's “disappearing polymorph” theory, seeded the environment. Consequently, SmithKline caused the alleged infringement. The district court reasoned that Apotex should enjoy the right to practice the prior art by manufacturing PHC anhydrate. Accordingly, under its alternative equitable defense, the district court absolved Apotex of liability for the consequences of SmithKline's own conduct that rendered the practice of the prior art impossible without infringing the <a id="co_link_I66577ead232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. The district court also held that its inherent equitable powers and the equitable nature of injunctions in general placed the injunction mandated by <a id="co_link_I66577eae232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_f4aa000038542">35 U.S.C. § 271(e)(4)(A)</a> within the discretion of the district court. <em>Id.</em> at 1045–52.</div></div><div class="co_paragraph"><div class="co_paragraphText">SmithKline also sought to assert a claim of induced infringement against Apotex on the theory that PHC anhydrate tablets convert to PHC hemihydrate in the stomach of a patient due to the increased humidity and pressure present inside the stomach. <em>Id.</em> at 1014–15. The district court excluded SmithKline's evidence on this issue, finding that SmithKline would likely not meet its burden of showing “gastrointestinal infringement.” <em>Id.</em> at 1014–15. Finally, the district court considered other alternative claim constructions, which would allow claim 1 to cover PHC hemihydrate in amounts detectable either by methods available at the time the <a id="co_link_I66577eb2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> was filed or by any means that later became available. <a id="co_link_I66577eb3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1052.</a> The record shows that SmithKline presented the results of tests on various samples of Apotex tablets. These tests showed PHC hemihydrate in the Apotex product. The district court rejected this evidence as unreliable, mainly because SmithKline's counsel excluded certain tablets from the testing without reasonable explanation. <a id="co_link_I66577eb4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1032–42.</a> The trial court found these excluded tablets to represent the product Apotex would manufacture upon ANDA approval. <a id="co_link_I66577eb5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> Accordingly, the district court held that SmithKline did not prove that Apotex's tablets will contain any detectable amount of PHC hemihydrate.</div></div><div class="co_paragraph"><div class="co_paragraphText">SmithKline presents five arguments on appeal. First, the district court erred in  <span class="co_starPage" id="co_pp_sp_506_1337"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1337&quot; }" alt="metadata" type="hidden">*1337</span> limiting claim 1 to commercially significant amounts of PHC hemihydrate. Second, contrary to the district court's ruling, a claim construction that covers PHC hemihydrate in any amount does not render claim 1 indefinite. Third, the district court erred in creating an equitable defense to infringement based on SmithKline's contribution to causing the infringement. Fourth, the district court erred in holding that the injunctive relief required under <input id="co_docMarker_6" type="hidden"><a id="co_link_I66577eb6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">35 U.S.C. § 271(e)(4)</a> is within the district court's discretion. Fifth, the district court abused its discretion in excluding SmithKline's evidence of induced infringement.</div></div><div class="co_paragraph"><div class="co_paragraphText">In its cross-appeal, Apotex argues that the district court erred in granting summary judgment that SmithKline's clinical tests qualified as an experimental use. In particular, Apotex asserts that claim 1 of the <a id="co_link_I66577eb7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> is invalid for public use under <a id="co_link_I66577eb8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C. § 102(b)</a> as a matter of law. This court has jurisdiction over these appeals under <a id="co_link_I66577eb9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS1295&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_7b9b000044381">28 U.S.C. § 1295(a)(1)</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28b9a232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">II.</span></div><div class="co_headtext co_hAlign1"><em>Standards of Review</em></div><div class="co_paragraph"><div class="co_paragraphText">This court reviews summary judgments without deference. <em>See </em><a id="co_link_I66577eba232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1993091070&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_1245&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_1245"><em>Beech Aircraft Corp. v. EDO Corp.,</em> 990 F.2d 1237, 1245 (Fed.Cir.1993)</a>. Of course, a denial of summary judgment, by itself, is not a final judgment amenable to appeal like a grant of summary judgment. However, when both parties move for summary judgment, each motion “must be independently assessed on its own merit.” <a id="co_link_I66577ebb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001474602&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1380&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1380"><em>California v. United States,</em> 271 F.3d 1377, 1380 (Fed.Cir.2001)</a>. In such circumstances, this court reviews summary judgment under the standard rules of <a id="co_link_I66577ebc232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000600&amp;cite=USFRCPR56&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><span class="co_smallCaps">F</span><span class="co_smallCaps">ed. R. Civ. P</span>. 56</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">In this case, both parties sought summary judgment; the district court granted one and denied the other. Thus, the record shows that the parties conceded, and the district court found, that no material factual issues remain in dispute. <em>See </em><a id="co_link_I66577ebd232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1993091070&amp;pubNum=350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_1245&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_1245"><em>Beech Aircraft,</em> 990 F.2d at 1245.</a> If this court determines that no material facts remain in dispute, it may proceed to determine entitlement to judgment under the law. <em>See </em><a id="co_link_I66577ebe232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001454897&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_962&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_962"><em>Eli Lilly &amp; Co. v. Barr Labs., Inc.,</em> 251 F.3d 955, 962 (Fed.Cir.2001)</a> (“[R]eversal is required if the district court ‘engaged in a faulty legal analysis in applying the law to the facts and a correct application of the law to those facts might bring a different result.’ ” (quoting <a id="co_link_I66577ebf232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985109809&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_164&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_164"><em>Litton Indus. Prods., Inc. v. Solid State Sys. Corp.,</em> 755 F.2d 158, 164 (Fed.Cir.1985)</a>)); <em>see also </em><a id="co_link_I66577ec0232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1986132674&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Anderson v. Liberty Lobby Inc.,</em> 477 U.S. 242, 248, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F12006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF1">1</a><a id="co_anchor_B12006436300"></a><a href="#co_anchor_F22006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF2">2</a><a id="co_anchor_B22006436300"></a> This court reviews a district court's judgment following a bench trial for errors of law or clearly erroneous findings of fact. <em>See </em><a id="co_link_I66577ec1232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002479186&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1343&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1343"><em>Allen Eng'g Corp. v. Bartell Indus., Inc.,</em> 299 F.3d 1336, 1343–44 (Fed.Cir.2002)</a>. Patent infringement proceeds under a two-step analysis. First, the court interprets the claims to determine their proper scope and meaning. <em>See </em><a id="co_link_I66577ec2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998077754&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1454&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1454"><em>Cybor Corp. v. FAS Techs., Inc.,</em> 138 F.3d 1448, 1454 (Fed.Cir.1998)</a> (<em>en banc</em> ). Next, the court measures the accused product or process against the standard of the properly interpreted claims. <em>Id.</em></div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F32006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF3">3</a><a id="co_anchor_B32006436300"></a><a href="#co_anchor_F42006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF4">4</a><a id="co_anchor_B42006436300"></a><a href="#co_anchor_F52006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF5">5</a><a id="co_anchor_B52006436300"></a> This court reviews claim construction without deference. <em>See </em><a id="co_link_I66577ec4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1995081690&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_979&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_979"><em>Markman v. Westview Instruments, Inc.,</em> 52 F.3d 967, 979 (Fed.Cir.1995)</a> (<em>en banc</em> ), <em>aff'd,</em> <a id="co_link_I66577ec5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1996098750&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">517 U.S. 370, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996)</a>. This court reviews the second step, measurement of the accused product or process against the claim, as a question of fact. <em>See </em> <span class="co_starPage" id="co_pp_sp_506_1338"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1338&quot; }" alt="metadata" type="hidden">*1338</span> <a id="co_link_I66577ec6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002479186&amp;pubNum=506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1343&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1343"><em>Allen Eng'g,</em> 299 F.3d at 1343–44;</a> <a id="co_link_I66577ec7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1997028879&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_981&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_981"><em>Gen. Mills, Inc. v. Hunt–Wesson, Inc.,</em> 103 F.3d 978, 981 (Fed.Cir.1997)</a>. The review of indefiniteness under <a id="co_link_I66577ec8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 112</a>, paragraph 2, proceeds as a question of law without deference. <em>See </em><a id="co_link_I66577ec9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2000390748&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1377&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1377"><em>Solomon v. Kimberly–Clark Corp.,</em> 216 F.3d 1372, 1377 (Fed.Cir.2000)</a>; <a id="co_link_I66577eca232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998239545&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_702&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_702"><em>Personalized Media Communications, LLC v. Int'l Trade Comm'n,</em> 161 F.3d 696, 702 (Fed.Cir.1998)</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28b9b232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign1"><em>Factual Findings</em></div><div class="co_paragraph"><div class="co_paragraphText">As an initial matter, this court holds that the record, for the most part, supports the district court's factual findings. In particular, the district court did not clearly err in concluding that Apotex's PHC anhydrate product will include trace amounts of PHC hemihydrate based on the record evidence that the anhydrate form inevitably changes into the hemihydrate form. <input id="co_docMarker_7" type="hidden"><em>See </em><a id="co_link_I66577ecb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1019&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1019"><em>SmithKline Beecham Corp.,</em> 247 F.Supp.2d at 1019–23</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court also did not clearly err in finding that Apotex's anhydrate product will not contain detectable quantities of PHC hemihydrate because SmithKline selectively tested the Apotex samples without explaining its reasons for excluding some Apotex products from the examination. Specifically, the district court's discretionary exclusion of SmithKline's unreliable evidence on this issue does not render the subsequent factual finding clearly erroneous.</div></div><div class="co_paragraph"><div class="co_paragraphText">Although the district court clearly accepts as true the theories of “disappearing polymorphs” and “seeding,” it did not make findings of fact regarding precisely how or when PHC hemihydrate first came into existence. Indeed, traces of PHC hemihydrate in PHC anhydrate pills were not detectible in amounts less than five percent before 1985. However, Curzons undisputedly made his serendipitous discovery of PHC hemihydrate while making PHC anhydrate presumably pursuant to the teachings of the <a id="co_link_I66577ecc232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a>. Moreover, although Curzons does not claim to have discovered PHC hemihydrate until March 1985, further review of samples of SmithKline's PHC anhydrate revealed that SmithKline's Harlow plant had unwittingly made PHC hemihydrate as early as December 1984. These undisputed facts conclusively establish that PHC anhydrate made in accordance with the <a id="co_link_I66577ecd232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> converts into PHC hemihydrate both with and without seeding. Accordingly, this court decides the legal issues in this appeal against the factual background as determined by the district court.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28b9c232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign1"><em>Claim Construction &amp; Indefiniteness</em></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F62006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF6">6</a><a id="co_anchor_B62006436300"></a><a href="#co_anchor_F72006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF7">7</a><a id="co_anchor_B72006436300"></a><a href="#co_anchor_F82006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF8">8</a><a id="co_anchor_B82006436300"></a> Claim interpretation requires the court to ascertain the meaning of the claim to one of ordinary skill in the art at the time of invention. <a id="co_link_I66577ece232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003703604&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1378&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1378"><em>ResQNet.com, Inc. v. Lansa, Inc.,</em> 346 F.3d 1374, 1378 (Fed.Cir.2003)</a>; <a id="co_link_I66577ecf232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998195208&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_871&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_871"><em>Phillips Petroleum Co. v. Huntsman Polymers Corp.,</em> 157 F.3d 866, 871 (Fed.Cir.1998)</a>. This task requires the court to place the claim language in its proper technological and temporal context. The best tools for this enterprise are the various forms of intrinsic evidence and, when appropriate, extrinsic evidence. <em>See </em><a id="co_link_I66577ed0232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1996170371&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1582&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1582"><em>Vitronics, Corp. v. Conceptronic, Inc.,</em> 90 F.3d 1576, 1582 (Fed.Cir.1996)</a>. The intrinsic evidence, “i.e., the patent itself, including the claims, the specification and, if in evidence, the prosecution history ... is the most significant source of the legally operative meaning of disputed claim language.” <em>Id.</em></div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F92006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF9">9</a><a id="co_anchor_B92006436300"></a><a href="#co_anchor_F102006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF10">10</a><a id="co_anchor_B102006436300"></a> Of course, at all times, the language of the claims governs their scope  <span class="co_starPage" id="co_pp_sp_506_1339"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1339&quot; }" alt="metadata" type="hidden">*1339</span> and meaning. <em>See </em><a id="co_link_I66577ed2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001653152&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1372&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1372"><em>Dow Chem. Co. v. Sumitomo Chem. Co.,</em> 257 F.3d 1364, 1372 (Fed.Cir.2001)</a>. Unless the intrinsic evidence compels a contrary conclusion, the claim language carries the meaning accorded those words in the usage of skilled artisans at the time of invention. <em>See id.; </em><a id="co_link_I66577ed4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1996170371&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1582&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1582"><em>Vitronics,</em> 90 F.3d at 1582</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F112006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF11">11</a><a id="co_anchor_B112006436300"></a> As stated earlier, claim 1 of the <a id="co_link_I66577ed5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> reads: “Crystalline paroxetine hydrochloride hemihydrate.” This language is not ambiguous but rather describes a very specific compound. The record repeatedly shows that artisans in this area of technology at the time of invention would have understood that the claim embraces PHC hemihydrate without further limitation.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F122006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF12">12</a><a id="co_anchor_B122006436300"></a> The inquiry proceeds to the remainder of the intrinsic record to determine if the patent applicant gave these unambiguous words some unexpected definition. The district court limited claim 1 to commercially significant amounts of PHC hemihydrate. The trial court found support for this limitation in portions of the <input id="co_docMarker_8" type="hidden"><a id="co_link_I66577ed6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> that discuss the pharmaceutical and commercial properties of PHC hemihydrate. <a id="co_link_I66577ed7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1029&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1029"><em>SmithKline Beecham Corp.,</em> 247 F.Supp.2d at 1029–30.</a> For example, the specification discusses the superior handling properties of the hemihydrate form that improve the manufacture of PHC. Those references, however, do not redefine the compound in terms of its commercial properties, but emphasize that the new compound exhibits favorable characteristics. A description of characteristics does not redefine a compound with an established and unambiguous structural definition.</div></div><div class="co_paragraph"><div class="co_paragraphText">Moreover, nothing in the <a id="co_link_I66577ed8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> limits that structural compound to its commercial embodiments. Rather, the <a id="co_link_I66577ed9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723</a> specification discloses PHC hemihydrate as a compound without reference to its commercial applications. For example, the specification states that the “present invention provides crystalline paroxetine hydrochloride hemihydrate as a novel compound.” <a id="co_link_I66577eda232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>, col. 1, II. 57–58. Furthermore, nothing in the prosecution history of the <a id="co_link_I66577edb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> defines the invention in terms of commercially significant quantities. Thus, reading claim 1 in the context of the intrinsic evidence, the conclusion is inescapable that the claim encompasses, without limitation, PHC hemihydrate—a crystal form of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_6">paroxetine</a> hydrochloride that contains one molecule of bound water for every two molecules of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_7">paroxetine</a> hydrochloride in the crystal structure.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F132006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF13">13</a><a id="co_anchor_B132006436300"></a> The district court openly discussed the policies that led to its insertion of commercially significant quantities as a limitation on the meaning of the claimed compound. <a id="co_link_I66577ede232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1028&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1028"><em>SmithKline Beecham Corp.,</em> 247 F.Supp.2d at 1028–30.</a> The district court observed that a claim construction that covers trace amounts of PHC hemihydrate would likely preclude attempts to make the prior art PHC anhydrate compound. <em>Id.</em> After explaining the “<em>in terrorem</em> effect” of such a “broad” claim construction, the district court rejected the literal scope of claim 1 because it would produce “absurd results” and would “not serve any policy of patent law.” <em>Id.</em> Claim construction, however, is not a policy-driven inquiry. As stated earlier, it is a contextual interpretation of language. The scope of patent claims can neither be broadened nor narrowed based on abstract policy considerations regarding the effect of a particular claim meaning. <em>See </em> <span class="co_starPage" id="co_pp_sp_506_1340"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1340&quot; }" alt="metadata" type="hidden">*1340</span> <a id="co_link_I66577ee1232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1995192217&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1584&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1584"><em>Quantum Corp. v. Rodime, PLC,</em> 65 F.3d 1577, 1584 (Fed.Cir.1995)</a> (“[I]t is well settled that no matter how great the temptations of fairness or policy making, courts do not redraft claims.”). For this precise reason, this court has repeatedly stated that a court must construe claims without considering the implications of covering a particular product or process. <a id="co_link_I66577ee2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002249584&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1074&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1074"><em>See NeoMagic Corp. v. Trident Microsys. Inc.,</em> 287 F.3d 1062, 1074 (Fed.Cir.2002)</a>; <a id="co_link_I66577ee3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985150771&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_1118&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_1118"><em>SRI Int'l v. Matsushita Elec. Corp.,</em> 775 F.2d 1107, 1118 (Fed.Cir.1985)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F142006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF14">14</a><a id="co_anchor_B142006436300"></a> The district court also justified its commercial-significance limitation to preserve the claim's validity in the face of a challenge to its definiteness under <a id="co_link_I66577ee4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 112</a>, second paragraph. In essence, the district court considered the claim indefinite if construed to cover undetectable trace amounts of PHC hemihydrate. In other words, the trial court feared that potential infringers would not be able to determine (and avoid) infringement if they cannot detect the claimed compound. <em>See </em><a id="co_link_I66577ee5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1993182709&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1469&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1469"><em>Morton Int'l, Inc. v. Cardinal Chem. Co.,</em> 5 F.3d 1464, 1469–70 (Fed.Cir.1993)</a>. This reasoning misses the proper purpose of the definiteness requirement.<input id="co_docMarker_9" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F152006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF15">15</a><a id="co_anchor_B152006436300"></a><a href="#co_anchor_F162006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF16">16</a><a id="co_anchor_B162006436300"></a> The second paragraph of <a id="co_link_I66577ee6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 112</a> requires the specification of a patent to “conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.” <a id="co_link_I66577ee7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 112</a>, ¶ 2 (2000). To satisfy this requirement, the claim, read in light of the specification, must apprise those skilled in the art of the scope of the claim. <em>See </em><a id="co_link_I66577ee8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1993122377&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_875&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_875"><em>Miles Labs., Inc. v. Shandon, Inc.,</em> 997 F.2d 870, 875 (Fed.Cir.1993)</a>. Moreover, claims need not “be plain on their face in order to avoid condemnation for indefiniteness; rather, what [this court has] asked is that the claims be amenable to construction, however difficult that task may be.” <a id="co_link_I66577ee9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001795150&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1375&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1375"><em>Exxon Research &amp; Eng'g Co. v. United States,</em> 265 F.3d 1371, 1375 (Fed.Cir.2001)</a>. In this case, the claim covers a definite chemical structure. To a chemist in this field, this claim is plain on its face. Thus, claim 1 of the <a id="co_link_I66577eea232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> cannot be invalid for indefiniteness under <a id="co_link_I66577eeb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 112</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F172006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF17">17</a><a id="co_anchor_B172006436300"></a> In <em>Morton,</em> this court affirmed a district court's judgment of indefiniteness because “one skilled in the art could not determine whether a given compound was within the scope of the claims.” <a id="co_link_I66577eed232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1993182709&amp;pubNum=506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1470&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1470">5 F.3d at 1470.</a> Thus, the claims at issue were “not sufficiently precise to permit a potential competitor to determine whether or not he is infringing.” <em>Id.</em> The <em>Morton</em> case, therefore, does not hold that the inability to detect the claimed compound in the infringing device renders a compound claim indefinite. Rather, <em>Morton</em> stands for the unremarkable proposition that a compound claim, to be definite, must apprise a skilled artisan of the bounds of the claim. The record in <em>Morton</em> contained “considerable evidence showing that those skilled in the art could not make the claimed compounds using the procedures of the specification, and no evidence that such compounds even exist.” <a id="co_link_I66577ef2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1993182709&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1469&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1469"><em>Id.</em> at 1469–70</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">This case bears little similarity to <em>Morton.</em> Here, claim 1 unambiguously identifies the bounds of the claim. It states: “Crystalline paroxetine hydrochloride hemihydrate.” Thus, this claim recites in clear terms a discernible chemical structure. It would be difficult to imagine a more clear and definite claim.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F182006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF18">18</a><a id="co_anchor_B182006436300"></a> The test for indefiniteness does not depend on a potential infringer's ability to ascertain the nature of its own accused <span class="co_starPage" id="co_pp_sp_506_1341"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1341&quot; }" alt="metadata" type="hidden">*1341</span>  product to determine infringement, but instead on whether the claim delineates to a skilled artisan the bounds of the invention. In this case, the problem for Apotex is that it cannot accurately ascertain the nature of its own product. The scope of this claim is clear; the infringement of the Apotex product is not. Even if a claim is broad enough to embrace undetectable trace amounts of the claimed invention, “[b]readth is not indefiniteness.” <a id="co_link_I66577ef4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1970102187&amp;pubNum=350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_788&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_788"><em>In re Gardner,</em> 57 C.C.P.A. 1207, 427 F.2d 786, 788 (CCPA 1970)</a>. Stated more precisely, this claim is neither broad nor narrow, but definitive of this particular chemical structure. For inventing and disclosing this structure, the inventor enjoys the exclusive right to practice that invention for the patent's limited term. Accordingly, claim 1, as construed above, is not indefinite under <a id="co_link_I66577ef5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 112</a>, second paragraph.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28b9d232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign1"><em>Infringement and Equity</em></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F192006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF19">19</a><a id="co_anchor_B192006436300"></a> Having interpreted claim 1 to cover PHC hemihydrate without further limitation, this court turns to infringement. In anticipation of this very scenario, the district court performed a factual infringement analysis based on this correct claim construction. The district court held that the evidence showed that Apotex's PHC anhydrate tablets would contain trace amounts of PHC hemihydrate. <input id="co_docMarker_10" type="hidden"><a id="co_link_I66577ef6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1043&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1043"><em>SmithKline Beecham Corp.,</em> 247 F.Supp.2d at 1043.</a> As indicated above, the record supports this factual finding. This court, therefore, affirms the district court's finding that Apotex's product will infringe under this court's claim construction.</div></div><div class="co_paragraph"><div class="co_paragraphText">Because Apotex seeks to practice the prior art, and because that practice infringes, the next logical inquiry involves anticipation. That is, if the prior art infringes now, logically the prior art should have anticipated the claim before the filing of the <a id="co_link_I66577ef7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. <em>See </em><a id="co_link_I66577ef8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001324901&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1378&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1378"><em>Bristol–Myers Squibb Co. v. Ben Venue Labs., Inc.,</em> 246 F.3d 1368, 1378 (Fed.Cir.2001)</a> (restating the axiom that “that which would literally infringe if later in time anticipates if earlier”). At trial, Apotex asserted that Ferrosan's process of making PHC anhydrate inherently resulted in trace amounts of the hemihydrate prior to the <a id="co_link_I66577ef9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> and thus inherently anticipated that patent. The district court, however, determined that Apotex did not present clear and convincing evidence of inherent anticipation. According to the district court's findings, “no one knows when the hemihydrate form of paroxetine came into existence, although it is a reasonable inference that it did not exist in a detectable amount until” SmithKline's “serendipitous” discovery. <a id="co_link_I66577efa232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1022&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1022"><em>SmithKline Beecham Corp.,</em> 247 F.Supp.2d at 1022, 1025.</a> Apotex does not dispute that PHC hemihydrate was first detected by Curzons in 1985, or that it is unable to prove precisely when PHC hemihydrate came into existence.</div></div><div class="co_paragraph"><div class="co_paragraphText">SmithKline argues that practicing the <a id="co_link_I66577efb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> infringes claim 1 of the <a id="co_link_I66577efc232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>, but that the <a id="co_link_I66577efd232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> does not anticipate claim 1 of the <a id="co_link_I66577efe232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. SmithKline uses the “disappearing polymorph” theory to justify its apparently inconsistent positions. On the one hand, SmithKline asserts that the creation of a prior art compound will result in a product containing at least trace amounts of their patented compound. On the other hand, SmithKline contends that the creation of the prior art compound before SmithKline's discovery of its compound did not have the same result. For this reason, the district court was understandably uncomfortable about allowing claim 1 to embrace its literal scope. The district court feared  <span class="co_starPage" id="co_pp_sp_506_1342"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1342&quot; }" alt="metadata" type="hidden">*1342</span> such a construction would result in “a considerable extension in the effective patent term of paroxetine because it might become difficult or even impossible to manufacture the pure anhydrous form after the Ferrosan patent expired.” <a id="co_link_I66577eff232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1019.</a> While these concerns are certainly legitimate, claim construction, as noted before, proceeds independent of its policy implications. Fortunately, the district court had the foresight to consider alternative analyses in this unique situation.</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court, in its alternative infringement analysis, properly found infringement, but created a new equitable defense to shield Apotex from liability for that infringement. <a id="co_link_I66577f00232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1043–45.</a> In short, the defense would apply where the patentee significantly contributed to causing the infringement. After all, SmithKline's creation of the hemihydrate form of PHC created a seeded environment that, under the facts found by this district court, makes the practice of the prior art an infringement, while arguably precluding the operation of anticipation by inherency. In this unique and unprecedented circumstance, the trial court understandably reached out to find an equitable remedy to protect Apotex. In any event, notwithstanding the potential merit of a new equitable doctrine in this unprecedented instance, this court can resolve this case without its application because claim 1 is invalid as inherently anticipated under <input id="co_docMarker_11" type="hidden"><a id="co_link_I66577f01232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C. § 102(b)</a>. Accordingly, this court declines to address the trial court's proposed equitable defense.</div></div><div class="co_paragraph"><div class="co_paragraphText">The concurring opinion seeks to remedy the perceived inequity in this case by applying <a id="co_link_I66577f02232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>, arguing the subject matter of claim 1 does not cover patentable subject matter. Unfortunately, the concurrence confuses patent eligibility under <a id="co_link_I66577f03232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> with patentability under other provisions in the Patent Act, such as <a id="co_link_I66577f04232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 102</a>. The concurrence admits that PHC hemihydrate is a synthetic, man-made compound eligible for patent protection. In fact, the claimed invention is without question a “composition of matter” or an article of “manufacture” within the terms of <a id="co_link_I66577f05232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. Accordingly, the claimed invention represents subject matter eligible for patent protection under <a id="co_link_I66577f06232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. With that conclusion, the inquiry under <a id="co_link_I66577f07232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> ends.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F202006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF20">20</a><a id="co_anchor_B202006436300"></a> The concurring opinion, however, would expand the subject matter eligibility analysis under <a id="co_link_I66577f08232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> to encompass some review of the scope of the claims. To the contrary, “[e]ither the subject matter falls within <a id="co_link_I66577f09232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Section 101</a> or it does not.” <a id="co_link_I66577f0a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1991085540&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_930&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_930"><em>Animal Legal Def. Fund v. Quigg,</em> 932 F.2d 920, 930 (Fed.Cir.1991)</a>. The scope of the claims is not relevant to subject matter eligibility. Subject matter does not take on a different eligibility status with adjustments in the scope of the proposed claim. Patent eligibility under <a id="co_link_I66577f0b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> is simply not an issue in this case.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28b9e232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign1"><em>Anticipation—<a id="co_link_I66577f0c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 102(b)</a></em></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F212006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF21">21</a><a id="co_anchor_B212006436300"></a><a href="#co_anchor_F222006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF22">22</a><a id="co_anchor_B222006436300"></a><a href="#co_anchor_F232006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF23">23</a><a id="co_anchor_B232006436300"></a> A patent claim is not valid if “the invention was patented or described in a printed publication in this ... country ... more than one year prior to the date of the application for patent in the United States....” <a id="co_link_I66577f0d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C. § 102(b) (2000)</a>. For prior art to anticipate a claim “it must be sufficient to enable one with ordinary skill in the art to practice the invention.” <a id="co_link_I66577f0e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002555369&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1301&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1301"><em>Minn. Mining &amp; Mfg. Co. v. Chemque, Inc.,</em> 303 F.3d 1294, 1301 (Fed.Cir.2002)</a> (citing <a id="co_link_I66577f0f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1964100558&amp;pubNum=350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_855&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_855"><em>In re Borst,</em> 52 C.C.P.A. 1398, 345 F.2d 851, 855 (CCPA 1965)</a>). “Whether a prior art reference is enabling is a question of law based upon underlying factual  <span class="co_starPage" id="co_pp_sp_506_1343"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1343&quot; }" alt="metadata" type="hidden">*1343</span> findings.” <em>Id.</em> (citing <a id="co_link_I66577f11232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002300292&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1376&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1376"><em>Crown Operations Int'l Ltd. v. Solutia, Inc.,</em> 289 F.3d 1367, 1376 (Fed.Cir.2002)</a>). Anticipation is a question of fact. <em>See id.</em> However, without genuine factual disputes underlying the anticipation inquiry, the issue is ripe for judgment as a matter of law.</div></div><div class="co_paragraph"><div class="co_paragraphText">The <a id="co_link_I66577f13232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> is undisputed prior art under <a id="co_link_I66577f14232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C. § 102(b)</a>, even though the <a id="co_link_I66577f15232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> discloses how to make PHC anhydrate and does not discuss PHC hemihydrate. PHC hemihydrate was not even discovered until years after the <a id="co_link_I66577f16232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> was filed. Nonetheless, the <a id="co_link_I66577f17232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> anticipates claim 1 of the <a id="co_link_I66577f18232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> because the <a id="co_link_I66577f19232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196</a> inherently discloses PHC hemihydrate.</div></div><div class="co_paragraph"><div class="co_paragraphText">This court recently set forth the standards for anticipation by inherency:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>A patent is invalid for anticipation if a single prior art reference discloses each and every limitation of the claimed invention. <a id="co_link_I66577f1a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1987106063&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_747&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_747"><em>Lewmar Marine, Inc. v. Barient Inc.,</em> 827 F.2d 744, 747 (Fed.Cir.1987)</a>. Moreover, a prior art reference may anticipate without disclosing a feature of the claimed invention if that missing characteristic is necessarily present, or inherent, in the single anticipating reference. <a id="co_link_I66577f1b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1991186642&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_1268&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_1268"><em>Continental Can Co. v. Monsanto Co.,</em> 948 F.2d 1264, 1268 (Fed.Cir.1991)</a>.</div></blockquote></div></div><div class="co_paragraphText co_flush"><a id="co_link_I66577f1c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003535318&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1377&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1377"><em>Schering Corp. v. Geneva Pharms., Inc.,</em> 339 F.3d 1373, 1377 (Fed.Cir.2003)</a>. In <em>Schering Corp.,</em> this court also decided that the doctrine of inherent anticipation applies to the entire claimed subject matter just as it does to a single claimed feature. <input id="co_docMarker_12" type="hidden"><a id="co_link_I66577f1e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003535318&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1379&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1379"><em>Id.</em> at 1379</a> (“Because inherency places subject matter in the public domain as well as an express disclosure, the inherent disclosure of the entire claimed subject matter anticipates as well as inherent disclosure of a single feature of the claimed subject matter.”). Moreover, this court reiterated in <em>Schering Corp.</em> that inherent anticipation does not require a person of ordinary skill in the art to recognize the inherent disclosure in the prior art at the time the prior art is created. <a id="co_link_I66577f20232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003535318&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1377&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1377"><em>Id.</em> at 1377</a> (citing <a id="co_link_I66577f21232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002529055&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1351&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1351"><em>In re Cruciferous Sprout Litig.,</em> 301 F.3d 1343, 1351 (Fed.Cir.2002)</a>; <a id="co_link_I66577f22232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1999224124&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1366&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1366"><em>MEHL/Biophile Int'l Corp. v. Milgraum,</em> 192 F.3d 1362, 1366 (Fed.Cir.1999)</a>; <a id="co_link_I66577f23232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1999205673&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1348&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1348"><em>Atlas Powder Co. v. Hanex Prods., Inc.,</em> 190 F.3d 1342, 1348–49 (Fed.Cir.1999)</a>).</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F242006436300" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF24">24</a><a id="co_anchor_B242006436300"></a> The district court addressed the issue of inherent anticipation in this case, but it found in favor of SmithKline because Apotex did not prove by clear and convincing evidence that it was impossible to make pure PHC anhydrate in the United States before the critical date of the <a id="co_link_I66577f24232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. <em>See </em><a id="co_link_I66577f25232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1026&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1026"><em>SmithKline Beecham Corp.,</em> 247 F.Supp.2d at 1026</a> (“[I]t is equally possible, as far as anyone knows, that practicing patent [']196 in non-seeded premises—and goodness knows there were some in the United States as of [the critical] date—would not have produced any hemihydrate.”). The district court erred in requiring Apotex to meet this standard of proof, which is too exacting. Apotex did not need to prove that it was impossible to make PHC anhydrate in the United States that contained no PHC hemihydrate, but merely that “the disclosure [of the prior art] is sufficient to show that the natural result flowing from the operation as taught [in the prior art] would result in” the claimed product. <a id="co_link_I66577f27232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1981151399&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_581&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_581"><em>In re Oelrich,</em> 666 F.2d 578, 581 (CCPA 1981)</a>; <em>accord </em><a id="co_link_I66577f28232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1999224124&amp;pubNum=506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1366&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1366"><em>MEHL/Biophile Int'l Corp.,</em> 192 F.3d at 1366;</a> <em>see also </em><a id="co_link_I66577f29232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1999205673&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1349&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1349"><em>Atlas Powder,</em> 190 F.3d at 1349–50</a> (affirming the district court's finding of inherent anticipation despite a finding that the inherent element could be avoided by taking “extraordinary measures” when  <span class="co_starPage" id="co_pp_sp_506_1344"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1344&quot; }" alt="metadata" type="hidden">*1344</span> practicing the prior art). Contrary to this court's precedents, the district court's analysis of inherent anticipation did not consider the teachings of the <a id="co_link_I66577f2a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> separately from the actual production of PHC hemihydrate. <em>See </em><a id="co_link_I66577f2b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003535318&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1380&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1380"><em>Schering Corp.,</em> 339 F.3d at 1380</a> (“Anticipation does not require the actual creation or reduction to practice of the prior art subject matter; anticipation requires only an enabling disclosure.”) (citing <a id="co_link_I66577f2c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985133989&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_533&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_533"><em>In re Donohue,</em> 766 F.2d 531, 533 (Fed.Cir.1985)</a>). Thus, whether it was actually possible to make pure PCH anhydrate before the critical date of the <a id="co_link_I66577f2d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> is irrelevant. The <a id="co_link_I66577f2e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> suffices as an anticipatory prior art reference if it discloses in an enabling manner the production of PHC hemihydrate. <em>See id.</em> The <a id="co_link_I66577f2f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> discloses a method of manufacturing PHC anhydrate that naturally results in the production of PHC hemihydrate. Consequently, applying the facts as found by the district court to the correct standard, this court holds that claim 1 of the <a id="co_link_I66577f30232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> is invalid for anticipation by the <a id="co_link_I66577f31232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The record shows, and SmithKline admits through its proffered arguments, that producing PHC anhydrate according to the <a id="co_link_I66577f32232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> inevitably results in the production of at least trace amounts of anticipating PHC hemihydrate. The parties do not dispute that the first known existence of PHC hemihydrate resulted from an attempt to produce PHC anhydrate according to the <a id="co_link_I66577f33232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a>. In December 1984, SmithKline serendipitously made PHC hemihydrate at its Harlow plant while attempting to manufacture PHC anhydrate according to the <input id="co_docMarker_13" type="hidden"><a id="co_link_I66577f34232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a>. As discussed previously, Curzons's discovery of PHC hemihydrate in Worthing also occurred while he was making PHC anhydrate according to the <a id="co_link_I66577f35232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a>. Both of these undisputed events support a finding that practicing the <a id="co_link_I66577f36232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> naturally results in the production of PHC hemihydrate. The district court also found, and the parties do not dispute, that neither Apotex nor SmithKline can presently produce PHC anhydrate that does not contain at least trace amounts of PHC hemihydrate. <em>See, e.g., </em><a id="co_link_I66577f37232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1044&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1044"><em>SmithKline Beecham Corp.,</em> 247 F.Supp.2d at 1044</a> (“Apotex cannot eliminate <em>all</em> crystals of hemihydrate ....” (emphasis in original)). In sum, the record shows that the manufacture of PHC anhydrate according to the <a id="co_link_I66577f38232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> necessarily results in the production of PHC hemihydrate. This fact finds further record support in the holding that Apotex would infringe claim 1 of the <a id="co_link_I66577f39232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> under the “single crystal” claim construction. <a id="co_link_I66577f3a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1043.</a></div></div><div class="co_paragraph"><div class="co_paragraphText">The district court made these findings, at least in part, because PHC anhydrate produced at the parties' manufacturing facilities would convert to PHC hemihydrate because the facilities had been “seeded” with PHC hemihydrate crystals. <a id="co_link_I66577f3b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> SmithKline takes the position that Apotex's infringement will result wholly from the PHC hemihydrate “seeds” present in Apotex's facility, and that Apotex could avoid infringement if it manufactured PHC anhydrate in a facility clean of hemihydrate “seeds.” While PHC hemihydrate “seeds” will certainly exacerbate the presence of PHC hemihydrate in Apotex's PHC anhydrate pills, this court does not accept SmithKline's assertion that the hemihydrate “seeds” will be the sole cause of the undesired PHC hemihydrate in Apotex's anhydrate pills. Indeed, SmithKline argued at trial that PHC hemihydrate “seeds” are not necessary to produce PHC hemihydrate.</div></div><div class="co_paragraph"><div class="co_paragraphText">SmithKline's position on the source of Apotex's alleged infringement is inconsistent <span class="co_starPage" id="co_pp_sp_506_1345"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1345&quot; }" alt="metadata" type="hidden">*1345</span>  with the undisputed creation of PHC hemihydrate as discussed <em>supra.</em> The production of PHC anhydrate at both SmithKline's Harlow and Worthing plants resulted in the serendipitous production of PHC hemihydrate. The only plausible explanation for this appearance of PHC hemihydrate at the Harlow plant and the likely explanation for its appearance at the Worthing plant is that PHC hemihydrate arises as a natural derivative of practicing the <a id="co_link_I66577f3d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a>. SmithKline did not offer any evidence that pure PHC anhydrate can be produced in facilities that are not seeded. <a id="co_link_I66577f3e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1035&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1035"><em>Id.</em> at 1035</a> (district court noting the absence of any experiments by SmithKline to show the difference between PCH anhydrate manufactured in a facility both before and after it is “seeded”). SmithKline's only counter to this explanation is that it had been manufacturing PHC anhydrate according to the <a id="co_link_I66577f3f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> for years before the hemihydrate was first detected in 1995. SmithKline would have the court infer from this argument that it is possible to make pure PHC anhydrate according to the <a id="co_link_I66577f40232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> in unseeded conditions. The district court, however, properly dismissed this logic noting that “existence and detection are not the same thing.” <a id="co_link_I66577f41232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1022.</a> The district court went on to explain that PHC hemihydrate may have existed in undetectable amounts since Ferrosan first produced PHC anhydrate in the 1970s, particularly because the technology to detect PCH hemihydrate in small amounts did not exist until 1985. The district court reasoned that it may also be possible for PHC anhydrate to coexist with low levels of PHC hemihydrate without further conversion, thereby rejecting SmithKline's argument that the absence of conversion in early batches of PHC anhydrate prove that the hemihydrate form did not exist prior to 1984. <input id="co_docMarker_14" type="hidden"><em>See </em><a id="co_link_I66577f42232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1022&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1022"><em>id.</em> at 1022–23</a> (reconciling conflicting expert testimony by discussing a possible equilibrium point at which conversion plateaus at a few percentage points), 1031 (“[H]emihydrate in small amounts does nothing for the anhydrate with which it is mixed.”) &amp; 1035 (noting that inconsistent test results “impl[y] that the hemihydrate and the anhydrate can coexist in an equilibrium”).</div></div><div class="co_paragraph"><div class="co_paragraphText">Because the record contains clear and convincing evidence that production of PHC anhydrate in accordance with the <a id="co_link_I66577f43232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> inherently results in at least trace amounts of PHC hemihydrate, this court holds that the <a id="co_link_I66577f44232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> inherently anticipates claim 1 of the <a id="co_link_I66577f45232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> under <a id="co_link_I66577f46232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C. § 102(b)</a>. Consequently, it was legal error for the district court to base its finding of no inherent anticipation upon a finding that Apotex did not present clear and convincing evidence that PHC hemihydrate existed before the critical date of the <a id="co_link_I66577f47232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. Additionally, the district court's supposition that Apotex could possibly prevent PHC anhydrate from converting to PHC hemihydrate by building a new plant that was not seeded with PHC hemihydrate, or by preventing the PHC anhydrate from being exposed to moisture, does not change this result. This court's law does not require Apotex to take extraordinary measures to practice the prior art without infringing claim 1 of the <a id="co_link_I66577f48232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. <em>See </em><a id="co_link_I66577f49232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1999205673&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1349&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1349"><em>Atlas Powder,</em> 190 F.3d at 1349–50</a> (affirming the district court's finding of inherent anticipation despite a finding that the inherent element could be avoided by taking “extraordinary measures” when practicing the prior art).</div></div><div class="co_paragraph"><div class="co_paragraphText">SmithKline has sued Apotex for infringement of the <a id="co_link_I66577f4a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> in an express attempt to prevent Apotex from practicing the <a id="co_link_I66577f4b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> upon its expiration. In  <span class="co_starPage" id="co_pp_sp_506_1346"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1346&quot; }" alt="metadata" type="hidden">*1346</span> <em>Atlas Powder,</em> this court noted that one of the principles underlying the doctrine of inherent anticipation is to ensure that “[t]he public remains free to make, use or sell prior art compositions or processes, regardless of whether or not they understand their complete makeup or the underlying scientific principles which allow them to operate.” <a id="co_link_I66577f4d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1999205673&amp;pubNum=506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1348&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1348">190 F.3d at 1348;</a> <em>accord </em><a id="co_link_I66577f4e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003535318&amp;pubNum=506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1379&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1379"><em>Schering Corp.,</em> 339 F.3d at 1379–80.</a> Invalidating claim 1 of the <a id="co_link_I66577f4f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> for inherent anticipation by the <a id="co_link_I66577f50232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> furthers this policy of allowing the public to practice expired patents.</div></div><div class="co_paragraph"><div class="co_paragraphText">This holding is also in accord with this court's precedent. <a id="co_link_I66577f51232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1963104637&amp;pubNum=350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>In re Seaborg,</em> 51 C.C.P.A. 1109, 328 F.2d 996 (CCPA 1964)</a>, held that claims for an isotope of americium made by a nuclear reaction were not inherently anticipated by a prior art patent disclosing a similar nuclear reaction process but with no disclosure of the claimed isotope. In finding no anticipation, this court's predecessor found “no positive evidence” that the claimed isotope was inherently produced by the prior art process. <a id="co_link_I66577f52232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1963104637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 999.</a> The court properly held that the mere “possibility” that the small amount of the claimed element “may have been produced” was insufficient to invalidate the claim for anticipation. <em>Id.</em> Similarly, it is undisputed that SmithKline's and Apotex's practice of the <a id="co_link_I66577f53232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> results in the production of the claimed PHC hemihydrate in trace amounts.</div></div><div class="co_paragraph"><div class="co_paragraphText">As noted in <em>Schering Corp.,</em> a patentee may obtain patent protection for an inherently anticipated compound through proper claiming. <a id="co_link_I66577f55232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003535318&amp;pubNum=506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1381&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1381">339 F.3d at 1381.</a> This court's holding today merely precludes patent protection for the bare compound PHC hemihydrate as claimed in claim 1 of the <a id="co_link_I66577f56232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> because the compound is inherently anticipated by the <input id="co_docMarker_15" type="hidden"><a id="co_link_I66577f57232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28b9f232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign1"><em>Miscellaneous Issues</em></div><div class="co_paragraph"><div class="co_paragraphText">SmithKline also appealed the district court's decision to prevent SmithKline from pursuing its contributory infringement claim. As discussed above, that claim asserted that the ingestion of Apotex's PHC anhydrate tablet by a patient would result in conversion to PHC hemihydrate. Again, SmithKline's allegations of contributory infringement based upon the theory that PHC anhydrate converts into PHC hemihydrate upon ingestion further supports this court's finding of inherent anticipation. Nevertheless, because claim 1 is invalid for anticipation under <a id="co_link_I66577f58232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">§ 102(b)</a>, SmithKline's appeal on contributory infringement is moot.</div></div><div class="co_paragraph"><div class="co_paragraphText">Similarly, SmithKline's appeal of the district court's ruling that injunctive relief under <a id="co_link_I66577f59232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">35 U.S.C. § 271(e)(4)</a> is within the district court's discretion is also moot. That ruling was not necessary for the district court's judgment below and is immaterial to the determination of this appeal. This court, therefore, does not address that issue in this opinion.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28ba0232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">III.</span></div><div class="co_paragraph"><div class="co_paragraphText">In summary, this court reverses the claim construction of the district court and holds that claim 1 of the <a id="co_link_I66577f5a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> covers any amount of crystalline paroxetine hydrochloride hemihydrate without further limitation. Based on the factual findings of the district court, this court affirms the district court's finding that Apotex's PHC anhydrate product will infringe claim 1 under that broad construction. Notwithstanding that conclusion, this court holds, based on the undisputed facts, that claim 1 of the <a id="co_link_I66577f5b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> is invalid for inherent anticipation by the <a id="co_link_I66577f5c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> under <a id="co_link_I66577f5d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">§ 102(a)</a>. Apotex is, therefore, not liable  <span class="co_starPage" id="co_pp_sp_506_1347"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1347&quot; }" alt="metadata" type="hidden">*1347</span> for infringing claim 1 of the <a id="co_link_I66577f5e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. This court affirms the district court's judgment.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28ba1232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">COSTS</span></div><div class="co_paragraph"><div class="co_paragraphText">Each party shall bear its own costs.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28ba2232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">AFFIRMED</span></div></div></div></div></div></div><div class="co_contentBlock co_briefItState co_opinionBlock"><h2 id="co_concurrance_opinion"></h2><div class="co_docDelivery_dottedLine"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/co_docDelivery_dottedLine.png" alt=""></div><div class="co_contentBlock x_opinionBlockBody"><div class="co_contentBlock x_opinionConcurrance"><div class="co_contentBlock x_concurranceAuthorLineBlock"><div class="co_contentBlock x_concurranceAuthorLine">GAJARSA, Circuit Judge, concurring.</div></div><div class="co_contentBlock x_opinionBody"><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28ba7232211e89bf099c0ee06c731"><div class="co_paragraph"><div class="co_paragraphText">I join in the judgment of the court, however, I reach the judgment by a different road. I would find that the trial court erred in construing Claim 1 of the <a id="co_link_I66577f60232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. Under the correct construction, SmithKline Beecham (“SKB”) has proven a prima facie case that Apotex's product will infringe Claim 1. Claim 1, however, is invalid because it encompasses subject matter that is unpatentable under <a id="co_link_I66577f61232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>.<sup id="co_footnoteReference_B00212006436300_ID0E4EAK"><a href="#co_footnote_B00212006436300" class="co_footnoteReference">1</a></sup> I would affirm the district court's judgment in favor of Apotex on the basis that Claim 1 encompasses unpatentable subject matter pursuant to <a id="co_link_I66577f62232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> contrary to the finding of the majority that claim 1 is invalid pursuant to <a id="co_link_I66577f63232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">§ 102(b)</a>. Although the majority outlines the factual background, I deem it necessary to add more specificity to the historical background.</div></div><div class="co_paragraph"><div class="co_paragraphText">In the 1970s, scientists at the Danish company of A/S Ferrosan (“Ferrosan”) first synthesized a new class of chemical compounds. At least some of these compounds were reported to selectively inhibit the reuptake of serotonin, a naturally occurring chemical in the brain. Several commercial antidepressants common at the time inhibited the neuronal reuptake of serotonin. Ferrosan's laboratory tests indicated that its new compounds inhibited serotonin-uptake in a manner comparable to that exhibited by these existing antidepressant drugs.</div></div><div class="co_paragraph"><div class="co_paragraphText">Ferrosan applied for, and on February 8, 1977, was assigned, <a id="co_link_I66577f65232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent No. 4,007,196 (“the '196 patent”)</a>. Paroxetine was among the compounds that Ferrosan discovered and that the <a id="co_link_I66577f66232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977141053&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=I3f2ec170728311d792e6e58f3e66f41c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'196 patent</a> protected. In 1980, Ferrosan granted Beecham Group Limited (now part of SKB) an exclusive license to make, to have made, to use, and to sell paroxetine throughout the world (save for specified Scandinavian countries).<input id="co_docMarker_16" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">In 1981, SKB began manufacturing <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_8">paroxetine</a> hydrochloride in its Harlow (U.K.) plant. These early manufacturing activities did not lead to a commercial product immediately. Before a new pharmaceutical drug can be placed on the U.S. market, it must undergo elaborate testing for safety and efficacy. Quantities of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_9">paroxetine</a> hydrochloride were distributed to different parts of the world, including the U.S., for use in clinical trials. SKB scientists also experimented with <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_10">paroxetine</a> hydrochloride in its bulk form (i.e., its form prior to being made into pills) to improve the production of the bulk material.</div></div><div class="co_paragraph"><div class="co_paragraphText">SKB's experimentation on bulk form <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_11">paroxetine</a> led to an important discovery. On May 29, 1985, an SKB scientist named Alan Curzons issued a memorandum entitled “<a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_12">Paroxetine</a> Polymorphism.” In the memorandum, Curzons stated that <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_13">paroxetine</a> “had been shown to exist in two discreet [sic] crystalline polymorphic FORMS,” a stable, nonhygroscopic hemihydrate and a hygroscopic anhydrate. Curzons's <span class="co_starPage" id="co_pp_sp_506_1348"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1348&quot; }" alt="metadata" type="hidden">*1348</span>  tests confirmed that the anhydrate and the hemihydrate were indeed distinct crystalline forms of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_14">paroxetine</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Crystallinity is central to understanding both Curzons's reference to polymorphism and this case. “Polymorphs” are distinct crystalline structures containing the same molecules. These structural differences can affect various properties of the crystals, such as melting points and hardness (e.g., graphite and diamonds are both crystalline forms of carbon). The two forms of paroxetine hydrochloride that Curzons discovered were technically “pseudopolymorphs,” though pseudopolymorphs are often loosely called polymorphs (an apparently common looseness that the district court adopted and that I have retained in this opinion). Pseudopolymorphs not only have their molecules arranged differently but also have a slightly different molecular composition. A common type of pseudopolymorph is a <em>solvate,</em> which is a crystal in which the molecules defining the crystal structure “trap” molecules of a solvent. The crystal molecules and the solvent molecules then bond to form an altered crystalline structure. When the trapped and bonded solvent is water, the solvate is called a <em>hydrate.</em> Hydrates bonding one water molecule to every two of the other molecules constituting the unit crystal cell are called <em>hemihydrates.</em> <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_15">Paroxetine</a> hydrochloride hemihydrate (“<a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_16">paroxetine</a> hemihydrate”) is a crystalline structure binding one water molecule to every two <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_17">paroxetine</a> hydrochloride molecules. Despite the presence of water molecules, a hemihydrate is a solid, a powder, at room temperature.</div></div><div class="co_paragraph"><div class="co_paragraphText">Prior to Curzons's discovery, the only known form of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_18">paroxetine</a> hydrochloride had been an anhydrate, a crystalline form of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_19">paroxetine</a> that does not contain a bound water molecule. In May 1985, Curzons made a batch of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_20">paroxetine</a>, added isopropyl alcohol, a solvent, and found that the batch crystallized as a hemihydrate rather than as an anhydrate. Curzons immediately recognized the significance of the hemihydrate—its superior handling properties—as well as its potential for a new patent relating to those properties.</div></div><div class="co_paragraph"><div class="co_paragraphText">These superior handling properties are natural effects of water bonded into the <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_21">paroxetine</a> hemihydrate. The anhydrous form of crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_22">paroxetine</a> hydrochloride (“<a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_23">paroxetine</a> anhydrate”) is hygroscopic; that is, it attracts water. This water is not attached to the <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_24">paroxetine</a> anhydrate by molecular bonds. As a result, the water is easily dispersed by heating <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_25">paroxetine</a> anhydrate at a significantly lower temperature than would be required to liberate the water molecule bound in <input id="co_docMarker_17" type="hidden"><a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_26">paroxetine</a> hemihydrate crystals. The anhydrate's hygroscopicity makes it difficult to handle in the manufacturing process; measures must be taken to control humidity and other sources of moisture, lest “soggy” anhydrate degrade into other compounds in ways that might impair the safety or the efficacy of the product. Because the hemihydrate is not hygroscopic, it is easier to handle with fewer precautionary measures protecting its safety and efficacy.</div></div><div class="co_paragraph"><div class="co_paragraphText">Beecham applied for a British patent on Curzons's discovery on October 25, 1985, and for a U.S. patent on October 23, 1986. On January 26, 1988, the U.S. Patent and Trademark Office (PTO) issued the <a id="co_link_I66577f7a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>, entitled “Anti-depressant Crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_27">Paroxetine</a> Hydrochloride Hemihydrate,” which, according to the Abstract, “provides crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_28">paroxetine</a> hydrochloride hemihydrate, processes for its preparation, compositions containing the same  <span class="co_starPage" id="co_pp_sp_506_1349"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1349&quot; }" alt="metadata" type="hidden">*1349</span> and its therapeutic use as an anti-depressant.” <a id="co_link_I66577f7d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The claims as issued were identical to those in the original application. The <a id="co_link_I66577f7e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> combines product claims (Claims 1, 2, 3, and 5), process claims (Claim 4), and use claims (Claims 5 and 6). Only Claim 1 is at issue in the current litigation. It reads:</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28ba8232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign1">1. Crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_29">paroxetine</a> hydrochloride hemihydrate.</div><div class="co_paragraph"><div class="co_paragraphText">Subsequent experimentation taught SKB a few additional lessons about <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_30">paroxetine</a> hemihydrate. First, SKB learned that hemihydrate likely existed at least as early as December 1984 (and possibly earlier), even though Curzons did not identify it as such until 1985. Second, and more significantly, SKB learned that the two forms of paroxetine are related through a phenomenon known as “disappearing polymorphs.”<sup id="co_footnoteReference_B00322006436300_ID0E5SAK"><a href="#co_footnote_B00322006436300" class="co_footnoteReference">2</a></sup> At times, the appearance of a new polymorph (or pseudopolymorph)—hemihydrate—may affect the process that was previously used to make the old polymorph—anhydrate. The result is such that the same process will no longer produce the old polymorph—at least (as here) in its pure form.</div></div><div class="co_paragraph"><div class="co_paragraphText">The causal mechanism of polymorphic creation and transformation is not clear. Modern science does not yet understand the full complexity of the atomic interactions at play in the phenomenon of polymorphism, and specifically in the disappearance of some polymorphs. Scientists have, however, identified three factors believed to be significant. First, later-appearing polymorphs tend to be more stable than earlier ones. Because a stable crystalline form is not as likely to change into a less stable one than vice versa, there tends to be a “natural” drift toward more stable polymorphs. Second, impurities retard crystallization, including crystallization into new forms. Technological progress in manufacturing—including chemical manufacturing—has allowed manufacturers to reduce the impurities in their products. Because of this increased purity technology creates increasingly favorable conditions for the “natural” drift towards stability. Third, and most significantly to this case, once a new and more stable crystal emerges, should it be mixed, even in very small quantities, with the old, less stable crystal, the old form may convert to the new.</div></div><div class="co_paragraph"><div class="co_paragraphText">This process of “seeding” a batch of the old crystalline structure with its new, stable polymorphs can serve as a method of manufacturing the new polymorph by “converting” the old into the new. Seeding and conversion can also be accidental side-effects of new, stable crystals becoming airborne and “contaminating” the laboratory or plant in which the old crystal is being manufactured. While controlled conversions in the former case are obviously desirable production methods, natural conversion in the latter case may be undesirable interferences with the production of the old polymorph.<input id="co_docMarker_18" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">Seeding and conversion are central to this case. A single crystal of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_31">paroxetine</a> hemihydrate can seed an environment to induce conversion—and to render the production of pure paroxetine anhydrate in  <span class="co_starPage" id="co_pp_sp_506_1350"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1350&quot; }" alt="metadata" type="hidden">*1350</span> that environment impossible. While it is often possible, at least in theory, to build clean unseeded environments in which the old process will produce pure forms of the original polymorph, that possibility often remains only a matter of theory; seeds introduced into the environment frequently permeate all parts of the globe and render it impossible to develop such clean environments. No one knows whether it is possible today to build clean environments in which a pharmaceutical company could produce pure <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_32">paroxetine</a> anhydrate. Nor, for that matter, is anyone certain precisely what caused the first crystal of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_33">paroxetine</a> hemihydrate to form—though it does appear likely that a crystal from that December 1984 batch of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_34">paroxetine</a> hemihydrate seeded Curzons's laboratory prior to his initial identification of the <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_35">paroxetine</a> hemihydrate polymorph.</div></div><div class="co_paragraph"><div class="co_paragraphText">As noted, scientific uncertainty surrounds the entire phenomenon of disappearing polymorphs, as well as its particular manifestation in <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_36">paroxetine</a>. Apotex's expert,<sup id="co_footnoteReference_B00432006436300_ID0ESWAK"><a href="#co_footnote_B00432006436300" class="co_footnoteReference">3</a></sup> in fact, testified that the phenomenon does not manifest itself in <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_37">paroxetine</a>, and that <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_38">paroxetine</a> anhydrate and <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_39">paroxetine</a> hemihydrate can coexist happily in a single batch of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_40">paroxetine</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">After weighing the testimony of all of the experts, the district court hypothesized that while the presence of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_41">paroxetine</a> hemihydrate seeds in a batch of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_42">paroxetine</a> anhydrate is likely, only a small percentage of the <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_43">paroxetine</a> anhydrate is likely to convert to hemihydrate under normal conditions of humidity, temperature, or pressure. The district court continued to hypothesize that given enough humidity, heat, or pressure, conversion may continue until it reaches 100 percent, and that by the same token, with much tighter controls less, maybe no, conversion will take place despite the presence of seeds. Finally, the district court noted that the clearest case of limited conversion occurs where there are no water molecules in the environment of the anhydrate.</div></div><div class="co_paragraph"><div class="co_paragraphText">For the purposes of this case, the district court admitted all proffered expert testimony concerning both disappearing polymorphism as a scientific phenomenon and its applicability to paroxetine, and found it to be a credible explanation of various factual occurrences in the discovery and the spread of paroxetine hemihydrate.</div></div><div class="co_paragraph"><div class="co_paragraphText">This language is all straightforward, and Claim 1—containing only four words—is the most straightforward of all. The plain language of a claim asserting rights to “crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_44">paroxetine</a> hydrochloride hemihydrate” claims any amount of “crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_45">paroxetine</a> hydrochloride hemihydrate.” The plain language of this claim is precisely the “single crystal” theory that the district court rejected on other grounds. The district court explicitly recognized that the claim's plain language included even a single crystal of hemihydrate; the district court rejected that construction on the grounds that it would have “absurd consequences.”</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court suggested that even SKB had expressed some discomfort with the implications of the “single crystal” construction of Claim 1. As a result, throughout the course of this litigation, both parties and two trial judges have considered multiple limitations that could be read into the claim—each of which proposed a minimum amount considerably larger than a single crystal. During the summary judgment<input id="co_docMarker_19" type="hidden"> <span class="co_starPage" id="co_pp_sp_506_1351"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1351&quot; }" alt="metadata" type="hidden">*1351</span>  hearing, Judge Kocoras dismissed several attempts to introduce such limitations. Though he himself never adopted a construction, his ruling that SKB could admit evidence of infringement developed using all available testing techniques implies that SKB could pursue an infringement claim against anyone making, using, or selling detectable amounts of paroxetine hemihydrate. In his ruling following the bench trial, Judge Posner noted that under “ordinary” circumstances, claims with unambiguous plain language should be interpreted in a manner consistent with that plain language. There is little doubt that the “single crystal” interpretation is the only one consistent with the claim's plain language.</div></div><div class="co_paragraph"><div class="co_paragraphText">Nevertheless, many of the “absurd consequences” that that the district court foresaw are, in fact, absurd, and would ill-serve the public were they the law. The proper place for resolutions of such conflicts between patent law and patent policy, however, is Congress, not the courts. For the most part, though, such absurdities are likely to lie not in the law itself, but rather in misapplications of the law. Here, the district court applied two additional elements of patent law to avoid the perceived absurdities. The district court found the single crystal theory indefinite, and applied various rules of claim construction to save the claim by limiting its scope. The district court introduced a limitation explicitly excluding hemihydrate produced by involuntary conversion of a proportion of an anhydrous mixture so small as to lack any commercial significance.</div></div><div class="co_paragraph"><div class="co_paragraphText">This conclusion, however, misinterprets the meaning of indefiniteness. The district court was certainly correct that indefinite claims could create socially undesirable “zone[s] of uncertainty which enterprise and experimentation may enter only at the risk of infringement claims.” <a id="co_link_I66577f90232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1942121246&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>United Carbon Co. v. Binney &amp; Smith Co.,</em> 317 U.S. 228, 236, 63 S.Ct. 165, 87 L.Ed. 232 (1942)</a>. Such zones would undoubtedly “discourage invention only a little less than [would] unequivocal foreclosure of the field.” <em>Id.</em> The district court nevertheless erred in concluding that the mere possibility that a single crystal interpretation might discourage innovation and experimentation necessarily rendered the claim indefinite. The proper standard for assessing whether a patent claim satisfies the statutory requirement of definiteness is whether one skilled in the art would understand the bounds of the claim when read in light of the specification. <a id="co_link_I66577f92232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1993122377&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_875&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_875"><em>Miles Labs., Inc. v. Shandon, Inc.,</em> 997 F.2d 870, 875 (Fed.Cir.1993)</a>; <a id="co_link_I66577f93232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001795150&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1375&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1375"><em>Exxon,</em> 265 F.3d 1371, 1375 (Fed.Cir.2001)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">As the Supreme Court has noted, all patents are capable of discouraging at least some innovation. <a id="co_link_I66577f94232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1966112620&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Brenner v. Manson,</em> 383 U.S. 519, 534, 86 S.Ct. 1033, 16 L.Ed.2d 69 (1966)</a> (“[H]ow likely is disclosure of a patented process to spur research by others into the uses to which the product may be placed? To the extent that the patentee has power to enforce his patent, there is little incentive for others to undertake a search for uses.”). This discouragement, however, is simply part of the cost that the public bears to promote an overall patent system whose goal is to motivate more innovation than it deters. It is certainly possible that some individual patents will not have the desired effect, and will deter more innovation than they motivate. While such a result would hardly serve the public interest, this negative policy outcome is insufficient alone to render a patent claim indefinite. Indefiniteness<input id="co_docMarker_20" type="hidden"> <span class="co_starPage" id="co_pp_sp_506_1352"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1352&quot; }" alt="metadata" type="hidden">*1352</span>  must be examined within the framework provided by statute as clarified by our case law. We recently explained that “[a] claim is indefinite if, when read in light of the specification, it does not reasonably apprise those skilled in the art of the scope of the invention.” <a id="co_link_I66577f95232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003065297&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1342&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1342"><em>Amgen Inc. v. Hoechst Marion Roussel,</em> 314 F.3d 1313, 1342 (Fed.Cir.2003)</a>. The contrapositive of this statement is also true. If the claim, read in light of the specification, reasonably apprises those skilled in the art of the scope of the invention, it is definite within the meaning of <a id="co_link_I66577f96232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 112(2)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Given that standard, the district court's error is evident. The plain language of Claim 1 is unambiguous. It claims “crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_46">paroxetine</a> hydrochloride hemihydrate,” unambiguously meaning <em>all</em> “crystalline paroxetine hydrochloride hemihydrate,” without any exceptions. Nothing in the claim language contradicts this straightforward interpretation—nor, for that matter, does anything in the patent's written description, the patent's figures, or the prosecution history. There is no reason for anyone, much less one skilled in the art, to read this plain language as meaning anything else, nor to believe that the patent meant to exclude small or trace amounts of crystalline paroxetine hydrochloride hemihydrate from its coverage. Those skilled in the art should certainly have appreciated the scope of the invention—even if they also viewed its breadth as damaging to their own efforts in experimentation and invention.</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court read limitations from the written description into the claim language for reasons that appear to have stemmed from its public policy concerns. The court's motivation notwithstanding, the practice of reading limitation from written descriptions into claims invariably leads to misconstrued claims. Simply pointing to discussions in the specification or prosecution history cannot rebut the presumption that claims should be afforded their ordinary meanings. <a id="co_link_I66577f98232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002284108&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1366&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1366"><em>CCS Fitness, Inc. v. Brunswick Corp.,</em> 288 F.3d 1359, 1366 (Fed.Cir.2002)</a>. “We recognize that there is sometimes a fine line between reading a claim in light of the specification, and reading a limitation into the claim from the specification.” <a id="co_link_I66577f99232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998191488&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1187&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1187"><em>Comark Communications v. Harris Corp.,</em> 156 F.3d 1182, 1187 (Fed.Cir.1998)</a> (citations omitted). In this case, there is little doubt that the district court crossed that line.</div></div><div class="co_paragraph"><div class="co_paragraphText">The “single crystal” theory provides the only interpretation that is entirely consistent with the language of Claim 1 of the <a id="co_link_I66577f9a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. This interpretation meets the statutory requirement for definiteness. It puts those skilled in the art on notice that the <a id="co_link_I66577f9b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> protects crystalline paroxetine hydrochloride hemihydrate, in all amounts, and that any manufacture, use, or sale of this compound—including inadvertent manufacture, use, or sale—would infringe the <a id="co_link_I66577f9c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>. The correct construction of Claim 1 adheres to the single crystal theory.</div></div><div class="co_paragraph"><div class="co_paragraphText">Because the <a id="co_link_I66577f9d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> claims every single crystal of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_47">paroxetine</a> hemihydrate, and because Apotex's paroxetine product contains at least some hemihydrate crystals, SKB has proven that Apotex's product prima facie infringes—if Claim 1 is valid. Because Claim 1 is broad enough to encompass both patentable and unpatentable subject matter, however, I would find that it is invalid under <a id="co_link_I66577f9f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28ba9232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">I.</span></div><div class="co_headtext co_hAlign2"><em>Authority</em></div><div class="co_paragraph"><div class="co_paragraphText">The question of patentability under <a id="co_link_I66577fa0232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> does not arise often, and a court's  <span class="co_starPage" id="co_pp_sp_506_1353"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1353&quot; }" alt="metadata" type="hidden">*1353</span> decision to raise it sua sponte is even less common. The centrality of patentable subject matter to the entire scope of the patent law suggests that there are times when such inquiries are critical. The Supreme Court established long ago that <input id="co_docMarker_21" type="hidden">“the question whether the invention, which is the subject-matter in controversy, is patentable or not is always open to the consideration of the court, whether the point is raised by the answer or not.” <a id="co_link_I66577fa1232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1883180181&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Slawson v. Grand St. R.R.,</em> 107 U.S. 649, 652, 2 S.Ct. 663, 27 L.Ed. 576 (1882)</a>. <em>See also </em><a id="co_link_I66577fa2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1895180061&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Richards v. Chase Elevator Co.,</em> 158 U.S. 299, 301, 15 S.Ct. 831, 39 L.Ed. 991 (1895)</a>. These precedents remain good law, though the courts have relied upon them infrequently. The policy that drove them, however, remains vibrant. Less than a decade after <em>Slawson,</em> in the context of an interference, the Supreme Court stressed that</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>[t]he parties to the present suit appear to have been willing to ignore the question as to patentability in the present case, and to have litigated merely the question of priority of invention, on the assumption that the invention was patentable. But neither the Circuit Court nor this court can overlook the question of patentability.</div></blockquote></div></div><div class="co_paragraphText co_flush"><a id="co_link_I66577fa4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1890180162&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Hill v. Wooster,</em> 132 U.S. 693, 698, 10 S.Ct. 228, 33 L.Ed. 502 (1890)</a>. In our law, <a id="co_link_I66577fa5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000547&amp;cite=37CFRS41.77&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">37 C.F.R. § 41.77(b)</a> specifically allows an administrative patent judge to raise the issue of patentability sua sponte as to claims designated to correspond to a count of an interference.</div></div><div class="co_paragraph"><div class="co_paragraphText">Beyond administrative proceedings, courts have found the occasional need to raise <a id="co_link_I66577fa6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> issues sua sponte—even subsequent to the 1952 revisions to the Patent Act. At least three of our sister circuits, whose rulings on patent law prior to 1982 do not bind this court but retain persuasive value, raised <a id="co_link_I66577fa7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> issues that the parties had not addressed. The Ninth Circuit announced that “it is the duty of the court to dismiss a patent infringement suit whenever it affirmatively appears that the patent is invalid.” <a id="co_link_I66577fa8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1954117182&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_2&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_2"><em>Barkeij v. Lockheed Aircraft Corp.,</em> 210 F.2d 1, 2 (9th Cir.1954)</a>. According to the Second Circuit, “[e]ven were <a id="co_link_I66577fa9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> not raised by appellees, it was not error for the district court to consider it since it had the power to do so. <a id="co_link_I66577faa232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Section 101</a> deals with the subject matter of patents and, as such, it is always open to the consideration of the court ....” <a id="co_link_I66577fab232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1982126026&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_1028&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_1028"><em>Howes v. Great Lakes Press Corp.,</em> 679 F.2d 1023, 1028 (2d Cir.1982)</a>. And the Third Circuit explained that</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>[i]t has been clear from an early date, that the court could dismiss a bill because the invention described in the patent was not patentable, even when no defense of invalidity was set up in the answer.... Accordingly, when a party brings suit on a patent alleging infringement, it is accountable for the validity of the patent....</div></blockquote></div></div><div class="co_paragraphText co_flush"><a id="co_link_I66577fac232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1966123111&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_99&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_99"><em>Borden Co. v. Clearfield Cheese Co.,</em> 369 F.2d 96, 99–100 (3d Cir.1966)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The Federal Circuit has independently raised <a id="co_link_I66577fad232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> concerns without prompting from the parties at least once before. In <a id="co_link_I66577fae232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985154699&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Titanium Metals Corp. v. Banner,</em> 778 F.2d 775 (Fed.Cir.1985)</a>, we considered a patent that the PTO had rejected as both anticipated under <a id="co_link_I66577faf232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Section 102</a> and obvious under Section 103. <a id="co_link_I66577fb0232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985154699&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_776&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_776"><em>Id.</em> at 776</a>. The district court reversed, and issued an order authorizing the Commissioner of Patents and Trademarks to issue the patent. <a id="co_link_I66577fb1232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985112097&amp;pubNum=0000345&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_345_91&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_345_91"><em>Titanium Metals Corp. v. Mossinghoff,</em> 603 F.Supp. 87, 91 (D.D.C.1984)</a>. The government appealed. The matter therefore reached this court on issues relevant <span class="co_starPage" id="co_pp_sp_506_1354"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1354&quot; }" alt="metadata" type="hidden">*1354</span>  to <a id="co_link_I66577fb2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">sections 102</a> and <a id="co_link_I66577fb3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS103&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">103</a>, not to <a id="co_link_I66577fb4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. We explained, however, that</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>[t]he patent law imposes certain fundamental conditions for patentability, paramount among them being the condition that what is sought to be patented, as determined by the claims, be new. The basic provision of <input id="co_docMarker_22" type="hidden"><a id="co_link_I66577fb5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Title 35</a> applicable here is <a id="co_link_I66577fb6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> .... The title of the application here involved is “Titanium Alloy,” a composition of matter. Surprisingly, in all of the evidence, nobody discussed the key issue of whether the alloy was new, which is the essence of the anticipation issue....</div></blockquote></div></div><div class="co_paragraphText co_flush"><a id="co_link_I66577fb7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985154699&amp;pubNum=350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_781&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_781"><em>Titanium Metals,</em> 778 F.2d at 781.</a> We concluded that “the decision and order of the district court holding that claims 1, 2, and 3 are directed to patentable subject matter and authorizing the issuance of a patent thereon were clearly erroneous and are reversed.” <a id="co_link_I66577fb8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985154699&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 783.</a> In other words, we recognized that we could neither affirm nor reverse the district court's holdings under <a id="co_link_I66577fb9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Sections 102</a> and <a id="co_link_I66577fba232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS103&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">103</a> in a principled way without addressing the underlying erroneous assumption that the invention at issue met the requirements of <a id="co_link_I66577fbb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. <em>See also </em><a id="co_link_I66577fbc232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002529055&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1350&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1350"><em>Brassica Prot. Prods. LLC v. Sunrise Farms (In re Cruciferous Sprout Litig.),</em> 301 F.3d 1343, 1350 (Fed.Cir.2002)</a> (characterizing as “common sense” <em>Titanium Metals'</em> rationale, including the injection of <a id="co_link_I66577fbd232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> into an anticipation analysis).</div></div><div class="co_paragraph"><div class="co_paragraphText">Both this court and the Supreme Court have recognized that there is a significant public policy interest in removing invalid patents from the public arena. In <a id="co_link_I66577fbe232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1993105330&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Cardinal Chem. Co. v. Morton Int'l, Inc.,</em> 508 U.S. 83, 100, 113 S.Ct. 1967, 124 L.Ed.2d 1 (1993)</a>, the Supreme Court reversed our practice of vacating findings of invalidity where the court found non-infringement in light of the strong public interest in resolving questions of patent validity. In <a id="co_link_I66577fbf232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1971127063&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Blonder–Tongue Labs., Inc. v. Univ. of Ill. Found.,</em> 402 U.S. 313, 91 S.Ct. 1434, 28 L.Ed.2d 788 (1971)</a>, the Supreme Court commented at length on the wasteful consequences of relitigating the validity of a patent after it has once been held invalid. In <a id="co_link_I66577fc0232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1973126326&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>United States v. Glaxo Group, Ltd.,</em> 410 U.S. 52, 57–58, 93 S.Ct. 861, 35 L.Ed.2d 104 (1973)</a>, the Supreme Court ruled that the government, like patent licensees, could always challenge the validity of a patent in the course of prosecuting an antitrust action “to vindicate the public interest in enjoining violations of the Sherman Act.” The Court cited numerous cases<sup id="co_footnoteReference_B00542006436300_ID0EWZBK"><a href="#co_footnote_B00542006436300" class="co_footnoteReference">4</a></sup> as “sufficient authority” to support this holding, <em>id.,</em> which it saw as furthering a longstanding policy: “It is as important to the public that competition should not be repressed by worthless patents, as that the patentee of a really valuable invention should be protected in his monopoly....” <a id="co_link_I66577fc2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1892140146&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Pope Mfg. Co. v. Gormully,</em> 144 U.S. 224, 234, 12 S.Ct. 632, 36 L.Ed. 414 (1892)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">These decisions mirror our own recognition that “[p]ublic policy requires that only inventions which fully meet the statutory standards are entitled to patents.” <a id="co_link_I66577fca232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988076600&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_1564&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_1564"><em>Constant v. Advanced Micro–Devices, Inc.,</em> 848 F.2d 1560, 1564 (Fed.Cir.1988)</a> (citations <span class="co_starPage" id="co_pp_sp_506_1355"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1355&quot; }" alt="metadata" type="hidden">*1355</span>  omitted), and that “[t]here is a stronger public interest in the elimination of invalid patents than in the affirmation of a patent as valid.” <a id="co_link_I66577fcb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1984137636&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_1581&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_1581"><em>Nestier Corp. v. Menasha Corp.-Lewisystems Div.,</em> 739 F.2d 1576, 1581 (Fed.Cir.1984)</a>. The best way to ensure that patents issue only for inventions in full compliance with the statutory standards is to allow “the validity of a patent, which was originally obtained in ex parte proceedings in the PTO, [to] be challenged in court.” <a id="co_link_I66577fcc232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988076600&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_1564&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_1564"><em>Constant,</em> 848 F.2d at 1564</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The sua sponte <a id="co_link_I66577fcd232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> inquiry that this case warrants therefore falls well within a long if somewhat sparse tradition, driven in part by concerns of public policy but grounded entirely in legal authority. Where, as here, the facts are both unusual<input id="co_docMarker_23" type="hidden"><sup id="co_footnoteReference_B00652006436300_ID0EUBCK"><a href="#co_footnote_B00652006436300" class="co_footnoteReference">5</a></sup> and undisputed, where the legal implication of these facts is clear, and where a consideration of fundamental aspects of law and policy is necessary to maintain the integrity of the patent law, a sua sponte inquiry into the patentability of the claimed subject matter is appropriate.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28baa232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">II.</span></div><div class="co_headtext co_hAlign2"><em>Theory of Infringement</em></div><div class="co_paragraph"><div class="co_paragraphText">Because the proper construction of Claim 1 follows the “single crystal” theory, SKB must prove that Apotex's product does and will continue to contain at least some hemihydrate. Though SKB's legal burden is only to prove infringement by a preponderance of the evidence, <a id="co_link_I66577fcf232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1996213354&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1376&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1376"><em>S. Bravo Sys., Inc. v. Containment Techs. Corp.,</em> 96 F.3d 1372, 1376 (Fed.Cir.1996)</a>, SKB nevertheless faces a significant challenge. As the district court found, Apotex wants to manufacture pure anhydrate; any hemihydrate present in its product is an undesirable impurity. <a id="co_link_I66577fd0232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1015&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1015"><em>See SK II,</em> 247 F.Supp.2d at 1015, 1025 &amp; 1045</a>. Both SKB and the district court explicitly rejected the possibility that the anhydrous and hemihydrous forms of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_48">paroxetine</a> came into existence simultaneously, and that every batch of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_49">paroxetine</a> ever manufactured (or that ever will be manufactured) contains at least trace elements of hemihydrate—an argument that would not only prove SKB's point about Apotex's product, but would also invalidate the <a id="co_link_I66577fd3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> as inherent in the prior art. <a id="co_link_I66577fd4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1025.</a></div></div><div class="co_paragraph"><div class="co_paragraphText">SKB's basic theory of infringement, which the district court recognized as establishing a prima facie case of infringement when applied to the single crystal construction, <a id="co_link_I66577fd5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>id.</em> at 1043,</a> rests upon two scientific principles that remain matters of controversy within the scientific community, both as a general phenomena and as applied to paroxetine: seeding and conversion. <em>See </em><a id="co_link_I66577fd6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>id.</em> at 1021–23.</a> Under this infringement theory, the form of paroxetine discovered in the 1970s was, indeed, pure anhydrate; hemihydrate did not exist until late 1984.</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div> <span class="co_starPage" id="co_pp_sp_506_1356"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1356&quot; }" alt="metadata" type="hidden">*1356</span> [SKB's expert] Dr. Bernstein testified that he was ‘absolutely convinced’ that no hemihydrate had existed before December 1984... Dr. Terence Threlfall, Apotex's expert on polymorphism, testified [that] Dr. Bernstein's absolute certainty ... is not tenable. No one knows when the hemihydrate form of paroxetine came into existence, although it is a reasonable inference that it did not exist in a detectable amount until then.</div></blockquote></div></div><div class="co_paragraphText co_flush"><a id="co_link_I66577fd7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1022.</a> From that date forward, however, it was impossible to produce pure anhydrate in a “seeded” environment because even under normal climactic conditions, at least some of the anhydrate would “convert” to become hemihydrate.</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>This process of ‘seeding’ the old with the new can be deliberate—that is, can be a method of manufacturing the new polymorph—or adventitious, a result of the fact that some of the crystals become airborne and ‘contaminate’ the laboratory or plant in which the old crystal is being manufactured.... [T]he seeds relevant to this case are seeds that cause one polymorph to convert to another and these seeds are crystals of the form to which conversion occurs. A single tiny crystal, constituting a single seed, might induce conversion.... The creation of the new polymorph is likely to make the laboratory or plant where it is produced seeded, with the result that efforts to produce the old polymorph may instead produce the new one, since it is the more stable form. In principle it should be possible to re-create the old polymorph, just by replicating the exact procedure by which it used to be created, only this time in a seed-free environment<input id="co_docMarker_24" type="hidden">.... [I]n practice efforts to re-create old polymorphs do not always succeed, probably because the critical mass of molecules that is required to cause conversion is so minute....</div></blockquote></div></div><div class="co_paragraphText co_flush"><a id="co_link_I66577fd8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1020.</a> SKB therefore argues that any <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_50">paroxetine</a> manufactured in a seeded environment must inevitably contain at least some hemihydrate, that this condition has only prevailed since some time in late 1984, and that Apotex's facilities have been or inevitably will become seeded.</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>According to SmithKline, the BCI plant [in which Apotex manufactures anhydrate] is seeded with hemihydrate crystals because it was there that Apotex, exercising the broadened experimental-use privilege conferred by the Hatch–Waxman Act, used and made hemihydrate in the course of developing its anhydrous product.</div></blockquote></div></div><div class="co_paragraphText co_flush"><a id="co_link_I66577fda232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1024.</a></div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28bab232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">III.</span></div><div class="co_paragraph"><div class="co_paragraphText">SKB's proof supporting this theory must rest upon factual demonstrations. As an appellate court, we accept all facts found by the district court unless they are clearly erroneous. <a id="co_link_I66577fdb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001392892&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1357&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1357"><em>Shockley v. Arcan, Inc.,</em> 248 F.3d 1349, 1357 (Fed.Cir.2001)</a>. The district court, however, stated its most significant finding as an hypothesis:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>The conflicting testimony of Bernstein ... on the one hand and of Threlfall on the other can largely be reconciled on the following hypothesis: while the presence of hemihydrate seeds in a batch of anhydrate is likely, provided the ambient humidity and temperature are no lower than is normal in the temperate zone, to produce conversion within a short time, once the amount converted reaches a few percent of the mixture further conversion is unlikely without substantially greater humidity, temperature, or pressure.</div></blockquote></div></div><div class="co_paragraphText co_flush"> <span class="co_starPage" id="co_pp_sp_506_1357"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1357&quot; }" alt="metadata" type="hidden">*1357</span> <a id="co_link_I66577fdc232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1022&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1022"><em>SK II,</em> 247 F.Supp.2d at 1022–23.</a> Findings of fact stated as hypotheses pose particularly challenging problems for appellate courts. Did the district court accept this hypothesis as a fact upon which legal arguments and conclusions can rest, or was the district court merely trying to make sense of the scientific testimony that the two experts proffered?</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court's own legal conclusions make it clear that the court accepted them as facts, by stating, for example, that “[Apotex's] BCI plant <em>is</em> seeded as a result of the mid–1990s experiments,” <a id="co_link_I66577fdd232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1032&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1032"><em>id.</em> at 1032</a> (emphasis added), and that “the anhydrate as it proceeds through the process [at the BCI plant] will at several junctures be exposed to air that contains enough water molecules to permit conversion of anhydrate to hemihydrate.” <em>Id.</em> These statements make sense <em>only</em> if the district court found that both seeding and conversion are valid scientific facts, at least as applied to paroxetine for the purposes of this case.</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court's understandable hedging of its language when dealing with controversial scientific theories nevertheless led it to definitive factual conclusions: “BCI <em>probably</em> will be ‘making’ at least some hemihydrate crystals and therefore infringing, at least prima facie, patent 723 if claim 1 is interpreted to cover single crystals of the hemihydrate.” <a id="co_link_I66577fdf232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1838036099&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> (emphasis added). “Some conversion from anhydrate to hemihydrate <em>is likely</em> to occur in a seeded facility in which the anhydrate is exposed to air; BCI's plant is seeded; and the anhydrate manufactured there is exposed to nondehumidified air before it leaves the plant.” <a id="co_link_I66577fe0232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1838036099&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> (emphasis added). But in concrete syllogistic conclusion, “[t]his evidence <em>is sufficient to support an inference</em> that BCI will be making at least tiny amounts of the hemihydrate if it is permitted to manufacture the anhydrate.” <a id="co_link_I66577fe1232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1838036099&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> (emphasis added).<input id="co_docMarker_25" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">The district court therefore found, as a matter of fact, that <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_51">paroxetine</a> anhydrate in a seeded environment characterized by normal climactic conditions <em>can</em> convert itself spontaneously into paroxetine hemihydrate. <a id="co_link_I66577fe3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1838036099&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> The district court further found that SKB had met its burden of proving, by a preponderance of the evidence, that such conversion <em>was inevitable</em> at Apotex's BCI manufacturing facility. <a id="co_link_I66577fe4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1838036099&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1042–43.</a></div></div><div class="co_paragraph"><div class="co_paragraphText">The district court next turned to consider Apotex's defenses. “If ... claim 1 is valid and will be infringed ... by a single crystal of hemihydrate ... [then] Apotex has a complete affirmative defense that SmithKline is the cause of the infringement.” <a id="co_link_I66577fe5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1838036099&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1052.</a> This conclusion makes sense only after a factual finding that Apotex's legal experimentation with <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=bdrug&amp;entityId=I37eacf5d475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I37eacf5d475111db9765f9243f53508a">Paxil</a><sup id="co_footnoteReference_B00762006436300_ID0EQVCK"><a href="#co_footnote_B00762006436300" class="co_footnoteReference">6</a></sup> seeded the BCI plant. <a id="co_link_I66577fe7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1838036099&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1024.</a> “Apotex cannot eliminate <em>all</em> crystals of hemihydrate; under a single-crystal interpretation of claim 1, [and] SmithKline is the sole cause of infringement.” <em>Id.</em> at 1044 (emphasis in the original).</div></div><div class="co_paragraph"><div class="co_paragraphText">Finally, the district court explained that</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>it is difficult, and in some cases it may be impossible (<a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_52">paroxetine</a> hydrochloride hemihydrate may be one of those cases—no one knows), to destroy all the  <span class="co_starPage" id="co_pp_sp_506_1358"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1358&quot; }" alt="metadata" type="hidden">*1358</span> seeds in seeded premises.... Dr. Bernstein testified that if Apotex, desperate to avoid a charge of infringement built a new plant in Antarctica where no hemihydrate seeds had ever been and started manufacturing anhydrate there, and a depressed worker in the plant dropped a <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=bdrug&amp;entityId=I37eacf5d475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I37eacf5d475111db9765f9243f53508a_0">Paxil</a> on the floor, the result might be to seed the plant and make it impossible from then on to produce pure anhydrate there.</div></blockquote></div></div><div class="co_paragraphText co_flush"><em>Id.</em> at 1020–21.</div></div><div class="co_paragraph"><div class="co_paragraphText">In short, the district court made four critical factual findings: (1) Hemihydrate crystals did not exist before their first emergence in an SKB laboratory in late 1984, <em>id.</em> at 1025; (2) Hemihydrate seeds spread easily, and increasingly large parts of the environment are becoming seeded, <em>id.</em> at 1020–21; (3) Under normal climactic conditions in a seeded environment, at least some anhydrate crystals will convert spontaneously to become hemihydrate crystals, <em>id.</em> at 1022–23; and (4) Apotex's manufacturing facilities have been seeded, <em>id.</em> at 1024.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28bac232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">IV.</span></div><div class="co_paragraph"><div class="co_paragraphText">These findings of fact highlight the unique challenge that the infringement analysis of the <a id="co_link_I66577ff2232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> poses: infringing matter has an unusual tendency to “appear” even where it is unwanted. Such a spontaneous appearance of a patented product vitiates the public notice function of patents. <em>See </em><a id="co_link_I66577ff3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>id.</em> at 1028.</a> Under normal circumstances,</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>one of ordinary skill in the art should be able to read a patent, to discern which matter is disclosed and discussed in the written description, and to recognize which matter has been claimed. The ability to discern both what has been disclosed and what has been claimed is the essence of public notice. It tells the public which products or processes would infringe the patent and which would not.</div></blockquote></div></div><div class="co_paragraphText co_flush"><a id="co_link_I66577ff4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2004073903&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1359&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1359"><em>PSC Computer Prods. v. Foxconn Int'l,</em> 355 F.3d 1353, 1359 (Fed.Cir.2004)</a>. When the claimed product can be “made” via the spontaneous conversion of a noninfringing product into an infringing one, adequate notice is impossible—even if the claimed product was initially synthesized in a laboratory.</div></div><div class="co_paragraph"><div class="co_paragraphText">Long before 1952, when <a id="co_link_I66577ff5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Section 112</a> formalized the modern written description requirement, the Supreme Court observed that:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>Whoever discovers that a certain useful result will be produced, in any art, machine, manufacture, or composition of matter, by the use of certain means, is entitled to a patent for it; provided he specifies the means he uses in a manner so full and exact, that any one skilled in the science to which it appertains, can, by using the means he specifies, without any addition to, or subtraction from them, produce precisely the result he describes. And if this cannot be done by the means he describes, the patent is void. And if it can be done, then the patent confers on him the exclusive right to use the means he specifies to produce the result or effect he describes, and nothing more.<input id="co_docMarker_26" type="hidden"></div></blockquote></div></div><div class="co_paragraphText co_flush"><a id="co_link_I66577ff6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1800105644&amp;pubNum=0000780&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_780_119&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_780_119"><em>O'Reilly v. Morse,</em> 15 How. 62, 119, 14 L.Ed. 601 (1853)</a>. The Supreme Court further explained that</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>[a]ccurate description of the invention is required by law, for several important purposes: 1. That the government may know what is granted, and what will become public property when the term  <span class="co_starPage" id="co_pp_sp_506_1359"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1359&quot; }" alt="metadata" type="hidden">*1359</span> of the monopoly expires. 2. That licensed persons desiring to practise the invention may know during the term how to make, construct, and use the invention. 3. That other inventors may know what part of the field of invention is unoccupied.</div></blockquote></div></div><div class="co_paragraphText co_flush"><a id="co_link_I66577ff7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1878145743&amp;pubNum=0000780&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_780_39&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_780_39"><em>Bates v. Coe,</em> 98 U.S. 31, 39, 25 L.Ed. 68 (1878)</a>. While these pre–1952 cases may not apply directly to the modern written description requirement of <a id="co_link_I66577ff8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Section 112</a>, they do demonstrate the longstanding centrality of the public notice function to patent policy.</div></div><div class="co_paragraph"><div class="co_paragraphText">Paroxetine hemihydrate forces us, for the first time, to confront the requirement that “a patentee specify in a manner so full and exact, that any one skilled in the science to which it appertains, can, by [<em>avoiding</em> ] the means he specifies,” <a id="co_link_I66577ff9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1800105644&amp;pubNum=780&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_780_119&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_780_119"><em>O'Reilly,</em> 15 How. at 119, 14 L.Ed. 601,</a> <em>avoid producing the claimed product.</em> Otherwise, there will be no way for “other inventors [to] know what part of the field of invention is unoccupied.” <a id="co_link_I66577ffa232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1878145743&amp;pubNum=780&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_780_39&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_780_39"><em>Bates,</em> 98 U.S. at 39.</a> Effective notice is impossible if a natural physical process can convert a noninfringing product into an infringing one.</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court was correct in concluding that Claim 1 of the <a id="co_link_I66577ffb232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>, subject to the proper single crystal construction, fails to provide suitable notice. <a id="co_link_I66577ffc232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1028&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1028"><em>SK II,</em> 247 F.Supp.2d at 1028, 1052.</a> A paroxetine anhydrate manufacturer, such as Apotex, could exert reasonable efforts to manufacture only products already in the public domain, could direct its entire production process toward developing only products that scrupulously respected all patent rights, and could nevertheless infringe because a natural physical process acting upon its legitimate anhydrous product “made” new hemihydrous crystals that Apotex then “sold” to the public. “Apotex has tried to prevent conversion of its product to the patented form and a principal issue in this case is whether it has succeeded; there is no suggestion that Apotex <em>desires</em> conversion.” <a id="co_link_I66577ffd232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1015&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1015"><em>SK II,</em> 247 F.Supp.2d at 1015</a> (emphasis in original).</div></div><div class="co_paragraph"><div class="co_paragraphText">Claim 1 therefore cannot be valid. But the failure of notice is a consequence of its invalidity, not the source of it. We must consider whether or not the <a id="co_link_I66577ffe232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> covers only patentable subject matter. <em>See </em><a id="co_link_I66577fff232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1883180181&amp;pubNum=0000780&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_780_652&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_780_652"><em>Slawson,</em> 107 U.S. at 652</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28bad232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">V.</span></div><div class="co_headtext co_hAlign2"><em>Patentable Subject Matter</em></div><div class="co_paragraph"><div class="co_paragraphText">“Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent thereof ....” <a id="co_link_I66578000232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>. The Supreme Court has interpreted this statutory range of patentable subject matter to be quite broad, but hardly universal. “In choosing such expansive terms as ‘manufacture’ and ‘composition of matter,’ modified by the comprehensive ‘any,’ Congress plainly contemplated that the patent laws would be given wide scope.” <a id="co_link_I66578001232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Diamond v. Chakrabarty,</em> 447 U.S. 303, 308, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980)</a>. That wide scope nevertheless excludes laws of nature, natural phenomena, and abstract ideas. “Such discoveries are ‘manifestations of ... nature, free to all men and reserved exclusively to none.’ ” <a id="co_link_I66578002232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 309, 100 S.Ct. 2204,</a> (quoting <a id="co_link_I66578003232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros. Seed Co. v. Kalo Inoculant Co.,</em> 333 U.S. 127, 130, 68 S.Ct. 440, 92 L.Ed. 588 (1948)</a>). <em>See also </em><a id="co_link_I66578004232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1981109598&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Diamond v. Diehr,</em> 450 U.S. 175, 185, 101 S.Ct. 1048, 67 L.Ed.2d 155 (1981)<input id="co_docMarker_27" type="hidden"></a>; <a id="co_link_I66578005232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1978139495&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Parker v. Flook,</em> 437 U.S. 584, 589, 98 S.Ct. 2522, 57 L.Ed.2d 451 (1978)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">“Phenomena of nature, though just discovered, mental processes, and abstract  <span class="co_starPage" id="co_pp_sp_506_1360"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1360&quot; }" alt="metadata" type="hidden">*1360</span> intellectual concepts are not patentable, as they are the basic tools of scientific and technological work.” <a id="co_link_I66578006232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1972137547&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Gottschalk v. Benson,</em> 409 U.S. 63, 67, 93 S.Ct. 253, 34 L.Ed.2d 273 (1972)</a>. A single standard applies to product claims and process claims alike. <em>Id.</em> “[W]hether patents are allowable for [challenged subject matter] is not a matter of discretion, but of law.... Either the subject matter falls within <a id="co_link_I66578008232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Section 101</a> or it does not.” <a id="co_link_I66578009232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1991085540&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_929&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_929"><em>Animal Legal Def. Fund v. Quigg,</em> 932 F.2d 920, 929–30 (Fed.Cir.1991)</a>. And as a matter of law, the critical distinction guiding all <a id="co_link_I6657800a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> inquiries into the patentability of subject matter is that human-made, or synthetic, products or processes are patentable, while products and processes of nature are not. <em>See </em><a id="co_link_I6657800b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 313, 100 S.Ct. 2204;</a> <a id="co_link_I6657800c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001526212&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>J.E.M. AG Supply v. Pioneer Hi–Bred Int'l,</em> 534 U.S. 124, 130, 122 S.Ct. 593, 151 L.Ed.2d 508 (2001)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court found as a matter of fact that at some point, likely in late 1984, something occurred in SKB's laboratories that gave rise to two new phenomena simultaneously. <a id="co_link_I6657800d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1021&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1021"><em>SK II,</em> 247 F.Supp.2d at 1021–22.</a> The first was a synthetic crystal later named <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_53">paroxetine</a> hemihydrate, <em>id.,</em> ostensibly a patentable human-made invention under <em>Chakrabarty.</em> The second was a natural physical process whereby <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_54">paroxetine</a> anhydrate (a pre-existing synthetic crystal that today is in the public domain) could, under normal climactic conditions and with no human intervention, bond with water molecules and convert itself into <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_55">paroxetine</a> hemihydrate, <a id="co_link_I66578012232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1021&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1021"><em>SK II,</em> 247 F.Supp.2d at 1021–22,</a> ostensibly an unpatentable, newly discovered natural process under <em>Chakrabarty.</em></div></div><div class="co_paragraph"><div class="co_paragraphText">This distinction between the synthetic product and its natural “reproduction” process is subtle, but critical. Paroxetine hemihydrate is not the first invention to blur the line between a natural process and a synthetic product, nor is it the first to engender confusion in the patent law. In the Nineteenth Century, the conflation of the natural acoustical principles of telephony with the invention of telephone equipment gave rise to massive litigation. <em>See </em><a id="co_link_I66578014232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1888180103&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Telephone Cases,</em> 126 U.S. 1, 8 S.Ct. 778, 31 L.Ed. 863 (1888)</a>. In disentangling this complex patent litigation, the Supreme Court noted that:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">In one of the cases on appeal ... the court says: “There can be no patent for a mere principle. The discoverer of a natural force or a scientific fact cannot have a patent for that.” But it proceeds to make this exception nugatory by confounding the natural process (or scientific fact) with the invented process for working the apparatus; sustaining the patent for the last upon a construction which blindly sweeps in the first.</div></div><div class="co_paragraphText co_flush"><a id="co_link_I66578015232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1888180103&amp;pubNum=708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 270–71, 8 S.Ct. 778.</a> The <a id="co_link_I66578016232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> similarly confounds the scientific fact of paroxetine conversion with the invented product of paroxetine hemihydrate—and SKB similarly asks us to “sustain[ ] the patent for the last upon a construction which blindly sweeps in the first.” <a id="co_link_I66578017232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> We should not only decline to do so, as the majority has and as the district court did in the alternative, but we should be clear about both the character and the implications of the underlying request.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_56">Paroxetine</a> hemihydrate is presumably a synthetic compound, created by humans in a laboratory, never before existing in nature, that is nevertheless capable of “reproducing” itself through a natural process. <input id="co_docMarker_28" type="hidden"><a id="co_link_I66578019232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1022&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1022"><em>SK II,</em> 247 F.Supp.2d at 1022–23.</a> This crystalline compound raises a question similar to one that might arise when considering the invention of a fertile plant  <span class="co_starPage" id="co_pp_sp_506_1361"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1361&quot; }" alt="metadata" type="hidden">*1361</span> or a genetically engineered organism, capable of reproduction, released into the wild. Consider, for example, what might happen if the wind blew fertile, genetically modified blue corn protected by a patent, from the field of a single farmer into neighboring cornfields. The harvest from those fields would soon contain at least some patented blue corn mixed in with the traditional public domain yellow corn—thereby infringing the patent. The wind would continue to blow, and the patented crops would spread throughout the continent, thereby turning most (if not all) North American corn farmers into unintentional, yet inevitable, infringers.<sup id="co_footnoteReference_B00872006436300_ID0ETYDK"><a href="#co_footnote_B00872006436300" class="co_footnoteReference">7</a></sup> The implication—that the patent owner would be entitled to collect royalties from every farmer whose cornfields contained even a few patented blue stalks—cannot possibly be correct. The underlying question that engaged the district court, and that led it to develop numerous alternative holdings, is <em>why</em> this implication is incorrect.</div></div><div class="co_paragraph"><div class="co_paragraphText">At oral argument, when faced with this hypothetical, SKB expressed its belief that such a blue-corn patent would be “very strong.” Such a belief is misplaced. The implicit concept of “inevitable infringement” stems from the inevitable failure of the patent to provide public notice—which, in turn, stems from the inherently unpatentable nature of the claimed subject matter.</div></div><div class="co_paragraph"><div class="co_paragraphText">This <a id="co_link_I6657801b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> problem therefore brings us full circle, back to the impossibility of public notice. Under normal circumstances, inventors other than the patentee will understand how to avoid infringing a patent by avoiding the claimed product. Because products, such as our hypothetical blue corn or SKB's paroxetine hemihydrate, that can be “made” through a natural process of spontaneous conversion imply inevitable infringement, no combination of claim language and written description could possibly teach even one skilled in the art how to avoid infringement. It is unsurprising that a requirement considered so trivial for most patentable products that we are content to let it remain implicit, namely a lesson in infringement avoidance, is effectively impossible for subject matter unpatentable under <a id="co_link_I6657801c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. In short, patent claims drawn broadly enough to encompass products that spread, appear, and “reproduce” through natural processes cover subject matter unpatentable under <a id="co_link_I6657801d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>—and are therefore invalid.</div></div><div class="co_paragraph"><div class="co_paragraphText">The majority asserts that a patentability analysis under <a id="co_link_I6657801e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> does not consider whether a claimed product includes within its coverage naturally occurring compositions. The majority's view is not, and has never been, the law. Patentability “requires an examination of the contested claims to see if the claimed subject matter as a whole” comes within the subject matter described in <a id="co_link_I6657801f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. <em>See </em><a id="co_link_I66578020232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1999101875&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1357&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1357"><em>AT&amp;T Corp. v. Excel Communications, Inc.,</em> 172 F.3d 1352, 1357 (Fed.Cir.1999)</a>; <em>accord </em><a id="co_link_I66578021232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1994160591&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1557&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1557"><em>In re Alappat,</em> 33 F.3d 1526, 1557 (Fed.Cir.1994)</a> (en banc). As this court has stated, “[t]he substantive issue at hand, whether the [patent] is invalid for failure to claim statutory subject matter under <a id="co_link_I66578022232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>, is a matter of both claim construction and statutory construction.” <a id="co_link_I66578023232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998154385&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1370&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1370"><em>State Street Bank &amp; Trust Co. v. Signature Fin. Group, Inc.,</em> 149 F.3d 1368, 1370 (Fed.Cir.1998)</a>. Both <em>AT &amp; T</em> and <em>State Street</em> considered the  <span class="co_starPage" id="co_pp_sp_506_1362"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1362&quot; }" alt="metadata" type="hidden">*1362</span> scope of patent claims to determine their validity under <input id="co_docMarker_29" type="hidden"><a id="co_link_I66578025232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. The analysis provided by this concurrence is fully consistent with that approach.</div></div><div class="co_paragraph"><div class="co_paragraphText">Both <em>Animal Legal Defense Fund,</em> which the majority relies upon, and <em>Chakrabarty,</em> which <em>Animal Legal Defense Fund</em> relies upon, considered the patentability of “non-naturally occurring” organisms. <a id="co_link_I66578029232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1991085540&amp;pubNum=350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_927&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_927"><em>Animal Legal Def. Fund,</em> 932 F.2d at 927.</a> The PTO rule at issue in <em>Animal Legal Defense Fund</em> announced that “nonnaturally occurring non-human multicellular living organisms” were patentable within <a id="co_link_I6657802b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. <a id="co_link_I6657802c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1991085540&amp;pubNum=0000350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_928&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_928"><em>Id.</em> at 928</a>. The same rule specificallyannounced that it “did not affect the principle that products found in nature will not be considered” patentable. <em>Id.</em> When the court, as the majority quotes, asserted that “[e]ither the subject matter falls within <a id="co_link_I6657802d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> or it does not,” it adverted to that underlying taxonomy. Whether subject matter is patentable under <a id="co_link_I6657802e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> cannot be decided without classifying it as “nonnaturally occurring” or “found in nature.”</div></div><div class="co_paragraph"><div class="co_paragraphText">Because the claimed PHC hemihydrate falls into both categories, it is not patentable under <a id="co_link_I6657802f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. Merely limiting the claim to “synthetic PHC hemihydrate” would have solved the problem. But SmithKline Beecham did not.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I18e28bae232211e89bf099c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">VI.</span></div><div class="co_paragraph"><div class="co_paragraphText">Technological advances have forced this court, our predecessor court, and the Supreme Court to consider the line between the natural and the non-natural—including such inventions as non-naturally occurring plants and bacteria—several times over the past few decades. <em>See, e.g., </em><a id="co_link_I66578030232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1979112609&amp;pubNum=350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>In re Bergy,</em> 596 F.2d 952 (CCPA 1979)</a>, <em>rev'd sub nom </em><a id="co_link_I66578031232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Diamond v. Chakrabarty,</em> 447 U.S. 303, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980)</a>; <a id="co_link_I66578032232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2000034841&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Pioneer Hi–Bred Int'l, Inc. v. J.E.M. Agric. Supply, Inc.,</em> 200 F.3d 1374 (Fed.Cir.2000)</a>, <em>aff'd</em> <a id="co_link_I66578033232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001526212&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">534 U.S. 124, 122 S.Ct. 593, 151 L.Ed.2d 508 (2001)</a>. Paroxetine hemihydrate now appears to be the first patent litigated that forces the courts to consider the patentability of products and/or processes launched in a laboratory and released into nature.</div></div><div class="co_paragraph"><div class="co_paragraphText">Despite the complexity of the issue, the analysis is straightforward. An invention synthesized for the first time in a laboratory is eligible for patent protection under <a id="co_link_I66578034232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. Processes for producing this synthetic product in the laboratory and/or for using this synthetic product may also be eligible for patent protection under <a id="co_link_I66578035232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. However, a natural reproduction process, whether sexual, asexual, part of a chain reaction, or a process of decay, is ineligible for patent protection under <a id="co_link_I66578036232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. <a id="co_link_I66578037232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 309, 100 S.Ct. 2204;</a> <a id="co_link_I66578038232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros.,</em> 333 U.S. at 130, 68 S.Ct. 440.</a> An item reproduced by such a natural process, whether an inorganic structure or a life form, must ipso facto be ineligible for patent protection under <a id="co_link_I66578039232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The Supreme Court has cited with approval the Congressional Record surrounding the adoption of the Plant Patent Act of 1930:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>[A] plant discovery resulting from cultivation is unique, isolated, and is not repeated by nature, <em>nor can it be reproduced by nature unaided by man</em> ....” S.Rep. No. 315, supra, at 6; H.R.Rep. No. 1129, supra, at 7. Congress thus recognized that the relevant distinction was not between living and inanimate things, but between products of nature, whether living or not, and human-made inventions.</div></blockquote></div></div><div class="co_paragraphText co_flush"> <span class="co_starPage" id="co_pp_sp_506_1363"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1363&quot; }" alt="metadata" type="hidden">*1363</span> <a id="co_link_I6657803e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. 303, 100 S.Ct. 2204, 65 L.Ed.2d 144</a> (emphasis added). In its recent ruling confirming that hybrid plants are patentable subject matter under <a id="co_link_I6657803f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>, the Supreme Court noted that “[h]ybrid plants ... generally do not reproduce true-to-type, i.e., seeds produced by a hybrid plant do not reliably yield plants with the same hybrid characteristics. Thus, a farmer who wishes to continue growing hybrid plants generally needs to buy more hybrid seed.”<input id="co_docMarker_30" type="hidden"> <a id="co_link_I66578040232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001526212&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>J.E.M.,</em> 534 U.S. at 128, 122 S.Ct. 593</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The principle unifying these statements about patentability made in 1930, 1980, and 2001, is that products capable of being “reproduced by nature unaided by man,” <a id="co_link_I66578041232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. 303, 100 S.Ct. 2204, 65 L.Ed.2d 144,</a> are not patentable subject matter under <a id="co_link_I66578042232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. Though the parties have not briefed this question directly, they and the district court have provided more than sufficient facts to obtain a dispositive and incontrovertible legal determination that Claim 1 of the <a id="co_link_I66578043232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> is invalid under <a id="co_link_I66578044232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The <a id="co_link_I66578045232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a>, correctly construed, claims every single crystal of paroxetine hemihydrate, including those crystals arising through natural conversion. The district court properly admitted SKB's proffered expert testimony about the scientific mechanism underlying natural conversion, <a id="co_link_I66578046232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1019&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1019"><em>SK II,</em> 247 F.Supp.2d at 1019–20,</a> under <a id="co_link_I66578047232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1993130674&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Daubert v. Merrell Dow Pharmaceuticals,</em> 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993)</a>, and <a id="co_link_I66578048232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1997242413&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>General Electric v. Joiner,</em> 522 U.S. 136, 118 S.Ct. 512, 139 L.Ed.2d 508 (1997)</a>, weighed it in conjunction with contradictory testimony proffered by Apotex's experts, <a id="co_link_I66578049232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1022&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1022"><em>SK II,</em> 247 F.Supp.2d at 1022,</a> and concluded that at least some of Apotex's anhydrate would convert itself to hemihydrate. <a id="co_link_I6657804a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1022&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1022"><em>SK II,</em> 247 F.Supp.2d at 1022–23</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">These findings lead to an inescapable conclusion—a conclusion that the majority attempts to dismiss as a question of “scope,” rather than of patentability. Had SKB claimed “<em>synthetic</em> or <em>non-naturally occurring</em> crystalline paroxetine hydrochloride hemihydrate,” the claim would have covered only patentable subject matter, and Apotex would be entitled to a judgment of noninfringement. Had SKB explicitly claimed the crystals converted in Apotex's facilities, as either “the <em>natural process</em> of converting <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_57">paroxetine</a> anhydrate to <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_58">paroxetine</a> hemihydrate” or “crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_59">paroxetine</a> hydrochloride hemihydrate <em>arising through natural conversion,</em>” unpatentability under <a id="co_link_I6657804e232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> would be manifest; though the claimed matter would be a useful composition, it would be one that occurred in nature. <em>See </em><a id="co_link_I6657804f232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 309, 100 S.Ct. 2204;</a> <a id="co_link_I66578050232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros.,</em> 333 U.S. at 130, 68 S.Ct. 440.</a> By claiming simply “crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_60">paroxetine</a> hydrochloride hemihydrate” with no reference to how it was produced, SKB effectively claimed “crystalline <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3c1f514e475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3c1f514e475111db9765f9243f53508a_61">paroxetine</a> hydrochloride hemihydrate <em>whether non-naturally occurring or arising through natural conversion.</em>” Claim 1, as issued, therefore combines patentable and unpatentable subject matter, and is invalid under <a id="co_link_I66578053232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. The “confusion” to which the majority alludes should never arise because we cannot reach <a id="co_link_I66578054232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS102&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Section 102</a> unless the claimed matter can overcome the hurdle of <a id="co_link_I66578055232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Inventors wishing to claim products that can either be synthesized in laboratories or generated by natural processes may protect themselves by incorporating negative limitation terms like “non-natural” or “non-human” into the claims that they submit for examination. <em>See </em><a id="co_link_I66578056232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003065297&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1329&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1329"><em>Amgen Inc. v. Hoechst Marion Roussel,</em> 314 F.3d 1313, 1329 (Fed.Cir.2003)</a>; <a id="co_link_I66578057232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1991085540&amp;pubNum=350&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_350_923&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_923"><em>Animal Legal Def. Fund,</em> 932 F.2d at 923;</a>  <span class="co_starPage" id="co_pp_sp_506_1364"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1364&quot; }" alt="metadata" type="hidden">*1364</span> <em>In re Wakefield,</em> 422 F.2d at 904. SKB made no such distinction. SKB, despite an early recognition of seeding and conversion, <a id="co_link_I66578059232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1022&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1022"><em>SK II,</em> 247 F.Supp.2d at 1022,</a> claimed all paroxetine hemihydrate crystals, including both those “born” of natural conversion without human intervention and those “made” in a laboratory through explicit human effort. SKB further demonstrated its claim to a possessory right in naturally occurring crystals by pursuing this litigation, and articulated this claim explicitly during oral argument.<input id="co_docMarker_31" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">The asserted breadth of Claim 1 makes sense only under the erroneous belief that patents may protect products spread and reproduced by natural processes, directly contradicting our well established understanding of the limits imposed by <a id="co_link_I6657805a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. Given current scientific trends, such a belief could easily lead to misdirected research investments, to inappropriately issued patents, and to a widespread in terrorem effect crippling entire industries whose artisans learn that even their best efforts to respect patent rights may not save them from liability as inadvertent, inevitable infringers. As the district court recognized, the notice function of patents is meaningless in such an environment, <a id="co_link_I6657805b232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1028&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1028"><em>SK II,</em> 247 F.Supp.2d at 1028.</a> The lack of suitable notice could easily chill innovation, inquiry, experimentation, and commercial development. The patent law does not sanction the concept of inevitable infringement.</div></div><div class="co_paragraph"><div class="co_paragraphText">Because SKB's assertion of the single crystal theory provides the correct construction of Claim 1, the <a id="co_link_I6657805c232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988263313&amp;pubNum=0004074&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=PA&amp;docFamilyGuid=Ib1605cb0720e11d7b100a463f186e11d&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'723 patent</a> claims paroxetine hemihydrate crystals reproduced by nature unaided by man—unpatentable subject matter—and is therefore invalid under <a id="co_link_I6657805d232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>.</div></div></div></div></div></div></div><div class="co_parallelCites"><h2 id="co_allCitations" class="co_parallelCitesBlockLabel co_printHeading">All Citations</h2>403 F.3d 1331, 74 U.S.P.Q.2d 1398</div><div id="co_footnoteSection" class="co_footnoteSection co_briefItState"><h2 class="co_footnoteSectionTitle co_printHeading">Footnotes</h2><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1333&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B0012006436300"><a href="#co_footnoteReference_B0012006436300_ID0EL4BG">*</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">Pursuant to an order issued by this court <em>en banc,</em> the present opinion replaces this panel's prior opinion entered on April 23, 2004, as amended <a id="co_link_I66577e81232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2004356611&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">April 28, 2004, and reported at 365 F.3d 1306 (Fed.Cir.2004)</a>.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1347&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00212006436300"><a href="#co_footnoteReference_B00212006436300_ID0E4EAK">1</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">“Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.” <a id="co_link_I66577f64232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1349&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00322006436300"><a href="#co_footnoteReference_B00322006436300_ID0E5SAK">2</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">Dr. Joel Bernstein, one of SmithKline's expert witnesses at the trial, is an authority on “disappearing polymorphs.” <em>See</em> Joel Bernstein, <em>Polymorphism in Molecular Crystals</em> 89–92 (2002); J.D. Dunitz &amp; J. Bernstein, “Disappearing Polymorphs,” 28 <em>Accounts of Chem. Res.</em> 193 (1995).</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1350&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00432006436300"><a href="#co_footnoteReference_B00432006436300_ID0ESWAK">3</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">Dr. Terence Threlfall.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1354&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00542006436300"><a href="#co_footnoteReference_B00542006436300_ID0EWZBK">4</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText"><a id="co_link_I66577fc3232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1897149134&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Telephone Cases,</em> 167 U.S. 224, 17 S.Ct. 809, 42 L.Ed. 144 (1897)</a>; <a id="co_link_I66577fc4232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948119024&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>United States v. United States Gypsum Co.,</em> 333 U.S. 364, 68 S.Ct. 525, 92 L.Ed. 746 (1948)</a>; <a id="co_link_I66577fc5232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1942122826&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Sola Elec. Co. v. Jefferson Elec. Co.,</em> 317 U.S. 173, 63 S.Ct. 172, 87 L.Ed. 165 (1942)</a>; <a id="co_link_I66577fc6232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1947114969&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Edward Katzinger Co. v. Chicago Metallic Mfg. Co.,</em> 329 U.S. 394, 67 S.Ct. 416, 91 L.Ed. 374 (1947)</a>; <a id="co_link_I66577fc7232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1947202066&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>MacGregor v. Westinghouse Elec. &amp; Mfg. Co.,</em> 329 U.S. 402, 67 S.Ct. 424, 91 L.Ed. 380 (1947)</a>; <a id="co_link_I66577fc8232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1892140146&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Pope Mfg. Co. v. Gormully,</em> 144 U.S. 224, 234, 12 S.Ct. 632, 36 L.Ed. 414 (1892)</a>; and <a id="co_link_I66577fc9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1969133016&amp;pubNum=0000708&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Lear, Inc. v. Adkins,</em> 395 U.S. 653, 670, 89 S.Ct. 1902, 23 L.Ed.2d 610 (1969)</a>.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1355&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00652006436300"><a href="#co_footnoteReference_B00652006436300_ID0EUBCK">5</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">The district court's maze of alternative claim constructions and theories finding Apotex not liable for infringement, plus the theory added by the majority, attest to the unique circumstances of this case. The district court's opinion, and in particular its attempt to introduce a novel equitable defense, <a id="co_link_I66577fce232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=0004637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1043&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1043"><em>SmithKline Beecham Corp. v. Apotex Corp.,</em> 247 F.Supp.2d 1011, 1043–45 (N.D.Ill.2003)</a> (“<em>SK II</em> ”), strongly imply that something “feels wrong” about holding an infringer liable for inevitable, spontaneous infringement. We therefore face a choice. We can either address the issue head-on and explain why an attempt to patent unpatentable subject matter leads to so many apparent anomalies, or we can try to contort the aspects of patent law raised by the parties in order to avoid those anomalies. I believe that the law is best served by adopting the straightforward approach.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1357&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00762006436300"><a href="#co_footnoteReference_B00762006436300_ID0EQVCK">6</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">Under the Hatch–Waxman Act, a generic drug manufacturer is allowed to experiment with a patented drug to prove that its planned product is bioequivalent to one already approved by the Food and Drug Administration (FDA). The district court viewed this statutory permission as an implied license, <input id="co_docMarker_32" type="hidden"><a id="co_link_I66577fe9232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;pubNum=4637&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_4637_1018&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_1018"><em>SK II,</em> 247 F.Supp.2d at 1018,</a> and attributed liability for the consequent seeding to SKB. <a id="co_link_I66577fea232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003192453&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1044.</a></div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S477d7e74b70011d993e6d35cc61aab4a&quot;, &quot;pageNumber&quot;: &quot;1361&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00872006436300"><a href="#co_footnoteReference_B00872006436300_ID0ETYDK">7</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">Although intent is not a factor in determining infringement, public notice is required as a predicate to the validity of a patent. <a id="co_link_I6657801a232211e89bf099c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1996088455&amp;pubNum=0000506&amp;originatingDoc=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;refType=RP&amp;fi=co_pp_sp_506_1570&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1570"><em>Jurgens v. CBK, Ltd.,</em> 80 F.3d 1566, 1570 n. 2 (Fed.Cir.1996)</a>. The hypothetical causes unavoidable infringement even in situations where the public would, in good faith, want to avoid infringing.</div></div></div></div></div><table id="co_endOfDocument"><tbody><tr><td>End of Document</td><td class="co_endOfDocCopyright">© 2018 Thomson Reuters. No claim to original U.S. Government Works.</td></tr></tbody></table></div><input class="co_chunkNumber" value="0" type="hidden"><input id="co_finalChunkMarker" type="hidden"></div><input id="co_document_metaInfo_I0a98a911a82a11d9bdd1cfdd544ca3a4" value="{&quot;FirstLineCite&quot;:null,&quot;PU&quot;:null,&quot;accessControl&quot;:null,&quot;accessionNumber&quot;:&quot;&quot;,&quot;acquirerCompany&quot;:null,&quot;activeDate&quot;:null,&quot;additionalLinks&quot;:null,&quot;agreementDisplayDate&quot;:null,&quot;announcementDate&quot;:null,&quot;articleTitle&quot;:null,&quot;borrower&quot;:null,&quot;caseRequired&quot;:null,&quot;ciCompany&quot;:null,&quot;cicOfficer&quot;:null,&quot;cipOfficer&quot;:null,&quot;cite&quot;:&quot;403 F.3d 1331&quot;,&quot;citeAbbreviation&quot;:null,&quot;citePrimary&quot;:null,&quot;city&quot;:null,&quot;collection&quot;:&quot;w_cs_fed2&quot;,&quot;compoundTitle&quot;:null,&quot;containerId&quot;:null,&quot;containerType&quot;:null,&quot;contentType&quot;:&quot;Cases&quot;,&quot;contentTypeId&quot;:&quot;1&quot;,&quot;correlationIds&quot;:null,&quot;country&quot;:null,&quot;countryDocumentCountry&quot;:null,&quot;countryDocumentGuid&quot;:null,&quot;court&quot;:&quot;C.A.Fed.&quot;,&quot;courtDocumentType&quot;:null,&quot;courtNumber&quot;:&quot;1760&quot;,&quot;courtYear&quot;:&quot;C.A.Fed.,2005.&quot;,&quot;date&quot;:&quot;April 08, 2005&quot;,&quot;dateFile&quot;:&quot;April 08, 2005&quot;,&quot;dealDate&quot;:null,&quot;dealTrackPublishDate&quot;:null,&quot;dealType&quot;:null,&quot;dealValue&quot;:null,&quot;description&quot;:null,&quot;docFamilyGuid&quot;:&quot;I0a98a913a82a11d9bdd1cfdd544ca3a4&quot;,&quot;docGuid&quot;:&quot;I0a98a911a82a11d9bdd1cfdd544ca3a4&quot;,&quot;docLink&quot;:&quot;https://1.next.westlaw.com/Document/I0a98a911a82a11d9bdd1cfdd544ca3a4/View/FullText.html?originationContext=document&amp;contextData=(sc.CustomDigest)&amp;needToInjectTerms=False&quot;,&quot;documentTitle&quot;:null,&quot;edgarFileNumber&quot;:null,&quot;entityId&quot;:null,&quot;expertType&quot;:null,&quot;fileName&quot;:null,&quot;fileNumber&quot;:&quot;&quot;,&quot;fileSize&quot;:0,&quot;fileType&quot;:null,&quot;filerCik&quot;:null,&quot;filerName&quot;:null,&quot;filingDate&quot;:null,&quot;filingYear&quot;:null,&quot;firmName&quot;:null,&quot;formNumber&quot;:null,&quot;formSubType&quot;:null,&quot;formType&quot;:null,&quot;formTypeDisplay&quot;:null,&quot;formVolume&quot;:null,&quot;functionalCite&quot;:&quot;403 F.3d 1331&quot;,&quot;fundFirmCompoundTitle&quot;:null,&quot;fundLocation&quot;:null,&quot;fundName&quot;:null,&quot;fundTargetSize&quot;:null,&quot;fundType&quot;:null,&quot;fundYear&quot;:null,&quot;fundraisingStatus&quot;:null,&quot;getTocData&quot;:false,&quot;hasDraftingNotes&quot;:null,&quot;hasVideoContent&quot;:null,&quot;impersonationKey&quot;:null,&quot;inlineKeyCiteFlagsIncluded&quot;:false,&quot;inlineKeyCiteFlagsResolutionStatus&quot;:null,&quot;insiderName&quot;:null,&quot;ip_assignmentsAction&quot;:null,&quot;ip_citeParallel&quot;:null,&quot;ip_derwentPublishedDate&quot;:null,&quot;ip_docket&quot;:null,&quot;ip_documentDate&quot;:&quot;April 08, 2005&quot;,&quot;ip_issuedDate&quot;:null,&quot;ip_litAlertAttorney&quot;:null,&quot;ip_patStatCode&quot;:null,&quot;ip_patentOwner&quot;:null,&quot;ip_publishedDate&quot;:null,&quot;ip_shortTitle&quot;:null,&quot;isDisplayMiniReport&quot;:false,&quot;isGatewayDocument&quot;:false,&quot;isLargeDocument&quot;:false,&quot;isPersistedContent&quot;:false,&quot;isPublicRecordsBlockedByPermissibleUse&quot;:false,&quot;isPublicRecordsBlockedBySocialSecurityAdmin&quot;:false,&quot;isPublicRecordsDocument&quot;:false,&quot;isRefsAndAnnos&quot;:false,&quot;isRegChangeDocument&quot;:false,&quot;isSearchable&quot;:null,&quot;isSecureContent&quot;:false,&quot;issueDate&quot;:null,&quot;issuerName&quot;:null,&quot;jobDescription&quot;:null,&quot;judge&quot;:&quot;RADER, Circuit Judge.&quot;,&quot;jurisAbbrev&quot;:null,&quot;jurisdiction&quot;:&quot;FE&quot;,&quot;jurisdictionFacet&quot;:&quot;Federal|**|Cts. of Appeals|**|Federal Cir.&quot;,&quot;jurisdictionText&quot;:&quot;Federal Cir.&quot;,&quot;knos&quot;:null,&quot;lastRoundExitComb&quot;:null,&quot;legacyId&quot;:&quot;2006436300&quot;,&quot;letterType&quot;:null,&quot;locationOfIncorporation&quot;:null,&quot;maxOfferingPrice&quot;:null,&quot;natureOfTransaction&quot;:null,&quot;newsImageHrefLarge&quot;:null,&quot;newsImageHrefSmall&quot;:null,&quot;normalizedDocType&quot;:null,&quot;normalizedFormType&quot;:null,&quot;offeringType&quot;:null,&quot;organizationName&quot;:null,&quot;originatingDoc&quot;:null,&quot;pageCount&quot;:null,&quot;persistedDocGuid&quot;:null,&quot;plcFirmStyleAvailable&quot;:false,&quot;plcResourceName&quot;:&quot;&quot;,&quot;portfolioCompanyLocation&quot;:null,&quot;portfolioCompanyName&quot;:null,&quot;prMetaInfo1&quot;:null,&quot;prMetaInfo2&quot;:null,&quot;prMetaInfo3&quot;:null,&quot;prMetaInfo4&quot;:null,&quot;prMetaInfo5&quot;:null,&quot;primaryEditorialService&quot;:null,&quot;profileType&quot;:null,&quot;pubSeries&quot;:null,&quot;publishDate&quot;:null,&quot;questionText&quot;:null,&quot;redlined&quot;:false,&quot;registrationDate&quot;:null,&quot;renditionId&quot;:&quot;I2B58C4AA1DD211B29E4B380092065EF5&quot;,&quot;royaltyId&quot;:&quot;0&quot;,&quot;rulebookNViews&quot;:null,&quot;serialNumber&quot;:&quot;2006436300&quot;,&quot;status&quot;:null,&quot;subContentType&quot;:&quot;Caselaw - NRS&quot;,&quot;subContentTypeId&quot;:&quot;27&quot;,&quot;subTitle&quot;:null,&quot;targetCompany&quot;:null,&quot;testimonyType&quot;:null,&quot;titleHtml&quot;:&quot;SmithKline Beecham Corp. v. Apotex Corp.&quot;,&quot;titleText&quot;:&quot;SmithKline Beecham Corp. v. Apotex Corp.&quot;,&quot;totalAmountIssuedWithCurrency&quot;:null,&quot;totalPages&quot;:&quot;&quot;,&quot;trademarkStatus&quot;:null,&quot;transactionAmountWithCurrency&quot;:null,&quot;transactionValue&quot;:null,&quot;valuationComb&quot;:null,&quot;viewExpressions&quot;:&quot;EZ5|E3I|000|EVD&quot;,&quot;westlawDatabaseIdentifier&quot;:&quot;AWFED&quot;,&quot;westlawDocumentNumber&quot;:&quot;3128737&quot;}" type="hidden"><input id="co_document_documentNavigation_Search_Search-v1-results-navigation-i0ad62aef0000016306ea58342bf062c8-Nav-CUSTOMDIGEST-fragmentIdentifier-I0a98a911a82a11d9bdd1cfdd544ca3a4-startIndex-1-contextData--28sc.CustomDigest-29-transitionType-CustomDigestItem_CUSTOMDIGEST_122" value="{&quot;AnswerSnippetId&quot;:null,&quot;CurrentDocumentGuid&quot;:&quot;I0a98a911a82a11d9bdd1cfdd544ca3a4&quot;,&quot;CurrentPosition&quot;:122,&quot;CurrentWatsonAnswerText&quot;:null,&quot;EnableConceptCounts&quot;:false,&quot;HighlightPoints&quot;:null,&quot;HighlightTerms&quot;:null,&quot;InPlanUrl&quot;:null,&quot;IsSnapSnippet&quot;:false,&quot;ListCount&quot;:718,&quot;Message&quot;:null,&quot;NextDocument&quot;:{&quot;SkipLinkOutDoc&quot;:false,&quot;Title&quot;:&quot;State Street Bank &amp; Trust Co. v. Signature Financial Group, Inc&quot;,&quot;Url&quot;:&quot;/Document/I4f2cbec0944f11d9bc61beebb95be672/View/FullText.html?navigationPath=Search%2Fv1%2Fresults%2Fnavigation%2Fi0ad62aef0000016306ea58342bf062c8%3FNav%3DCUSTOMDIGEST%26fragmentIdentifier%3DI4f2cbec0944f11d9bc61beebb95be672%26startIndex%3D1%26contextData%3D%2528sc.CustomDigest%2529%26transitionType%3DCustomDigestItem&amp;listSource=Search&amp;list=CUSTOMDIGEST&amp;rank=123&amp;grading=na&amp;sessionScopeId=8ddfa247da5ec522372afb44cc5a905f27604688c70f518919c93bafe2056482&amp;originationContext=Custom%20Digest&amp;transitionType=CustomDigestItem&amp;contextData=%28sc.CustomDigest%29&amp;listPageSource=b1be020b4aba9e28af6c04f62c735c28#co_anchor_F61998154385&quot;},&quot;NovusQueryType&quot;:null,&quot;NovusSearchResult&quot;:null,&quot;NumberOfSnips&quot;:0,&quot;ParagraphId&quot;:null,&quot;PreviousDocument&quot;:{&quot;SkipLinkOutDoc&quot;:false,&quot;Title&quot;:&quot;In re Bilski&quot;,&quot;Url&quot;:&quot;/Document/I71ccb24ba6fd11dd9876f446780b7bdc/View/FullText.html?navigationPath=Search%2Fv1%2Fresults%2Fnavigation%2Fi0ad62aef0000016306ea58342bf062c8%3FNav%3DCUSTOMDIGEST%26fragmentIdentifier%3DI71ccb24ba6fd11dd9876f446780b7bdc%26startIndex%3D1%26contextData%3D%2528sc.CustomDigest%2529%26transitionType%3DCustomDigestItem&amp;listSource=Search&amp;list=CUSTOMDIGEST&amp;rank=121&amp;grading=na&amp;sessionScopeId=8ddfa247da5ec522372afb44cc5a905f27604688c70f518919c93bafe2056482&amp;originationContext=Custom%20Digest&amp;transitionType=CustomDigestItem&amp;contextData=%28sc.CustomDigest%29&amp;listPageSource=b1be020b4aba9e28af6c04f62c735c28#co_anchor_F12017388082&quot;},&quot;ReturnTo&quot;:{&quot;SkipLinkOutDoc&quot;:false,&quot;Title&quot;:&quot;list&quot;,&quot;Url&quot;:&quot;/Search/Results.html?jurisdiction=CTAF&amp;contentType=CUSTOMDIGEST&amp;querySubmissionGuid=i0ad62aef0000016306ea58342bf062c8&amp;tocGuid=I4aee2539c6f64c1812a4c2f3395c2607&amp;categoryPageUrl=Home%2FWestKeyNumberSystem&amp;searchId=i0ad62aef0000016306ea4650fbf37b75&amp;collectionSet=w_cs_cd_toc&amp;transitionType=ReturnToList&amp;contextData=%28sc.CustomDigest%29#I0a98a911a82a11d9bdd1cfdd544ca3a4&quot;},&quot;SearchQuery&quot;:null,&quot;SearchQueryType&quot;:null,&quot;SearchWithinQuery&quot;:null,&quot;SecondaryHighlightTerms&quot;:null,&quot;ShowSkipOutOfPlanOption&quot;:false}" type="hidden"><div id="co_nrsOutline" class="co_hideState"></div><input id="co_documentContentCacheKey" value="WestlawNext|none|I0a98a911a82a11d9bdd1cfdd544ca3a4|||||||Search|Search/v1/results/navigation/i0ad62aef0000016306ea58342bf062c8?Nav=CUSTOMDIGEST&amp;fragmentIdentifier=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;startIndex=1&amp;contextData=%28sc.CustomDigest%29&amp;transitionType=CustomDigestItem|CUSTOMDIGEST|122|False|True|{&quot;HighlightPoints&quot;:null,&quot;HighlightTerms&quot;:null,&quot;SearchWithinQuery&quot;:null,&quot;SecondaryHighlightTerms&quot;:null}|False|||False|False|||True|S|False|Core|||001|False|False|False|False|False|" type="hidden"><input id="co_documentFlagInfo" value="{&quot;docGuid&quot;:&quot;I0a98a911a82a11d9bdd1cfdd544ca3a4&quot;,&quot;flags&quot;:[{&quot;categoryId&quot;:&quot;kcJudicialHistory&quot;,&quot;id&quot;:&quot;negative.indirect.history.mild&quot;,&quot;link&quot;:&quot;https://1.next.westlaw.com/Link/RelatedInformation/Flag?docGuid=I0a98a911a82a11d9bdd1cfdd544ca3a4&amp;originationContext=docHeaderFlag&amp;transitionType=Document&amp;contextData=%28sc.CustomDigest%29&quot;,&quot;metadata&quot;:{&quot;citation&quot;:&quot;75 U.S.P.Q.2d 1,801&quot;,&quot;court&quot;:&quot;Fed.Cir.(Cal.)&quot;,&quot;docFamilyGuid&quot;:&quot;I5337d32705c311da8ac8f235252e36df&quot;,&quot;docGuid&quot;:&quot;I5337d32605c311da8ac8f235252e36df&quot;,&quot;liveDate&quot;:&quot;August 5, 2005&quot;,&quot;title&quot;:&quot;Datamize, LLC v. Plumtree Software, Inc.&quot;,&quot;titleLink&quot;:&quot;https://1.next.westlaw.com/Document/I5337d32605c311da8ac8f235252e36df/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3Fguid%3DI5337d32605c311da8ac8f235252e36df%26ss%3D2006436300%26ds%3D2007091567&amp;listSource=RelatedInfo&amp;list=NegativeCitingReferences&amp;rank=0&amp;originationContext=docHeader&amp;transitionType=NegativeTreatment&amp;contextData=%28sc.CustomDigest%29&quot;,&quot;treatmentPhrase&quot;:&quot;Distinguished by&quot;},&quot;type&quot;:&quot;negative.indirect.history&quot;,&quot;value&quot;:&quot;mild&quot;}],&quot;metas&quot;:[{&quot;contentType&quot;:&quot;CASELAW&quot;,&quot;docCollection&quot;:&quot;w_cs_fed2&quot;,&quot;docFamilyGuid&quot;:&quot;I0a98a913a82a11d9bdd1cfdd544ca3a4&quot;,&quot;legacyId&quot;:&quot;2006436300&quot;,&quot;sourcePubId&quot;:&quot;506&quot;}]}" type="hidden">




							</div>

				</div>
			</div>
		</div>
	</div>
	<!-- LEFT COLUMN -->  
	<div id="co_leftColumn">
		<div class="co_innertube">
			<div id="coid_website_folderingWidgetDiv"></div>
		</div>
	</div>
			<!-- RIGHT COLUMN -->
			<div id="co_rightColumn" class="co_addFocusCorrection">
				<div class="co_innertube">		
					<div id="coid_website_relatedInfoIPWidgetDiv" style="display: none;" aria-expanded="false">
					</div>




<div id="coid_website_documentToolWidgetDiv"></div>
		<div id="coid_website_relatedInfoWidgetDiv"> </div>
		<div id="coid_website_recommendedDocuments" class="co_recommendedDocumentContainer">
		</div>

<div id="downloadUserDocument"></div>
					<div id="downloadUserDocument"></div>
				</div>
			</div>

 <input class="hideTopTopics" id="hideTopTopics" name="hideTopTopics" type="hidden">
		<div class="co_clear"></div>
	</div>


	<!-- BEGIN FOOTER -->
	<div id="co_footerContainer"><div id="co_cookiePolicyContainer">
	<div class="co_cookiePolicyContent">
			<h3><b>Our policy towards the use of cookies</b></h3>
			<p>All Thomson Reuters websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.</p>
			<ul class="co_inlineList">
				<li>
					<a id="coid_website_cookiePolicyLinkOut" href="javascript:void(0)">Read cookie policy</a>
				</li>
				<li>
					<a id="coid_website_closeCookiePolicy" href="javascript:void(0)">Close</a>
				</li>
			<p></p>
			<button type="button" id="coid_website_cookiePolicyAcknowledged" title="Close message to acknowledge cookie policy" class="co_absolute">
				<span class="icon25 icon_close_x"></span>
			</button>
	</ul></div>
</div>


		
		<div class="co_innertube co_clearfix" id="co_footer" style="display: none;">







<div class="co_floatLeft">
	<div id="co_footerLinks">
		<ul class="co_inlineList">
					<li><a id="coid_websiteFooter_userSettings" href="javascript:void(0);"><span class="icon25 icon_gear_document"></span>Preferences</a></li>
				<li><a id="coid_websiteFooter_helplink" href="javascript:void(0);"><span class="icon25 icon_question_mark"></span>Training &amp; Support</a></li>
				
					<li><a id="coid_websiteFooter_signofflink" href="javascript:void(0);"><span class="icon25 icon_exit_door"></span>Sign Off</a></li>

		</ul>
	</div>
	<div id="co_footerCopyright">
		<ul class="co_inlineList">

			<li>Westlaw. <a href="/Copyright?transitionType=Default&amp;contextData=(sc.Default)"> © 2018</a> Thomson Reuters</li>
			<li><a id="coid_websiteFooter_privacyPolicyLink" href="javascript:void(0)">Privacy Statement</a></li>
			<li><a href="/Accessibility?transitionType=Default&amp;contextData=(sc.Default)">Accessibility</a></li>
				<li id="co_footer_supplier"><a id="coid_website_supplierTerms" href="javascript:void(0);">Supplier Terms</a></li>
				<li id="co_footerContactUs"><a href="/ContactUs?transitionType=Default&amp;contextData=(sc.Default)">Contact Us</a></li>
				<li id="co_footerCs">1-800-REF-ATTY (1-800-733-2889)</li>
				<li id="co_footer_improve"><strong><a id="coid_websiteFooter_pageSurvey" href="javascript:void(0);">Improve Westlaw</a></strong></li>
		</ul>


	</div>
</div>





<div id="co_trLogo" class="co_floatRight">

	<a id="co_trLogo_link" href="#">
		<img alt="Thomson Reuters" src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v2/co_logo_thomsonReuters.png" width="134" height="30">
	</a>
</div>



		</div>
	</div>
			<div id="coid_Trmr" style="display:none; visibility:hidden"></div>
		</div>
	</div>
	
	<!--static content version number-->
<script type="text/javascript">





	
		window['Server/Routing'] = {
			Search: 'search.int.next.westlaw.com',
			TypeAhead: 'typeahead.int.next.westlaw.com',
			Nlu: 'nlu.int.next.westlaw.com',
			Document: 'document.int.next.westlaw.com',
			Foldering: 'foldering.int.next.westlaw.com',
			CSS: 'ca.next.westlaw.com/StaticContent_40.1.1015',
			Images: 'ia.next.westlaw.com/StaticContent_40.1.1015',
			JavaScript: 'ja.next.westlaw.com/StaticContent_40.1.1015',
			RelatedInfo: 'relatedinfo.int.next.westlaw.com',
			Events: 'events.int.next.westlaw.com',
			KM: 'NONE',
			RequestDirector: 'www.westlaw.com',
			SocialPlatform: 'https://community-sso.thomsonreuters.com',
			Sync: 'sync.westlaw.com',
			Video: 'v1.next.westlaw.com',
			FormsAssembly: 'formsassembly.int.forms.westlaw.com',
			Publishing: 'publishing.int.next.westlaw.com',
			WebContent: 'webcontent.int.next.westlaw.com',
			Alert: 'alert.int.next.westlaw.com',
			Report: 'report.int.next.westlaw.com',
			ProductMetadata: 'pmd.int.next.westlaw.com/pmd',
			Website: '1.next.westlaw.com',
			WebsiteDefault: '1.next.westlaw.com',
			HistoryListener: 'historylistener.int.next.westlaw.com',
			FormsAssemblyTest: ''
		};
	
		
			if (window.location.host !== '1.next.westlaw.com') {
				window['Server/Routing'].ProxiedWebsite = '1.next.westlaw.com';
				window['Server/Routing'].Website = window.location.host;
				window['Server/Routing'].WebsiteDefault = window.location.host;
			}
		
</script>

<script type="text/javascript"></script>

	<script type="text/javascript" src="https://1.next.westlaw.com/v2/js/UrlRouting.40.1.1013.0.js"></script>
	
	<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="https://ja.next.westlaw.com/StaticContent_40.1.1015/External/vendor/datejs@1.0/cultures/en-US.js"></script>
<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="https://ja.next.westlaw.com/StaticContent_40.1.1015/v2/Products/WestlawNext/js/LocalizationResources/Localized/Messages.js"></script>

	
<script type="text/javascript">

	







</script>





















	
	














<script type="text/javascript">
window['Server/User'] = {
  "FirmName": "SEOUL NATIONAL UNIV (LV A)",
  "_AlertsIsAdmin": false,
  "_FeatureExposure": "Released",
  "ClientId": "SEOUL NU - WL NEXT",
  "_AlertsAccessFunctionalityTurnedOn": true,
  "_AlertsAccessCategoryApplied": false,
  "_ShowErrorDetails": false,
  "OnePassUserName": "5405685",
  "OnePassUserNameEncoded": "5405685",
  "ClientMatter": {
    "ClientId": "SEOUL NU - WL NEXT",
    "CompositeClientMatter": "SEOUL NU - WL NEXT",
    "DefaultClientId": "Seoul NU - WL Next",
    "ClientIdPromptText": "",
    "IsClientNonChargeable": "False",
    "NoClientId": "False",
    "TrackableCode": "D",
    "UserTurnedTrackingOn": false
  },
  "ClientReportingAttributes": {
    "PracticeArea": "",
    "ResearchReasonCode": "",
    "ResearchDescription": ""
  },
  "BillingMethodForDisplayOnly": "TRANSACTIONAL",
  "HasFlashPlayer": false,
  "IsUltra": true,
  "CustomerStorageKey": "E41F133AB8A01ED395E1D85D67D9406C",
  "SessionCreatedDateTime": "04/27/2018 11:43:14",
  "HasLoggedAggregateNotificationCount": false
};


window['Server/ViewModelData'] = {
  "DocumentGuid": "I0a98a911a82a11d9bdd1cfdd544ca3a4",
  "DocumentCitation": "403 F.3d 1331",
  "DocumentTitle": "SmithKline Beecham Corp. v. Apotex Corp.",
  "DocumentMetaDescription": "View on Westlaw or start a FREE TRIAL today, SmithKline Beecham Corp. v. Apotex Corp., Cases",
  "ViewType": "FullText",
  "Rank": 122,
  "Grading": "na",
  "KMEnableTermNavigation": false,
  "KMEnableDocumentNavigation": false,
  "LegacyId": "2006436300",
  "DocumentSource": {
    "Key": "b1bccecc3f504e84942ac3ffd6cd2470",
    "NavigationPath": "Search/v1/results/navigation/i0ad62aef0000016306ea58342bf062c8?Nav=CUSTOMDIGEST&fragmentIdentifier=I0a98a911a82a11d9bdd1cfdd544ca3a4&startIndex=1&contextData=%28sc.CustomDigest%29&transitionType=CustomDigestItem",
    "ListSource": "Search",
    "List": "CUSTOMDIGEST",
    "ListPageSourceKey": "b1be020b4aba9e28af6c04f62c735c28"
  },
  "HasDraftingNotes": false,
  "HasDocumentSections": false,
  "EnableBestPortion": true,
  "SubContentTypeId": "27",
  "DisableDocMetaInfoRetrievalOnWarningPage": false,
  "TermNavigationPreference": "AllTerms",
  "ShowMainToolbar": true,
  "ShowRelatedAnalysis": false,
  "ListSource": "Search",
  "IsRelatedFullTextView": false,
  "KeyCiteAlertWarning": "None",
  "DocketTrackWarning": "None",
  "DocumentSections": [],
  "RulebookMode": false,
  "RulebookModeContent": false,
  "NotesOfDecisionsCount": 0,
  "TocReportDocGuids": [],
  "TocReportViewMode": false,
  "IsMedLitStubDocument": false,
  "TrackableCode": "D",
  "NonTrackableCode": "H",
  "FullTocOnDoc": false,
  "ViewExpressions": []
};


window['Server/WidgetDomIds'] = {
  "DocToolbar": "co_docToolbar",
  "DocDisplay": "coid_website_documentWidgetDiv",
  "DocTools": "coid_website_documentToolWidgetDiv",
  "DocTopToolbar": "co_docTopToolbar",
  "DocRightToolbar": "co_newDocToolbar",
  "TopTopics": "coid_website_relatedInfoWidgetDiv",
  "DocBottomToolbar": "co_docFooterToolbar"
};


window['Server/PageData'] = {
  "DocumentTabView": {
    "IsSkipOutOfPlanChecked": false,
    "IsUserDocument": false,
    "UserDocumentData": {
      "documentGuid": "I0a98a911a82a11d9bdd1cfdd544ca3a4"
    },
    "HasProfileSubTab": false,
    "DisplayOptions": {
      "showMainToolbar": true,
      "isNewDocumentView": false,
      "disableDocToolbar": false,
      "isAbstractView": false,
      "chunkSize": "L",
      "chunkableHeadnotes": false,
      "doCompleteSizeChecking": true,
      "ViewType": "FullText",
      "stickyHeader": true,
      "displayRelatedContentLink": true,
      "snippetRelocationInfo": {
        "contentType": "Cases",
        "subContentTypeId": "27"
      }
    },
    "ShowMainToolbar": true,
    "DocumentPersisted": false,
    "DocumentGuidNotFound": false,
    "ContentType": "Cases",
    "ExpandDocumentLevelTOC": true
  },
  "CobaltPageHeader": {
    "ShowPauseLink": false,
    "ShowCommunityContainer": false,
    "EnablePageHeaderV2": true,
    "ShowBetaFeedbackLink": false,
    "Notifications": {
      "HideNotificationToastAfterDuration": false,
      "NotificationClickGoDirectlyToAlerts": false
    }
  },
  "CompartmentStartPageId": "",
  "CobaltMasterFooterInSession": {
    "TRLogoImageLinkUrl": "http://www.thomsonreuters.com",
    "ShowWhatIsNewLink": false,
    "Unreleased": false,
    "IsAnonymousSession": false,
    "ShowMyContacts": false,
    "ShowPromotions": false,
    "ShowResetPromotions": false,
    "ShowCampusPolicy": false,
    "IsTransferContentAvailable": false,
    "ShowProductStartGuide": false,
    "HelpGuideDisplayName": "",
    "HelpGuideFileName": "",
    "HelpGuidePath": "",
    "CampusPolicyDisplayName": "",
    "CampusPolicyPath": "",
    "ShowAnalyticsLink": false,
    "AnalyticsPath": "Session/SignOn.html?transitionType=Default&contextData=(sc.Default)",
    "ShowMyAccountLink": false,
    "MyAccountPath": "WESTLAW/Common/Landing/MyAccountLanding",
    "LegalSolutionsLink": "http://legalsolutions.thomsonreuters.com/law-products/westlaw-legal-research/training-support",
    "SupplierTermsUrl": "http://legalsolutions.com/westlaw-additional-terms",
    "PrivacyPolicyPath": "https://www.thomsonreuters.com/en/privacy-statement.html"
  },
  "ActOnTracking": {
    "EnableActOnTracking": false,
    "ActOnTrackingInstanceId": ""
  },
  "CobaltPage": {
    "SetInCache": [
      {
        "Vertical": "Global",
        "Name": "ResultsPerPage",
        "Value": 20
      },
      {
        "Vertical": "Global",
        "Name": "ResultsPerPageAllowableValues",
        "Value": [
          "100",
          "20",
          "50"
        ]
      },
      {
        "Vertical": "Global",
        "Name": "Locale",
        "Value": ""
      },
      {
        "Vertical": "Global",
        "Name": "TimeZone",
        "Value": "Central Standard Time"
      },
      {
        "Vertical": "Global",
        "Name": "MultiFacetsEnabled",
        "Value": false
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_CASE",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_ANALYTICAL",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_PENDINGREG",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_PENDINGLEG",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_KNOWHOW",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "JurisdictionsContentType",
        "Value": "default"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_DOCKET",
        "Value": "CASE_TITLE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_BRIEF",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_TRIAL-TRANSCRIPTS",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_ADMINDECISION",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_FORM",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_NEWS",
        "Value": "DATE_DESCENDING"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_ORAL-ARGUMENTS",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "InstantSuggestions",
        "Value": true
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_TCO",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultNews_DuplicateIdentifier",
        "Value": false
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_REGULATION",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_EXPERTWITNESS",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "SliderDetail",
        "Value": "default"
      },
      {
        "Vertical": "Search",
        "Name": "ViewExpression",
        "Value": ""
      },
      {
        "Vertical": "Search",
        "Name": "DefaultPage",
        "Value": "ALL"
      },
      {
        "Vertical": "Search",
        "Name": "JurisdictionsGlobal",
        "Value": "CTAF"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_PMM",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_STATUTE",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_JURYVERDICT",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "SuppressRecentFiltersTooltip",
        "Value": false
      },
      {
        "Vertical": "Document",
        "Name": "HeadnotesDualColumnView",
        "Value": false
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorRulesSet",
        "Value": "standard"
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorItalicizeTitle",
        "Value": false
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorParallelCites",
        "Value": "CAFormat"
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorUseForCopyWithReference",
        "Value": true
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorCitationStyle",
        "Value": "LegalBriefs"
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorIncludeHistory",
        "Value": true
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorUnderlineTitle",
        "Value": true
      },
      {
        "Vertical": "Document",
        "Name": "HideHeadnotesBox",
        "Value": false
      },
      {
        "Vertical": "Foldering",
        "Name": "ShowAnnotationsPreferenceKey",
        "Value": "checked"
      },
      {
        "Vertical": "Website",
        "Name": "ShowKeyboardInstructions",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenShowTerms",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "NewFeatureLightboxDisplayBlackList",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenTextSize",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenMargin",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DeliveryOptionSelected",
        "Value": "None"
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenShowLinks",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "LastViewNotificationDate",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentDisplayTextSize",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DisplaySearchTerms",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "KnowHowSpeedReadExpandAll",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "DocumentDisplayFont",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentDisplayMargin",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenFont",
        "Value": ""
      },
      {
        "Vertical": "SAP",
        "Name": "PLAN ICONS",
        "Value": "NO"
      },
      {
        "Vertical": "SAP",
        "Name": "SKIP OUT OF PLAN",
        "Value": "NO"
      },
      {
        "Vertical": "SAP",
        "Name": "WARNING FLAG",
        "Value": "N"
      }
    ],
    "PingSync": "false",
    "ViewData": {
      "IsSponsorSession": true,
      "SearchWidgetParameters": {
        "search": {
          "renderCustomPageSearchWidget": false,
          "categoryPageTitle": "291 PATENTS",
          "isCategoryPageTopical": false,
          "topicKeyText": "291 PATENTS",
          "filters": {
            "jurisdiction": "CTAF",
            "sequence": 0,
            "content": "CUSTOMDIGEST",
            "index": false,
            "customDigest": true,
            "collectionSets": [
              "w_cs_cd_toc"
            ],
            "tocNode": "I4aee2539c6f64c1812a4c2f3395c2607",
            "keyNumber": "291",
            "displayJurisdictionSelector": true,
            "displayAdvancedSearchLink": false,
            "categoryPageUrl": "Home/WestKeyNumberSystem",
            "categoryPageContentType": "CUSTOMDIGEST",
            "categoryPageCheckboxLimit": 0,
            "resultsLimit": 0,
            "categoryPageAlertClippable": false,
            "isAdvancedSearchTemplatePage": false
          },
          "CustomPageSetForZone": false,
          "supportedFeatures": [],
          "skipSpellCheck": false,
          "browseHierarchyPathFromRoot": []
        },
        "SearchCompartmentName": "WestlawNext",
        "SearchDropDownItems": [],
        "grading": "na",
        "searchWidgetPosition": "Default",
        "hideSearchWidget": false,
        "makeSearchWidget": true,
        "prefersForceTnc": false,
        "prefersForceTncSingleQuote": true,
        "forceTncCounter": 0,
        "forceTncCounterThreshold": 5,
        "enableFavoriteSearch": false,
        "dynamicPage": false,
        "isAdvancedSearchTemplatePage": false
      },
      "ShowClientIdWidget": true,
      "OpenFindDropDown": false,
      "TimeoutInMinutes": 90,
      "FeatureConfigurations": {
        "FOLDERS": false,
        "HISTORY": true,
        "FOLDER_SHARING": false,
        "HIGHLIGHTS": false,
        "NOTES": false,
        "ANNOTATIONS": false,
        "BLOCK NOTES SHARING": false,
        "CONTACTS": false,
        "FAVORITES": false,
        "USER PROFILE": false,
        "KM": false,
        "FolderCachingDisabled": true,
        "KM IPAD": false,
        "SAO_INVITING": true,
        "SAO_SAMEEMAILDOMAIN": false,
        "CASENOTEBOOKEXPORT": false,
        "DOWNLOADDELIVERY": true,
        "DROPBOXDELIVERY": false,
        "EMAILDELIVERY": true,
        "EMAILWITHREFERENCEDELIVERY": false,
        "KINDLEDELIVERY": false,
        "PRINTDELIVERY": true,
        "KEYCITEALERTS": false,
        "LEGACYALERTACCESS": false,
        "BLOCKPERSISTENTINFO": true,
        "BLOCK100KANCILLARY": false,
        "DISPLAYMASHUPCHARGEWARNING": false,
        "SHOWCHARGEONWARNINGSCREEN": false,
        "SHOWCHARGELINKONWARNINGSCREEN": false,
        "USERISTRANSACTIONAL": true,
        "USER FORM UPLOAD": false,
        "MATTERUPLOADUSERDOC": false,
        "FOLDERUPLOADUSERDOC": false,
        "DISPLAY SESSION PAUSE LINK": false,
        "PASSTHRUPDFS": false,
        "processRIHistoryAsynchronously": true,
        "processDocumentHistoryAsynchronously": true,
        "PRINTBLANKFORMS": false,
        "WFBTRIALBLOCKSHARE": false,
        "ATTORNEY PORTAL": false,
        "SMALLLAWWORKBENCHMATTERTREE": false,
        "JUDICIALCHAMBERS": false,
        "CITATIONUS": false,
        "CITATIONCAN": false,
        "MYPLANSTATICDOC": true,
        "ALLOWFOLDERSHAREACROSSORGS": true,
        "BLOCKFOLDERSHAREFROMORGS": true,
        "ALLOWOFFLINEACCESS": false,
        "WEBHOSTEDCLIENTID": false,
        "WEBHOSTEDCLIENTIDIPAD": false,
        "WEBHOSTEDCLIENTIDSELECTION": false,
        "PRERELCONTENTFEAT": false,
        "ALERTS": false,
        "ALERTS ENHANCED": false,
        "ISEMULATEUSER": false,
        "WCLP": false,
        "NEWSLETTER": false,
        "KCALERT": false,
        "COINV ALERTS": false,
        "CITRANSITION": false,
        "BLCALERT": false,
        "DKTALERT": false,
        "DKTTRACK": true,
        "PUBALERT": false,
        "CWALERT": false,
        "POB ALERT": false,
        "POB WATCH": false,
        "CWALERTPremium": false,
        "CAPITOLWATCH": false,
        "ALERT SUMMARY REPORT": false,
        "WCLP CONTINUOUS": false,
        "KCALERT CONTINUOUS": false,
        "CWALERT CONTINUOUS": false,
        "POBA CONTINUOUS": false,
        "POBW CONTINUOUS": false,
        "NEWSLETTER DLY": false,
        "NEWSLETTER WKDY": false,
        "KCALERT DLY SINGLE": false,
        "KCALERT WKDY SINGLE": false,
        "BIALERT DLY SINGLE": false,
        "BLCALERT DAILY": false,
        "BLCALERT MULTI DAILY": false,
        "CWALERT DAILY": false,
        "BIALERT WKDY SINGLE": false,
        "BLCALERT BIWEEKLY": false,
        "BLCALERT CONTINUOUS": false,
        "WCLP WEEKLY": false,
        "NEWSLETTER WEEKLY": false,
        "KCALERT WEEKLY": false,
        "BIALERT WEEKLY": false,
        "BLCALERT WEEKLY": false,
        "DKTALERT WEEKLY": false,
        "DKTTRACK WEEKLY": true,
        "POBA WEEKLY": false,
        "POBW WEEKLY": false,
        "WCLP BIWEEKLY": false,
        "KCALERT BIWEEKLY": false,
        "BIALERT BIWEEKLY": false,
        "DKTALERT BIWEEKLY": false,
        "DKTTRACK BIWEEKLY": true,
        "NEWSLETTER BIWEEKLY": false,
        "POBA BIWEEKLY": false,
        "POBW BIWEEKLY": false,
        "WCLP MONTHLY": false,
        "NEWSLETTER MONTHLY": false,
        "KCALERT MONTHLY": false,
        "BIALERT MONTHLY": false,
        "BLCALERT MONTHLY": false,
        "DKTALERT MONTHLY": false,
        "DKTTRACK MONTHLY": true,
        "POBA MONTHLY": false,
        "POBW MONTHLY": false,
        "WCLP DLY SINGLE": false,
        "WCLP DLY MULT": false,
        "WCLP WKDY SINGLE": false,
        "WCLP WKDY MULT": false,
        "PUBALERT DLY SINGLE": false,
        "PUBALERT WKDY SINGLE": false,
        "DKTALERT WKDY SINGLE": false,
        "DKTALERT DLY SINGLE": false,
        "DKTTRACK WKDY SINGLE": true,
        "DKTTRACK DLY SINGLE": true,
        "CAPITOLWATCHTRACK DLY SINGLE": false,
        "CAPITOLWATCHTRACK DLY MULT": false,
        "CAPITOLWATCHTRACK WKDY SINGLE": false,
        "CAPITOLWATCHTRACK WKDY MULT": false,
        "CAPITOLWATCHTRACK WEEKLY": false,
        "CAPITOLWATCHTRACK BIWEEKLY": false,
        "CAPITOLWATCHTRACK MONTHLY": false,
        "POBA DLY SINGLE": false,
        "POBA DLY MULT": false,
        "POBA WKDY SINGLE": false,
        "POBA WKDY MULT": false,
        "POBW DLY SINGLE": false,
        "POBW DLY MULT": false,
        "POBW WKDY SINGLE": false,
        "POBW WKDY MULT": false,
        "showMatterTree": false,
        "WELCOME TO WLN BOX": false,
        "dataRoomReadSource": "Original",
        "dataRoomWriteDestination": "Single",
        "dataRoomFoldersWriteDestination": "SingleDataRoom",
        "showNapaContent": true,
        "PublicRecordsAccess": false,
        "PublicRecordsEnhancedSecurity": false,
        "PublicRecordsBlockRoaming": false,
        "PublicRecordsBlockHomeTrust": false,
        "PublicRecordsAllowRoamTrust": false,
        "PublicRecordsBypassCountry": false,
        "PublicRecordsBlockIPUndefined": false,
        "PublicRecordsBlockUndefinedTrust": false,
        "PublicRecordsDowngradeEmailIPRoaming": false,
        "PublicRecordsDowngradeEmailIPUndefined": false,
        "PublicRecordsUnmaskRoam": false,
        "DISABLE PR ANC MASK": false,
        "PublicRecordsSsnOnlyOK": false,
        "ReversePhoneGateway": false,
        "QSentReport": false,
        "CreditHeaderContentDatabaseGroup": false,
        "PolkGateway": false,
        "PolkReport": false,
        "DriversLicenseRecordsContentDatabaseGroup": false,
        "UCC COLUMN RESULTS": false,
        "matterTreeType": "None",
        "ISCAMPUSUSER": false,
        "ISCAMPUSNEWSUSER": false,
        "ISCAMPUSBUSINESSUSER": false,
        "isUnreleasedFeatureExposure": false,
        "WLANALYTICS ACCESS": false,
        "NEWSALERTAUTHOR": false,
        "NEWSALERTEDITOR": false,
        "UNRELEASED CAT PAGES": false,
        "INTERNAL ADMIN LIMITS": false,
        "DATAROOMALERTS": false,
        "DLVRY SESSION LIMIT": false,
        "DLVRY DAILY LIMIT": false,
        "DLVRY SESSION LIMIT PRAC LAW": false,
        "DLVRY DAILY LIMIT PRAC LAW": false,
        "DLVRY SESSN LIMIT PRAC LAW TRL": false,
        "DLVRY DAILY LIMIT PRAC LAW TRL": false,
        "CONTENT DLVRY RSTRCT": true,
        "BLOCKAUWLN": false,
        "BLOCKCANWLN": false,
        "BLOCKHKWLN": false,
        "BLOCKUKWLN": false,
        "ALERTS ADDRESS BOOK": true,
        "ALERTS BATCH PROCESSING": false,
        "ALERTS CALENDARING": true,
        "ALERTS FUNCTIONALITY": true,
        "ECHACCESS": false,
        "PMD VERSION": "5207",
        "USER ACADEMIC": true,
        "USER CORPORATE": false,
        "USER DEVELOPER": false,
        "USER GOVERNMENT": false,
        "USER INTERNAL": false,
        "USER LARGE LAW": false,
        "USER MEDIUM LAW": false,
        "USER SMALL LAW": false,
        "SIGNOFF SURVEY": false,
        "INLINE KC CASES BRIEF": false,
        "BYPASS WARN INLINE KC": false,
        "BLOCK PL ITEMS": false,
        "PRACTICAL LAW": false,
        "PRDCT PLCUK": false,
        "PRDCT PLCAU": false,
        "DISABLE PL REL CONTENT CACHE": false,
        "HISTORY UI": true,
        "EDSECTIONALLOW": false,
        "TAPSELECTED": false,
        "REDLINING": false,
        "WLNBYPASSBLOCK": false,
        "BLOCK NATIVE SIGNIN": false,
        "BLC ZONE": false,
        "CUSTOM PAGES": false,
        "CUSTOM PAGES READ": false,
        "CUSTOM PAGE ADMIN": false,
        "ELIBRARIES CP ZONE": false,
        "TYPE AHEAD": false,
        "PATRONHELP": false,
        "HISTORY RETENTION 1": false,
        "HISTORY RETENTION 180": false,
        "BLC POWERSEARCH": false,
        "PRDCT CORRECTIONAL": false,
        "EASY EDIT": false,
        "ENHANCED RB": false,
        "ENHANCED RB STICKY": false,
        "WMGRAPHICAL": false,
        "PRPTSUBSCRIBER": false,
        "BLOCK PRPT BLC": false,
        "PLCT DISPLAY LEGAL ANALYTICS": false,
        "PRPT SMALL": false,
        "PRPT CORPCOUNSEL": false,
        "PRPT LARGE": false,
        "BLOCK PRPT LARGE PAGES": false,
        "PRPT GOVT": false,
        "PRPT NONTRACKABLE": false,
        "PRPT KM LITIGATION": false,
        "PRPT KM TRANSACTIONAL": false,
        "WAYWO": false,
        "AnonymousSession": false,
        "AnonymousSessionBlock": false,
        "SOCIAL PLATFORM": false,
        "BLOCK TNP PLUS": false,
        "TNP TEPC CALC": false,
        "TNP CORTC CALC": false,
        "APFF ACCESS": false,
        "TDRC": false,
        "FPC": false,
        "FPP": false,
        "TAXHYPERION NLTR": false,
        "WCO ACCESS": false,
        "BLOCKMYSTARTPAGELINK": false,
        "TNP CEC CALC": false,
        "TNPNATLANG": false,
        "TAXNEWSCATEGORIES": false,
        "TNPDIGMCMECHAN": false,
        "TNPDIGBROWN": false,
        "TNPDIGNIKOLAKAKIS": false,
        "TNPDIGHAYHOETAXATION": false,
        "TNPDIGKERZNER": false,
        "TNPDIGSCHWARTZ": false,
        "TNPDIGINNES": false,
        "TNPDIGARON": false,
        "TNPDIGCARR": false,
        "TNPDIGGAMBLE": false,
        "TNPDIGTAXATIONOFREALESTATE": false,
        "TNPDIGBROOKS": false,
        "TNPDIGMUNRO": false,
        "TNPDIGTHAW": false,
        "TNPDIGVINER": false,
        "TNPDIGFRIEDLANDER": false,
        "TNPDIGBUTCHER": false,
        "TNPDIGALEXANDER": false,
        "TNPDIGHAYHOECASELAW": false,
        "TNPDIGHAYHOEFEDPROVLEGIS": false,
        "TNPDIGHAYHOEGOVPUBLICATIONS": false,
        "TNPDIGJOLIN": false,
        "TNPDIGSTILLABOWER": false,
        "TNPDIGCASESINDEXCITATOR": false,
        "TNPDIGSEGUIN": false,
        "TNPDIGWISE": false,
        "TNPDIGBOWEN": false,
        "TNPDIGBISCOTT": false,
        "TNPDIGEDMUNDS": false,
        "TNPDIGMANNGUIDETOREVIEW": false,
        "TNPDIGCOMPILATIONENGAGEMENTS": false,
        "TNPDIGGUIDETOESTATEANDTRUSTS": false,
        "TNPDIGITIZATION": false,
        "TNPLITIGATOR": false,
        "TNPCROSSREFFILTER": false,
        "RESULTLISTEASYEDIT": false,
        "RESULTLISTQDRAFT": false,
        "DISPLAY TEST PREF TAB": false,
        "BlindLog": false,
        "EncryptLog": false,
        "MASS EMAILER": false,
        "ADCVERREDLININGTOGGLE": false,
        "ENVHEALTHSAFETYPRACPG": false,
        "INSURCOMPLIANCEPRACPG": false,
        "BLOCK WLN PATRON": false,
        "DSP INT HEADNOTE INFO": false,
        "PRDCT WLNLINKS": false,
        "GAO LH PDFS OPEN IN LINKS": false,
        "WLNLINKS UK": false,
        "BLOCK WLNLINKS EMBEDDED LINKS": false,
        "BLOCK LICENSE AGREEMENT": false,
        "FIRMSTYLE": false,
        "SMART BREADCRUMB DISPLAY": false,
        "IRS WLN PAGE": false,
        "FORMSAUTOSHAREOFF": false,
        "WLNPLTRACK": false,
        "WLNPL GOVTHOMEPAGE": false,
        "WLNPL CORPHOMEPAGE": false,
        "WLNPL DEFAULTHOMEPAGE": true,
        "ENABLE-LEGI-GOV-LINKS": false,
        "ENABLE BAILII LINKS": false,
        "BLOCK SHARE NOTE LINK": false,
        "BLCCAN ZONE": false,
        "BLCCAN SUBSCRIBER": false,
        "BLOCKBLCCAN": true,
        "BLOCKBLC": false,
        "WM SEARCH RESULTS": false,
        "WMHK SEARCH RESULTS": false,
        "WMAU SEARCH RESULTS": false,
        "TAX PWC USER": false,
        "TAX KPMG USER": false,
        "COPY USER DATA": false,
        "ASSIGNCLIENTFILE": false,
        "RESEARCH REPORT": false,
        "FOLDER ANALYSIS": false,
        "FOLDER ANALYSIS ADDL CONTENT": false,
        "TIME ZONE AUSTRALIA": false,
        "TIME ZONE NEW ZEALAND": false,
        "EY WLN PAGE": false,
        "FOLDER DESCRIPTION": false,
        "ENABLE CONTRACT EXPRESS": false,
        "CONTRACT EXPRESS PL AU": false,
        "CONTRACT EXPRESS PL US": false,
        "ASK-EDITOR": false,
        "BLOCK OPEN WEB": false,
        "PLUK SUBSCRIBER": false,
        "WLUK SUBSCRIBER": false,
        "LIBRARY SUBSCRIBER": false,
        "CHECKPOINTDIRECTLINK": false,
        "BLOCKCHECKPOINTLINKS": false,
        "LINK BUILDER": false,
        "BCICALCULATOR": false,
        "PLUK-ENAB-ALLCONTACTS": false,
        "ALLOW ICLR": true,
        "BLOCK PROVIEW FEDERATED SEARCH": false,
        "DOC ANALYSIS": false,
        "DT DocAnalysis": false,
        "GENERATE WLUK TRANSTOKEN": false,
        "WFB USEMOCKFORMS": false,
        "BLOCKSESSIONPAUSEDISPLAY": false,
        "PWC WLN PAGE": false,
        "KPMG WLN PAGE": false,
        "CROSSBORDER DASHBOARD": false,
        "TR DISCOVER SEARCH": false,
        "VIRTUAL ASSISTANT": false,
        "BLCDEALTRACKALERT": false,
        "BLCDEALTRACKALERT BIWEEKLY": false,
        "BLCDEALTRACKALERT CONTINUOUS": false,
        "BLCDEALTRACKALERT DAILY": false,
        "BLCDEALTRACKALERT MONTHLY": false,
        "BLCDEALTRACKALERT MULTIDAY": false,
        "BLCDEALTRACKALERT WEEKLY": false,
        "EY MIGRATION POP UP": false,
        "KPMG MIGRATION POP UP": false,
        "PWC MIGRATION POP UP": false,
        "IRS MIGRATION POP UP": false,
        "TAX MIGRATE": false,
        "SEARCH TABS": false,
        "JOURNAL PURCHASE FORM": false,
        "WLUK EDITORS PICKS TAB": false,
        "LEGAL LIT ANALYTICS": false,
        "UKMATTERMAPS": false,
        "USMATTERMAPS": false,
        "DISPLAY PL MESSAGE 1": false,
        "DISPLAY PL MESSAGE 2": false,
        "GRADING TOOL": false,
        "MODERN DOC DISPLAY": false,
        "INDIGO SEARCH": false,
        "INDIGO DISPLAY": false,
        "PSEUDO BLOCK INDIGO DISPLAY": true,
        "INDIGO DISPLAY PREF": false,
        "INDIGO HOT DOCS": false,
        "INDIGO RESEARCH REPORT": false,
        "COMPARE BLACKLINING": false,
        "NOTIFICATION CENTER": false,
        "PRIOR USER INTERACTIONS": false,
        "COLD START": false,
        "TOC FOR CASES": false,
        "MATERIAL KEY FACT FILTER": false,
        "PROCEDURAL POSTURE FILTER": false,
        "FAVORITE SEARCHES": false,
        "FOLDER KEYCITE CHANGE": false,
        "FOLDER RECOMMEND CHANGE": false,
        "FOLDER RECOMMEND ALERT": false,
        "RECENT FILTERS": false,
        "SEARCH RESULT CITING REFS": false,
        "SEARCH RESULT NEG HISTORY": false,
        "QUESTIONANSWERING": false,
        "ITDEPENDS": false,
        "ITDEPENDSQUESTIONANSWER": false,
        "WLUK DOC ALERTS": false,
        "WLUK JCL ALERTS": false,
        "PA REGULATIONS STATUS FILTER": false,
        "ALWAYS CLIENT ID PROMPT": false,
        "PL US BANNER": false,
        "ANSWERS FEEDBACK": false,
        "KC IMPLIED OVERRULINGS": false,
        "ENHANCED THEME": false,
        "DOC ANALYZER TOUR": false,
        "LIT ANALYTICS TOUR": false,
        "HOME PAGE TOUR": false,
        "BUSINESS DEVELOPMENT PL US": false,
        "WLNPL SLF HOMEPAGE": false
      },
      "IsUserMigrated": false,
      "SupportedFeatures": [
        "PRACTICALLAW",
        "ALERTS",
        "BROWSE",
        "BROWSEPREVIEW",
        "CASEEVALUATORWLN",
        "CDN",
        "CLIENTID",
        "CONTACTS",
        "CONTENTTYPEDELIVERYLIMIT",
        "COREUI",
        "CUSTOMPAGES",
        "DELIVERY",
        "DOCKETS",
        "DOCUMENTORDERING",
        "DOCUMENTS",
        "DROPBOX",
        "ERRORS",
        "FAVORITESORGANIZER",
        "FINDANDPRINT",
        "FOLDERS",
        "FOLDERSEXTERNALSHARING",
        "GLOSSARY",
        "WAYWO",
        "IOS",
        "IPAD",
        "FACTORANALYSIS",
        "KEYNUMBERSEARCH",
        "KM",
        "LINKIN",
        "LINKOUT",
        "LIVECHAT",
        "MOBILE",
        "MYPLAN",
        "NYOFFICALDIGEST",
        "PRICINGGUIDE",
        "PROMOTIONS",
        "PUBLICATIONFAVORITES",
        "RELATEDINFORMATION",
        "RELATEDTOPICS",
        "REPORTSHARED",
        "REVERSEPROXY",
        "SEARCH",
        "SHAREPOINTSEARCH",
        "SHAREPOINTWIDGETS",
        "SOCIALPLATFORM",
        "SURVEY",
        "USERAGREEMENT",
        "USERDOCUMENTS",
        "USEREMULATION",
        "USERSETTINGS",
        "BANKRUPTCYEXPLORER",
        "BUSINESSINVESTIGATOR",
        "BUSINESSLAWCENTER",
        "CASENOTEBOOK",
        "DUNANDBRADSTREETBUSINESS",
        "EXPERIANBUSINESSCREDIT",
        "EXPERTDUEDILIGENCE",
        "EXPERTEVALUATOR",
        "MATTERBENCHMARKING",
        "RECENTHISTORY",
        "WEB2MASHUP",
        "AUTHORITYCOMPILER",
        "SEARCHTEMPLATEPREVIEW",
        "PEOPLEMAP",
        "PUBLICRECORDS",
        "DOCKETGATEWAY",
        "WEBCONTENT",
        "PROFESSIONAL",
        "SUGGESTEDDOCUMENTS",
        "EMBEDDEDTEXT",
        "PRODUCTVIEW",
        "PRIVATEFILES",
        "STATEQACOMPARE",
        "SOURCELINK",
        "PMDPROTECTEDCONTENT",
        "ROADRUNNER",
        "REDLINE",
        "SUPERBROWSE",
        "TOCREPORTVIEW",
        "DATACOMPARISONREPORT",
        "GRAPHICALFACETS",
        "COPYUSERDATA",
        "SHAREDNOTES",
        "RESEARCHACCELERATOR",
        "WEBINARS",
        "READINGMODE",
        "ANALYTICS",
        "HIDESEARCHTERMHIGHLIGHTINGPREFERENCE",
        "MONETIZATION",
        "SHOWDOCUMENTANALYZEROVERVIEWPREFERENCE",
        "SHOWLITANALYTICSOVERVIEWPREFERENCE",
        "SHOWHOMEPAGEOVERVIEWPREFERENCE",
        "FOUNDATION"
      ],
      "ActiveBrowserPingInitialWaitInMinutes": 3,
      "ActiveBrowserPingFrequencyInMinutes": 3,
      "ShowClientIdToast": false,
      "DataRoomFeatures": [],
      "SocialPlatformProductId": "140",
      "MaxFileUploadSize": 157286400,
      "SnapEngageScriptUrl": "",
      "DeliveryQueueQueried": false,
      "DeliveryQueueTotal": 0,
      "DeliveryQueueInProgress": 0,
      "DeliveryQueueDocketsInProgress": 0,
      "DeliveryQueueInError": 0,
      "DeliveryQueueNotification": 0
    },
    "WidgetDomIds": {
      "FooterDivId": "co_footer",
      "ErrorSummaryWidget": "coid_website_errorsSummaryPlaceHolder",
      "DockWidget": "co_dockContainer",
      "RecentFoldersWidget": "co_recentFoldersContainer",
      "RecentHistoryWidget": "co_recentHistoryContainer",
      "FrequentFavoritesWidget": "co_frequentFavoritesContainer",
      "AlertsCenter": "co_alertsCenterContainer",
      "ClientIdWidget": "co_clientIdContainer",
      "SignOff": "co_signOffContainer",
      "WhatIsNext": "co_whatIsNextContainer",
      "SearchWidget": "coid_website_searchWidget"
    },
    "RedirectError": {
      "Show": false
    },
    "DomStorageHasBeenCleared": false,
    "LiveChat": {
      "Show": false,
      "Options": {
        "QueueNumber": 0
      }
    },
    "WelcomeLightbox": {
      "Show": false
    },
    "SyncInitiated": false,
    "SyncCapable": false,
    "SubscriptionRenewalBanner": {
      "Show": false
    },
    "IsBusinessLawCenter": false
  },
  "TabScripts": {
    "DocSource": "b1bccecc3f504e84942ac3ffd6cd2470",
    "DocGuid": "I0a98a911a82a11d9bdd1cfdd544ca3a4",
    "NavigationPath": "Search/v1/results/navigation/i0ad62aef0000016306ea58342bf062c8?Nav=CUSTOMDIGEST&fragmentIdentifier=I0a98a911a82a11d9bdd1cfdd544ca3a4&startIndex=1&contextData=%28sc.CustomDigest%29&transitionType=CustomDigestItem",
    "ListSource": "Search",
    "List": "CUSTOMDIGEST",
    "Rank": 122,
    "DocumentVersionNumber": 0
  }
};


window['Server/KM'] = {
  "SessionId": "",
  "FirmName": "",
  "FirmLogoUri": "",
  "FirmWelcomeUri": "",
  "Protocol": "http"
};


window['Server/Configuration'] = {
  "CompartmentName": "WestlawNext",
  "CookieDomain": "next.westlaw.com",
  "EnableIpad": false,
  "EnableIphone": false,
  "IsIPadAppRenderingMode": false,
  "IsIPhoneAppRenderingMode": false,
  "IOSNativeVersion": "0.0.0",
  "EnableSync": false,
  "EnableDeliveryQueue": true,
  "EnableDeliveryWidget": true,
  "ProductName": "WestlawNext",
  "ProductDisplayName": "Westlaw",
  "ProductDisplayDelimiter": "|",
  "ProductViewName": "none",
  "DailyDeliveryLimit": -1,
  "DailyDeliveryCount": -1,
  "SessionDeliveryLimit": 20,
  "SupportedAlertTypes": [
    "WestClip",
    "KeyCite",
    "DocketAlert",
    "DocketTrack",
    "DealTrack",
    "PublicationAlert",
    "Newsletter",
    "BusinessInvestigator",
    "CourtWire",
    "BusinessLawCenterAlert",
    "PeopleMap",
    "CapitolWatchTrack"
  ],
  "EnableDataRoomAlerts": true,
  "GlobalizationKeyMode": "Default",
  "IsAnonymousSession": false,
  "EnableAccessibleLightbox": true,
  "EnableContactsPaging": true,
  "IsCrawlerSession": false,
  "IsGlobalizationI18NLocaleEnabled": false,
  "IsGlobalizationI18NLibraryLookupEnabled": true,
  "IsProcessCategoryPagesWithDifferentLocalesOn": false,
  "OverrideResultsPerPage": 0,
  "UseExpandableToc": true,
  "Locale": "en-US",
  "IsSmartFoldersEnabled": true,
  "IsFeatureOverlayEnabled": true,
  "IsTRDiscoverEnabled": true,
  "IsVideoTourEnabled": true,
  "IsBestPortionNavigationEnabled": true,
  "UsePageHeaderV2": true,
  "UseTypeAhead": true,
  "UseSnapshots": true,
  "IsBriefAnalyzerEnabled": true,
  "IsChargeableByDefaultForSession": true,
  "IsIssueFinderEnabled": true,
  "IsWestlawAnswersEnabled": true,
  "IsSharedHighlightsEnabled": true,
  "IsRealTimeNotificationEnabled": true,
  "EnableA11YLightboxKeyboardScroll": true,
  "IsA11YRedesignedHeaderEnabled": true,
  "IsA11YPreferencesLightboxEnabled": true,
  "SpeechToTextCustomizationIdOverride": "default",
  "InfrastructureAccessControls": [
    "iac-a11y-asbuilder-tmpl",
    "iac-a11y-header-redesign",
    "iac-accessible-clientid-widget",
    "iac-add-timezone",
    "iac-alert-admin-settings",
    "iac-alert-ny-sct-hourly",
    "iac-alerts-cal",
    "iac-alerts-customerinfo-olc",
    "iac-alerts-cw",
    "iac-alerts-docket-guid",
    "iac-alerts-productaware-history",
    "iac-alerts-standart-email-format",
    "iac-all-citations",
    "iac-allow-robots-indexing-sitemap-wln",
    "iac-analyticsclientidfeaturesenabled",
    "iac-analytics-related-filings",
    "iac-annotation-filtering",
    "iac-anonymous-cdn",
    "iac-appcommand",
    "iac-asm-policy",
    "iac-au-compartments",
    "iac-au-seo",
    "iac-autosuggest-au",
    "iac-batch-getsynopsis",
    "iac-bestlaw-tracking",
    "iac-blc-filersearch",
    "iac-blc-fs-next",
    "iac-blc-redlining",
    "iac-blc-ri-agreementsenh",
    "iac-blc-ri-newpathway",
    "iac-blc-ri-privateequity",
    "iac-blind-encrypted",
    "iac-blind-encrypted-header-enabled",
    "iac-block-uk-westlaw",
    "iac-blt-alertfulltext",
    "iac-blt-alert-type-mna-trans",
    "iac-blt-alert-type-sec-insider",
    "iac-blt-alert-type-sec-noninsider",
    "iac-blt-feature18",
    "iac-blt-feature3",
    "iac-blt-hoovers",
    "iac-blt-incorporationdata",
    "iac-blt-news",
    "iac-blt-oct2014-release",
    "iac-blt-officerlinks",
    "iac-blt-report-advisors",
    "iac-blt-securities",
    "iac-blt-securities-alerts",
    "iac-blt-subsidiaries",
    "iac-blt-table-sections",
    "iac-blt-tagged-sections",
    "iac-blt-tickercik",
    "iac-blt-webkitpdf",
    "iac-blt-xmlmindrtf",
    "iac-businesslawcenter-tdr",
    "iac-canadian-content",
    "iac-casetracking",
    "iac-change-uk-ntz-clientid",
    "iac-cig-addfoldereditem",
    "iac-cig-facet-orphan",
    "iac-cig-group-orphan",
    "iac-cig-orphan",
    "iac-cig-orphan-ind",
    "iac-cig-report-orphan",
    "iac-ci-resultlist",
    "iac-citation-reordering",
    "iac-client-chargeable-by-default",
    "iac-clientid-new-validation",
    "iac-concourselibrary-wln",
    "iac-content-finder",
    "iac-correct-dock-user-property-value",
    "iac-courtexpress",
    "iac-cpet-browseparts-novus",
    "iac-cr-effective-date-display",
    "iac-crossborder-dashboard",
    "iac-crossborder-itg",
    "iac-display-applied-filter-names-on-ssp",
    "iac-display-recent-items",
    "iac-docanalyzer-caselc-atlaslc",
    "iac-docanalyzer-cited-statutes",
    "iac-docanalyzer-filter",
    "iac-docanalyzer-footnotes",
    "iac-docanalyzer-rdintegration",
    "iac-docanalyzer-relevantportion",
    "iac-docanalyzer-secondarysources",
    "iac-docanalyzer-statutes",
    "iac-docanalyzer-ui-march-release",
    "iac-doc-medical-entities-link-out",
    "iac-docversioning-wln",
    "iac-dpa-browse-juris-landing-pg",
    "iac-dpa-curated",
    "iac-dpa-delivery-watson-answer",
    "iac-dpa-enforcementmap",
    "iac-dpa-featured-content",
    "iac-dpa-keyword-newjurs",
    "iac-dpa-keyword-novus",
    "iac-dpa-knowledgegraph",
    "iac-dpa-related-concepts",
    "iac-dpa-usabilla",
    "iac-dpa-watson-v11",
    "iac-dpa-watson-v12",
    "iac-dr-client-missed",
    "iac-dtp-bankruptcy-claims",
    "iac-dtp-dktptynmtbl",
    "iac-dtp-experts",
    "iac-dtp-openweb",
    "iac-dyn-stem-exceptions",
    "iac-enable-news-summary-alerts-delivery",
    "iac-enacted-legislation-link",
    "iac-enhanced-search-term-tooltip",
    "iac-factoranalysis-history",
    "iac-fa-searchbilling",
    "iac-fastdom-standarddocument",
    "iac-feature-overlay",
    "iac-findandprint",
    "iac-firmlibrary-wln",
    "iac-foldering-get-descendants-new",
    "iac-folderingshareacrossorgs",
    "iac-forcesignon-orphansession",
    "iac-gateway-do",
    "iac-get-renewalandtrialdata",
    "iac-grantonlyfacsinsessionbindings",
    "iac-guid-chasing-disable",
    "iac-hide-docket-monthly-frequency",
    "iac-hide-territorial-options",
    "iac-historical-datacorrections",
    "iac-image-module",
    "iac-improved-navigation",
    "iac-indigo-coldstart",
    "iac-indigo-cpet-browseparts",
    "iac-indigo-display-pref",
    "iac-indigo-fav-searches",
    "iac-indigo-folder-kc-change",
    "iac-indigo-folder-recommend-change",
    "iac-indigo-hot-docs",
    "iac-indigo-notification-center",
    "iac-indigo-paymenttype",
    "iac-indigo-pui",
    "iac-indigo-recent-filters",
    "iac-indigo-research-report",
    "iac-indigo-statutes-compare",
    "iac-indigo-typeahead",
    "iac-inlinehtmldelivery-dockettrackalert",
    "iac-internationalfind",
    "iac-ios-newadvancedsearch",
    "iac-ip2-markman",
    "iac-ip-trademark-viennacode-facet",
    "iac-itdepends",
    "iac-itg-tab",
    "iac-kc-alerts-patents",
    "iac-kc-citing-references",
    "iac-kc-citing-refs-enhanced-sw",
    "iac-kc-flags",
    "iac-kc-flags-green-c-by-boolean",
    "iac-kc-judicial-history",
    "iac-kc-negative-treatment",
    "iac-kc-rules-affected-by",
    "iac-kc-statutes-affected-by",
    "iac-kc-table-of-authorities",
    "iac-kc-validity",
    "iac-kc-wave-the-white-flag",
    "iac-keycite-nod-redesign-old-rels",
    "iac-keycite-sort-by-court-level",
    "iac-keynumber-facets",
    "iac-km-aliveserverconnection",
    "iac-km-fiacctprefs",
    "iac-la-case-outcomes",
    "iac-la-case-types",
    "iac-la-courts",
    "iac-la-delivery",
    "iac-la-law-firms",
    "iac-linkbuilder-docandcatpages",
    "iac-linkbuilder-searchresultspages",
    "iac-linkbuilder-topic-search",
    "iac-linkouturl-pubandserial",
    "iac-log-prdct-wlus-deny",
    "iac-lt-dpa-watson-integration",
    "iac-master-page",
    "iac-mattermaps-deliver-image",
    "iac-mattermaps-editmap",
    "iac-matters-by-number-wln",
    "iac-medlit",
    "iac-modal-footnotes",
    "iac-modernization-wln-ios-doc",
    "iac-most-cited-sort",
    "iac-move-menus-down",
    "iac-multipart-pdf",
    "iac-new-newsletter-template",
    "iac-newsroom-images",
    "iac-non-unique-cites",
    "iac-novustimezone",
    "iac-nyofficial-digestlink",
    "iac-oversized-and-error-email-delivery",
    "iac-pa-regulations-status-facets",
    "iac-partytype-checkbox",
    "iac-patron-category-page",
    "iac-pdf-multipart-check",
    "iac-planz-application-enabled",
    "iac-plconnect-tasks-and-synonyms",
    "iac-plconnect-tasks-ux-redesign",
    "iac-plc-rss-feeds",
    "iac-plct-crossclientid",
    "iac-plct-crossproductclientid",
    "iac-plct-globalsearch",
    "iac-plct-linkbuilder",
    "iac-plct-smalllawfirmmgmt",
    "iac-plct-ssrulebooks",
    "iac-plct-startupssmallbus",
    "iac-plct-viewalltasks",
    "iac-plc-viewonlydraftingnotes",
    "iac-plc-waywo",
    "iac-plplus-application-enabled",
    "iac-plplus-calendar",
    "iac-pl-scrollissues",
    "iac-pluk-asset-page-enable-wln-links",
    "iac-pluk-cdn-available-for-ip",
    "iac-plus-clientidinsession",
    "iac-plus-clientidpromptpltowl",
    "iac-plus-documentononepage",
    "iac-plus-feedback",
    "iac-plus-homebanner",
    "iac-plus-knowhowbooleanquery",
    "iac-plus-linkbuilder",
    "iac-plus-notesformating",
    "iac-plus-searchcontext",
    "iac-plus-truncatejurinsearch",
    "iac-plus-unhideannotations",
    "iac-plus-viewmorelessdetails",
    "iac-portalmanager-combined",
    "iac-portalmanager-contentlinks",
    "iac-portalmanager-findbypartyname",
    "iac-portalmanager-search",
    "iac-practical-law-display-changes",
    "iac-practicallaw-itg-dropdown",
    "iac-practical-law-subheadings",
    "iac-practiceareas-asterisknote",
    "iac-practicepoint-smartsearch-onesynonym",
    "iac-practicepoint-smartsearch-synonyms",
    "iac-practicepoint-smartsearch-treatises",
    "iac-practitioner-insights-alerts-no-logo",
    "iac-pr-add-bing",
    "iac-pr-addfoldereditem",
    "iac-pr-entity-extraction",
    "iac-pr-fein-plus3",
    "iac-price-guide-link",
    "iac-pricing-guide-redirect",
    "iac-privacy-policy",
    "iac-pr-polkrpt",
    "iac-pr-qsentrpt",
    "iac-pr-section-delivery",
    "iac-pr-ssn-only-search",
    "iac-pr-use-pipl-v5",
    "iac-public-record-prod-gateway",
    "iac-public-records",
    "iac-public-records-alerts",
    "iac-public-records-firstamerican",
    "iac-public-records-report-excel-delivery",
    "iac-public-records-report-filtering",
    "iac-pubrec-real-time-monitor",
    "iac-qanda",
    "iac-qanda-pinpoint",
    "iac-qanda-typeahead",
    "iac-raise-document-limit",
    "iac-ra-no-rank1docs-cache",
    "iac-remove-nyor-hard-coded-collections",
    "iac-remove-securedatatoken",
    "iac-research-accel",
    "iac-research-accel-synopsis",
    "iac-ri-bill-activity",
    "iac-ri-bill-tracking",
    "iac-ri-capitol-watch",
    "iac-ri-category-delivery",
    "iac-ri-citestyles-endpoint-v2-enable",
    "iac-ri-context-analysis",
    "iac-ri-editorial-materials",
    "iac-ri-filings",
    "iac-ri-fnd-newpathway",
    "iac-ri-form-families",
    "iac-ri-legislative-timeline",
    "iac-ri-no-single-rn-uds-post",
    "iac-ri-notes-of-decisions",
    "iac-ri-opinions",
    "iac-ri-professional-references",
    "iac-ri-reduce-uds-rn-data",
    "iac-ri-topics",
    "iac-ri-versions",
    "iac-sb-list-items-delivery",
    "iac-search-como-group1",
    "iac-search-como-group2",
    "iac-search-como-group3",
    "iac-search-como-group4",
    "iac-search-como-group6",
    "iac-search-como-group7",
    "iac-search-como-group8",
    "iac-search-como-public-records",
    "iac-search-como-recodocs",
    "iac-search-como-reghist",
    "iac-search-custom-nyor-reranking",
    "iac-search-delivery-group1",
    "iac-search-delivery-group2",
    "iac-search-delivery-group3",
    "iac-search-delivery-group4",
    "iac-search-delivery-group5",
    "iac-search-firmcentral",
    "iac-search-knowhowrankoption",
    "iac-search-matterroom",
    "iac-search-nl-thresholding-option",
    "iac-search-pmd-result-types",
    "iac-search-result-duplicate-identifier",
    "iac-search-suggestions",
    "iac-search-within-favourites-plcuk",
    "iac-searchwithin-ios",
    "iac-shared-highlights",
    "iac-share-folders-with-cobalt-contacts",
    "iac-sharing-with-the-same-domain",
    "iac-show50statesurvey-inlineflags",
    "iac-small-law-survey-redirect",
    "iac-smartbreadcrumb-add-navid",
    "iac-smartbreadcrumbs-au",
    "iac-smartfolders-ss",
    "iac-snapshots-state",
    "iac-snowdonia-beta",
    "iac-sortoption-courtlevel-pref",
    "iac-starpages-plcuk",
    "iac-staticqa",
    "iac-staticqa-history",
    "iac-staticqa-searchbilling",
    "iac-statutes-new-ast-pdfs",
    "iac-superbrowse-mult-gradeheads",
    "iac-superbrowse-paging",
    "iac-taxpage-eylogo",
    "iac-term-frequency-sorting",
    "iac-transfer-content",
    "iac-trd-alternate-search",
    "iac-trd-juris-facet",
    "iac-trd-legalanalytics",
    "iac-trd-lpafacet-subsearch",
    "iac-trillium-crsw-doc-enhance",
    "iac-trillium-link",
    "iac-uk-a11y-clientid-lightbox",
    "iac-uk-clientid",
    "iac-uk-compartments",
    "iac-uk-fd-and-fs",
    "iac-uk-keywordfinder",
    "iac-uk-linkbuilder",
    "iac-uk-linkbuilder-copy",
    "iac-uk-nonpltracking",
    "iac-uk-performance-new-static-content-or",
    "iac-unlink-unmigrated",
    "iac-use-new-training-user",
    "iac-userdoclink-wln",
    "iac-us-knowhow-algorithm",
    "iac-v3inapplibrary",
    "iac-validity-highlighting",
    "iac-verify-eaddress-against-existance",
    "iac-webinars",
    "iac-website-throttle",
    "iac-westsearch-cases-keynumberfacet",
    "iac-westsearch-cases-partyfacet",
    "iac-westsearch-cases-synopsis",
    "iac-westsearch-cases-topicfacet",
    "iac-westsearch-enhancements",
    "iac-without-flash-dependencies",
    "iac-wln-cig-linkedreport",
    "iac-wlndoc-sharednotes",
    "iac-wln-global-search-judicial-chambers",
    "iac-wln-historicalheader",
    "iac-wln-ios-display-toa",
    "iac-wln-newfiletype",
    "iac-wlnopenweb-serverbrowsepage",
    "iac-wln-ri-tabs",
    "iac-wln-save-snippet",
    "iac-wln-strong-downgrade-email",
    "iac-wlntax-blue-flag",
    "iac-wln-toc-keyciteflag",
    "iac-wl-startpage",
    "iac-wl-striphash",
    "iac-wordsphrases-snippet-support"
  ],
  "IsTypeAheadNewUiEnabled": true,
  "ContactsPageSize": 300,
  "ShowPrivacyPolicy": true,
  "ShowCookiePolicy": true,
  "ResearchReportDocumentLimit": 1000,
  "IsSaveSnippetEnabled": true,
  "IsHideAnnotationsSharedByInactiveUsersEnabled": true,
  "AllowPauseOnLinkOut": true,
  "IsMaintainDocumentPositionRIEnabled": true,
  "IsFormsEngine2Enabled": false,
  "IsFormsEngine2DownloadEnabled": false,
  "IsIndigoDisplayEnabled": false
};


window['Server/Mobile'] = {
  "IsNativeIPad": false,
  "IsNativeIPhone": false
};


window['Server/Messages'] = {
  "ProductName": "Westlaw",
  "ProductSupportNumber": "1-800-WESTLAW (1-800-937-8529)"
};


window['Server/Net'] = {
  "PageContextData": "(sc.CustomDigest)",
  "CacheScopeList": [
    "^/RelatedInfo/v[3456]/keycite/content/",
    "^/RelatedInfo/v3/content/json/",
    "^/RelatedInfo/v1/wlncCaselawHistory\\\\?",
    "^/RelatedInfo/v1/wlncCitingReferences\\\\?",
    "^/RelatedInfo/v1/wlncCourtDocs\\\\?",
    "^/RelatedInfo/v1/wlncLegalMemos\\\\?",
    "^/RelatedInfo/v1/kcJudicialHistory\\\\?",
    "^/RelatedInfo/v1/kcCitingReferences\\\\?",
    "^/RelatedInfo/v1/riFilings\\\\?",
    "^/RelatedInfo/v1/kcNegativeTreatment\\\\?",
    "^/RelatedInfo/v1/kcTableOfAuthorities\\\\?",
    "^/RelatedInfo/v1/kcBillDrafts\\\\?",
    "^/RelatedInfo/v1/kcLegislativeMaterials\\\\?",
    "^/RelatedInfo/v1/kcRegulatoryHistory\\\\?",
    "^/RelatedInfo/v1/kcValidity\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreements\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnSecCommentLetters\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnSecCommentLettersTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosures\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresTwoStepViaMA\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresExhibits\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresExhibitsTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresExhibitsTwoStepViaMAAndFD\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitions\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitionsEnhanced\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitionsEnhancedTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitionsRelated\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnRandPTransactionFullTextCategory\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnRandPTransactionFullTextCategoryTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingFullTextCategory\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestments\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestmentsV2\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestmentsTwoStepViaMA\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestmentsTwoStepViaFDAndMA\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnPefundsFundsFirms\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsEnh\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsEnhTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsEnhTwoStepViaMA\\\\?",
    "^/RelatedInfo/v1/tnpCases\\\\?",
    "^/RelatedInfo/v1/tnpCommentary\\\\?",
    "^/RelatedInfo/v1/tnpCompliance\\\\?",
    "^/RelatedInfo/v1/tnpGovernmentDocuments\\\\?",
    "^/RelatedInfo/v1/tnpHistory\\\\?",
    "^/RelatedInfo/v1/tnpHistoryAndTreatments\\\\?",
    "^/RelatedInfo/v1/tnpLegislation\\\\?",
    "^/Search/v1/search/external/results",
    "^/Search/v3/search/results",
    "^/Search/v1/results",
    "^/Document/v1/fulltext/",
    "^/Document/v1/list/fulltext/",
    "^/Document/v1/Mobile/FullText/",
    "^/Document/v1/fixedheader/",
    "^/Document/v1/list/fixedheader/",
    "^/Document/v1/list/Mobile/Fulltext/",
    "^/Document/v[12]/MetaInfo/"
  ],
  "SessionScope": "8ddfa247da5ec522372afb44cc5a905f27604688c70f518919c93bafe2056482",
  "UserScope": "5405685",
  "CacheScope": "f68fc5d826b1c202d2b2868aaf7c2178"
};


window['Server/Events'] = {
  "PageEventIdentifier": "7a17a9227df24382bfb0bbbc6a137407",
  "PageName": "Cobalt.Website.ServerPage.Document",
  "ResourceToken": "v1|8331b4064cc03a93d3b3a9ec9e1e026fbf175f710f225a93a089ffc9763cc333"
};

</script>


	
	

<!-- View Path: ~/Document/Views/DocumentTabView.cshtml -->
<script type="text/javascript">
window.__viewName = '~/Document/Views/DocumentTabView.cshtml';
</script>
<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="https://ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/webpack-loader.js"></script>

	

<div id="co_searchDisableDiv" class="co_screenOverlay co_hideState"></div></body></html>